

# Wave 2 Data Supplement

5-Amino-4-Chloro-o-Cresol

Charcoal

Prostaglandin Analogues

Yeast

EXPERT PANEL MEETING

DECEMBER 4-5, 2023



## Memorandum

**TO:** Bart Heldreth, Ph.D.  
Executive Director - Cosmetic Ingredient Review

**FROM:** Alexandra Kowcz, MS, MBA  
Industry Liaison to the CIR Expert Panel

**DATE:** November 16, 2023

**SUBJECT:** Draft Final Report: Amended Safety Assessment of 5-Amino-4-Chloro-o-Cresol and 5-Amino-4-Chloro-o-Cresol HCl as Used in Cosmetics (draft prepared for the December 2023 meeting)

The Personal Care Products Council respectfully submits the following comments on the draft final report, Amended Safety Assessment of 5-Amino-4-Chloro-o-Cresol and 5-Amino-4-Chloro-o-Cresol HCl as Used in Cosmetics.

### Key Issues

Margin of Safety –The reason for assuming 100% dermal penetration for an MoS calculation should not be “In consideration of the absence of dermal absorption data for 5-Amino-4-chloro-o-Cresol HCl at the maximum use concentration of 1%”. The dermal penetration data available are at a concentration of 1.6% which is applicable to the use concentration of 1%.

If the report is published without the information from the original report, the text should be modified to make it clear that the original report needs to be consulted to get summaries of all the studies on these ingredients. For example, under Subchronic, without the italicized text, it would be helpful to state something like: “A repeated-dose toxicity study of 5-Amino-4-Chloro-o-Cresol HCl was included in the original report. No additional repeat-dose studies were found in the updated literature search, and unpublished data were not submitted.”

The Summary should also clearly state that the original report should be consulted as the studies in that report are not included in the current report.

### Additional Considerations

Composition and Impurities – It would be helpful to use the same name for the impurity in the summary of the information from the old report (currently stated as 2-methyl-5-aminophenol) and in the summary of the new information (currently stated as 4-amino-2-hydroxytoluene).

Cosmetic Use; Margin of Safety – The 1% use concentration in the original report is cited to a specific company. It was a reference that is dated 1994. It was not a survey that was submitted in 1994. It was not a use concentration that “was reported by the Council” as stated in the Margin of Safety section.

Margin of Safety; Summary – The Margin of Safety section correctly states that the SCCP calculated the MoS under oxidative conditions. The Summary incorrectly states that the MoS was calculated “under non-oxidative conditions”.



**Memorandum**

**TO:** Bart Heldreth, Ph.D.  
Executive Director - Cosmetic Ingredient Review

**FROM:** Alexandra Kowcz, MS, MBA  
Industry Liaison to the CIR Expert Panel

**DATE:** November 16, 2023

**SUBJECT:** Draft Final Report: Safety Assessment of Plant-Derived Charcoal Ingredients as Used in Cosmetics (draft prepared for the December 2023 meeting)

The Personal Care Products Council respectfully submits the following comments on the draft final report, Safety Assessment of Plant-Derived Charcoal Ingredients as Used in Cosmetics.

Composition and Impurities – It would be helpful to state the carbon content of the charcoal used in the studies cited to ECHA in the Composition and Impurities section.

Cosmetic Use – Please add “shampoo” after “24” in the following: “Charcoal Powder is reported to be used in 24 formulations”

Dermal Irritation and Sensitization Studies; Summary – Please state that the results of the LLNAs indicate that Charcoal (at the tested concentrations) was not sensitizing. A person unfamiliar with the LLNA might not know the meaning of the inability to calculate a stimulation index in this assay.





---

*Commitment & Credibility since 1976*

**Memorandum**

To: Expert Panel for Cosmetic Ingredient Safety Members and Liaisons  
From: Priya Cherian, M.S., Senior Scientific Analyst/Writer, CIR  
Date: November 20, 2023  
Subject: Safety Assessment of Ethyl Tafluprostamide and Isopropyl Cloprostenate as used in Cosmetics – Wave 2

Enclosed is an assay in which subjects used an eyelash serum containing 0.0044% Isopropyl Cloprostenate for 8 mo (*data\_ProstaglandinAnalogues\_Wave2\_122023*). Please note, a summary of this assay was included in the report submitted to the Panel on November 9, 2023; however, at that time, the full study report had not been received (only summary data had been provided; *data20\_ProstaglandinAnalogues\_122023*; pdf page 753 in the original Prostaglandin Analogues submission to the Panel). Therefore, the full version of this study is being provided herein as Wave 2.

In addition, a report submitted to the Panel on November 9, 2023 included the following statement: “Ethyl Tafluprostamide is found to have a moderate oral absorption potential. This estimation is based on a molecular weight of 452.5 g/mol, water solubility of 1.05 g/l, and a log  $K_{ow}$  of 2.74” (*data1\_ProstaglandinAnalogues\_122023*; pdf page 67 in the original Prostaglandin Analogues submission to the Panel). However, the molecular weight of Ethyl Tafluprostamide is not 452.5 g/mol, but is 437.5 g/mol (the molecular weight of Tafluprost is a 452.5 g/mol). CIR staff requested clarification, and according to email correspondence, the reference to a molecular weight of 452.5 g/mol was found to be a typographical error. However, submitters stated that the marginal difference in molecular weight between Ethyl Tafluprostamide and Tafluprost would not affect the assessment, and therefore, Ethyl Tafluprostamide is still estimated to have a moderate oral absorption potential.

Comments on the Draft Tentative report have been received from Council. These comments may be found herein as *PCPCcomments\_ProstaglandinAnalogues\_Wave2\_122023*.



## Memorandum

**TO:** Bart Heldreth, Ph.D.  
Executive Director - Cosmetic Ingredient Review

**FROM:** Alexandra Kowcz, MS, MBA  
Industry Liaison to the CIR Expert Panel

**DATE:** November 16, 2023

**SUBJECT:** Draft Tentative Report: Safety Assessment of Ethyl Tafluprostamide and Isopropyl Cloprostenate as Used in Cosmetics (draft prepared for the December 2023 meeting)

The Personal Care Products Council respectfully submits the following comments on the draft tentative report, Safety Assessment of Ethyl Tafluprostamide and Isopropyl Cloprostenate as Used in Cosmetics.

Abbreviations; Pupil Constriction – For ED<sub>5</sub>, either the abbreviation or the definition is not correct. ED<sub>50</sub> is a median effective dose. The Pupil Constriction section says: “Potency was expressed as an ED<sub>5</sub> value which represents the dose estimated to produce a 5 unit area (mm\*hr) in a graph of the difference in pupil diameter in the dosed eye versus time (or median effective dose).” This section also is incorrectly calling ED<sub>5</sub> a median effective dose (5 should be 50 if it is representing a median). As noted in the text the study authors appear to have defined ED<sub>5</sub> as the dose estimated to produce a 5 unit area difference. If ED<sub>5</sub> is left in the Abbreviations table, it should be defined as it is defined in the text of the report. The abstract of reference 24 uses the term EC<sub>50</sub> a median effective concentration.

Composition and Impurities – The composition of a finished product does not belong in the section on composition and impurities. This information should be deleted from the report as it adds no useful information regarding the safety of Ethyl Tafluprostamide. If it is left in the report, it should be presented in the Cosmetic Use section.

DART, Parenteral, Isopropyl Cloprostenate; Summary – It is not clear what is meant by “reduced spermatozoa” and “decreased spermatozoa”. Were sperm numbers reduced or was the size of the sperm reduced?

Ocular Pigmentation and Periorbital Volume – It should be clearly stated that the eyelash serum containing 0.0044% Isopropyl Cloprostenate was used daily for 8 months. Currently, it just

states that the subjects were evaluated for 8 months with no information about the use of the product.

Endocrine Activity; Summary – Was there any information about what type of endocrine activity was predicted by the models?

Ocular Irritation; Summary; Table 5 – The eyelash product containing 0.018% Ethyl Tafluprostamide was tested in the HET-CAM (reference 6). It is not correct to state that the “test concentration was not stated”.

Summary – When discussing the DART studies in the summary, please either indicate that the treated mice and rats were males, or change “gonads” to testes to indicate that these studies were only in males.



# FINAL REPORT

**CLIENT:**



**ATTENTION:**



**TEST:**


Ophthalmological In-Use Safety Evaluation of an Eyelash Serum  
Protocol No.: LPQU01-002  
Protocol Date: 10/31/22


lash serum containing 0.0044% Isopropyl Cloprostenate


**TEST MATERIAL:**




**STUDY NUMBER:**



Reviewed by:  M.D.  
Board Certified Ophthalmologist




Approved by:  R.N.  
Executive Vice President, Clinical Evaluations

Revision Date: 11/3/2023



FDA Registration# 1000151293  
DEA Registration# RC0198744 Schedule I-V  
US EPA/NJ DEP Registration# NJD982726648  
ISO/IEC 17025:2017 Accredited





FDA Registration# 1000151293  
DEA Registration# RC0199744 Schedule I-V  
US EPA/RI DEP Registration# H10802726648  
ISO/IEC 17025:2017 Accreditation # 80971

## QUALITY ASSURANCE UNIT STATEMENT

Study Number: [REDACTED]

The Consumer Product Testing Company, Incorporated (CPTC) Quality Assurance Unit (QAU) is responsible for auditing the conduct, content and reporting of all clinical trials that are conducted at CPTC.

This trial has been conducted in accordance with the Declaration of Helsinki, the ICH Guideline E6 for *Good Clinical Practice*, the requirements of 21 CFR Parts 50 and 56, other applicable laws and regulations, CPTC Standard Operating Procedures, and the approved protocol.

The CPTC QAU has reviewed all data, records, and documents relating to this trial and also this Final Report. The following QAU representative signature certifies that all data, records, and documents relating to this trial and also this Final Report have been reviewed and are deemed to be acceptable, and that the trial conforms to all of the requirements as indicated above.

All records and documents pertaining to the conduct of this trial shall be retained in the CPTC archives for a minimum of five (5) years. At any time prior to the completion of the fifth archival year, a Sponsor may submit a written request to the CPTC QAU to obtain custody of trial records once the CPTC archive period has been completed. This transfer shall be performed at the Sponsor's expense. In the absence of a written request, trial-related records shall be destroyed at the end of the CPTC archive period with no further notice in a manner that renders them useless.

[REDACTED]  
\_\_\_\_\_  
Quality Assurance Representative

11-3-2023  
Date

[REDACTED]


- Objective:** The primary objective of the trial was to evaluate the safety and ocular irritation potential of an eyelash serum, when subjected to in-use conditions over a 1-month, 2-month, 4-month and 8-month period.
- The secondary objectives of the trial were: (i) to evaluate the potential for change in ocular pigmentation over a 1-month, 2-month, 4-month and 8-month period; and (ii) to evaluate the potential for periorbital fat loss over the same period.
- Participants:** One-hundred twenty female subjects, ranging in age from 18 to 55 years, were recruited and qualified for this trial. One-hundred fourteen subjects completed the trial.
- Subject #7 was a protocol violator and was removed from the trial.
  - Subject #s 58, 81 and 85 did not complete the trial due to personal reasons unrelated to test material use.
  - Subject #s 83 and 113 were removed from the trial by the Principal Investigator due to adverse events.
- Inclusion Criteria:**
1. Subjects who read, signed, and dated an Informed Consent Form that included a HIPAA statement;
  2. Female subjects aged 18 to 55 years, inclusive;
  3. Subjects who were willing to arrive at each Testing Facility visit with a clean face, wearing no eye make-up;
  4. Subjects who were considered dependable and able to follow directions; and
  5. Subjects must have signed a Non-Disclosure/Confidentiality Agreement (“N-DA”) agreeing to keep their participation in the study confidential.
- Exclusion Criteria:**
1. Subjects who were in ill health, as determined by the Principal Investigator;
  2. Subjects who were taking medication, other than birth control, such as any systemic or topical corticosteroids, immunosuppressants, anti-inflammatory, antihistamines, antibiotics, or other medication that, in the opinion of Investigator, may have influenced the purpose, integrity, or outcome of the trial;
  3. Subjects who were pregnant, planning to become pregnant, or lactating during the course of the trial;
  4. Subjects who experienced any type of ophthalmological issues within the past 6 months;
  5. Subjects who had facial tattoos, piercings, or scars that would have interfered with photographs;
  6. Subjects who had used eyelash serums within 6 months prior to trial initiation;

**Exclusion Criteria  
 (continued):**

7. Subjects who had permanent injectable fillers in and around the eye area within 12 months;
8. Subjects who had undergone any facial surgeries (e.g., eyebrow lift) within 3 months of trial initiation;
9. Subjects who had eyelash lifts, eyelash extensions, or eyelash tints;
10. Subjects who had any visible disease which might have been confused with a reaction to the test material;
11. Subjects who had a history of adverse reactions to cosmetics, OTC drugs, or other personal care products;
12. Subjects who introduced the use of any new cosmetic, toiletry, personal care products during the trial; or
13. Subjects who were prone to dry eyes, styes, or undergoing chemotherapy.

**Test Schedules:**

<u>Schedule</u>	<u>Initiation Date</u>	<u>Completion Date</u>	<u>Enrolled Subject #s</u>
1	January 5, 2023	August 17, 2023	1 - 46
2	January 26, 2023	September 7, 2023	47 - 94
3	February 9, 2023	September 15, 2023	95 - 121

**Test Material:**
 Lash Enhancing Serum

**Trial Design:**

This was a single-center, baseline controlled, monadic clinical trial design of 8 months duration.

Descriptions of the trial timepoints are shown below:

Description	Baseline (Day 0) Supervised Application	Test Phase (1-Month)	Test Phase (2-Months)	Test Phase (4-Months)	Test Phase (8-Months)
Board Certified Ophthalmologist Evaluations	X	X	X	X	X
VISIA-CR <sup>®</sup> , Digital Imaging	X	X	X	X	X
Aeva 3D HE Imaging - Periorbital Volume Measurement	X	X	X	X	X
Distribution of Test Material, Daily Diaries, and Instruction for Use	X				
Return of unused Test Material and completed Daily Diaries					X

**Instrumentation:****Environmentally-Controlled Rooms**

The environmentally controlled rooms used were maintained at a temperature of  $70 \pm 5$  °F ( $21.1 \pm 2.8$ °C) and at a relative humidity of  $40 \pm 5\%$ . Readings of temperature and humidity were electronically recorded with at least a 15-minute frequency.

Each subject equilibrated in the environmentally controlled room for at least 15 minutes prior to all measurements and photographs. All measurements were taken under these conditions.

**VISIA-CR®, Digital Imaging**

The VISIA-CR®, took a series of standardized, reproducible digital facial images, inside of a controlled lighting environment. Subject positioning was critical and was repeated at each time point. Items such as stool height and careful placement of the subject's chin and forehead into the imaging device was maintained. Also, the subject's hair was off their face, jewelry removed, and a black drape was used to standardize clothing.

Only the subjects' front view was captured with their eyes open using the following lighting parameters. Subjects removed contact lenses prior to image capture.

- Standard 1 - General purpose white light
- Standard 2 - Flat lighting
- Cross-polarized – Filters out surface reflections for superior visualization of sub-surface detail

Using the VISIA-CR®, a trained Bioinstrumentation technician captured standardized digital images of the eyes at baseline, after 1 month, 2 months, 4 months, and 8 months of test material usage. At the conclusion of the trial, all digital images were provided to the Sponsor.

The images captured with the VISIA-CR® were catalogued using MIRROR PhotoTools software (Canfield Scientific, Inc., Parsippany, NJ). The images for each subject were exported as a .dx2 file. These files were used for analysis using the VAESTRO™ Image analysis Toolkit. Color Analysis was performed, overall color was evaluated using  $\Delta E$ , where  $\Delta E = \sqrt{[(\Delta L^*)^2 + (\Delta a^*)^2 + (\Delta b^*)^2]}$ . Therefore, an increase in  $\Delta E$  represented an increase in color from baseline.

**Aeva<sup>3D</sup> -HE**

Aeva<sup>3D</sup>-HE is a high resolution, 3D Solution, measurement system for face topography, skin topography, and body morphological changes.



**Instrumentation  
(continued):**

Subjects were in a seated position in the Visio-4D bench for stable and repeatable alignment of the outer canthus area. The subjects' position was noted for re-positioning between the measurement time points, to ensure reliable and repeatable results.

The seating platform was remotely operated so that subjects could place the earplugs (part of Aeva<sup>3D</sup>-HE, aiding with positioning) into their ears comfortably. Subjects were asked to make fine adjustments so that a green laser light emits through the lip corners. A plate was placed behind the subjects' head. As subjects were not able to move while taking the images, images were not captured until subjects' positioning and comfort was achieved.

Front view Aeva<sup>3D</sup>-HE images were captured, using the 250 FOV Lens, for each subject. The view captured the subject's left and right orbital region. These images were used to assess measurements in periorbital volume.

Using Aeva<sup>3D</sup>-HE, a trained Bioinstrumentation technician captured images at Baseline (pre-application) and after 1, 2, 4, and 8 months of test material usage.

**Methodology:****Qualification (Day 0)**

Potential subjects reported to the Testing Facility at their scheduled appointment time, with a clean face, wearing no eye or face make-up and executed an Informed Consent Form to become subjects. Subjects executed a Photographic Release Form and a Non-Disclosure Agreement.

The informed consent process fully appraised each potential subject of the risks and benefits associated with the research clinical trial and of the confidentiality requirements relating to the subject's clinical trial records. If the potential subject agreed to participate in the research clinical trial, then the potential subjects executed the Informed Consent Form (ICF). Staff who conducted the informed consent process also executed the form, after which the potential subject entered the clinical trial as a subject. Each subject received a signed copy of the fully executed ICF.

If at any time during the clinical trial the subject had questions, the ICF directed the subject to a Subject Rights Advocate, whose contact information was in the Informed Consent Form.

Subjects completed a Medical History Form to determine initial qualification.

**Methodology  
(continued):**

Subjects were screened by a Board-Certified Ophthalmologist to determine qualification. The Ophthalmologist studied and evaluated by gross and/or slit lamp examination each subject's eyelids, conjunctivae, corneas, anterior chambers, and pupillary reactions, in addition to measuring visual acuity. Observations also included evaluations of dryness, erythema, and edema which were recorded on CRFs. If applicable, the correct fit and condition of their contact lenses were evaluated. Findings were noted on individual subject CRFs.

**Evaluation Key:**

0	None
0.5	Barely perceptible
1	Mild
2	Moderate
3	Marked
4	Severe

Subjects presenting a score of moderate (2) or greater for erythema, edema, or dryness were disqualified. All evaluation scores were recorded on CRFs.

**Test Phase (Day 0)**

Qualified subjects acclimated, in an environmentally controlled room, for at least 15 minutes. A Bioinstrumentation technician captured VISIA-CR and Aeva<sup>3D</sup>-HE images, as previously described.

Subjects were provided with an 8-month supply of the test material and a daily diary to document compliance and use. Written and verbal instructions for use and restrictions (listed below), supplied by the Sponsor, were provided to each subject. Subjects conducted the first application under Clinical Supervision.

**Instructions:**

- Arrive at each Testing Facility visit with a clean face, wearing no eye make-up.
- DO NOT use any eyelash serum other than the test material provided for the duration of this trial.
- You may wear your usual facial makeup products during the trial.
- Eyelash treatments such as eyelash lifts, eyelash extensions, and eyelash tints are prohibited during the trial.
- DO NOT introduce any new cosmetics, toiletry, or personal care products during the trial.
- CONTACT WEARERS: bring a contact lens case with solution to each visit. Contact lenses must be worn for the eye examination and then removed for image capture.

**Methodology  
(continued):**

Instructions for Use: (Once Daily)

- Apply once daily on clean, dry upper lash line only using a single stroke on your eyelid just above your upper lash line (like a liquid eyeliner).
- Do not apply to the lower lash line.
- Apply only with the product applicator.
- Use one dip into the bottle for both eyes and allow 1-2 minutes for the serum to fully dry before applying other products to your eye area.
- Use sparingly as dripping into the eye may cause irritation or other unwanted effects. If serum drips into the eye, immediately rinse thoroughly with cool water to completely remove serum from the eye.
- Apply every day for at least 3 months. After desired improvement is achieved, apply every other day for maintenance.
- The serum requires continued use to maintain benefits.

Keep out of reach of children. Do not let anyone else use the test material.

After each application of the test material, record the time under the APPLICATION column of the daily diary.

Report any adverse reactions or problems immediately to the Testing Facility staff.

Subjects were encouraged to document comments pertaining to the test material in their daily diaries.

Subjects agreed to use only the test material for all eyelash enhancement purposes for the duration of the trial. Eyelash treatments such as eyelash lifts, eyelash extensions, and eyelash tints were prohibited during the trial. Subjects were allowed to wear their usual facial makeup products during the trial. Subjects may not have introduced any new cosmetic, toiletry, or personal care products during the course of the trial.

**Test Phase (1 Month)**

After 1 month of test material use, subjects reported to the Testing Facility at their scheduled appointment time with a clean face, wearing no eye make-up.

The Board-Certified Ophthalmologist conducted an evaluation of each subject, as previously described.

Subjects acclimated in an environmentally controlled room, for at least 15 minutes. A Bioinstrumentation technician captured VISIA-CR and Aeva<sup>3D</sup>-HE images, as previously described.

**Methodology  
(continued):**

**Test Phase (2 Months)**

After 2 months of test material use, subjects reported to the Testing Facility at their scheduled appointment time with a clean face, wearing no eye make-up.

The Board-Certified Ophthalmologist conducted an evaluation of each subject, as previously described.

Subjects acclimated in an environmentally controlled room, for at least 15 minutes. A Bioinstrumentation technician captured VISIA-CR and Aeva<sup>3D</sup>-HE images, as previously described.

**Test Phase (4 Months)**

After 4 months of test material use, subjects reported to the Testing Facility at their scheduled appointment time with a clean face, wearing no eye make-up.

The Board-Certified Ophthalmologist conducted an evaluation of each subject, as previously described.

Subjects acclimated in an environmentally controlled room, for at least 15 minutes. A Bioinstrumentation technician captured VISIA-CR and Aeva<sup>3D</sup>-HE images, as previously described.

**Test Phase (8 Months)**

After 8 months of test material use, subjects reported to the Testing Facility at their scheduled appointment time with a clean face, wearing no eye make-up.

Any unused test material and completed daily diaries were returned. Daily diaries were reviewed for completeness and retained by the Testing Facility.

The Board-Certified Ophthalmologist conducted a final evaluation of each subject, as previously described.

Subjects acclimated in an environmentally controlled room, for at least 15 minutes. A Bioinstrumentation technician captured VISIA-CR and Aeva<sup>3D</sup>-HE images, as previously described.

**Amendments:**

**Amendment 1**

OLD VERSION:

5.2 Inclusion Criteria

3. Subjects must be willing to arrive at each Testing Facility with a clean face, wearing no eye make-up;

**Amendments  
(continued):**

5. Subjects shall signed a Non-Disclosure/Confidentiality Agreement (“NDA”) agreeing to keep their participation in the study confidential.

NEW VERSION:

5.2 Inclusion Criteria

3. Subjects must be willing to arrive at each Testing Facility visit with a clean face, wearing no eye make-up;
5. Subjects must sign a Non-Disclosure/Confidentiality Agreement (“N-DA”) agreeing to keep their participation in the study confidential.

ADDITION:

6.2.2 VISIA-CR®, Digital Imaging

Subjects will remove contact lenses prior image capture.

OLD VERSION:

6.2.3 Aeva3D -HE

Aeva3D-HE images will be captured, using the 160 FOV Lens, of the left and right sides of each subject’s left and right orbital region. The images will be used to assess measurements in periorbital volume.

NEW VERSION:

6.2.3 Aeva3D -HE

Front view Aeva3D-HE images will be captured, using the 250 FOV Lens, for each subject. This view will capture the subject’s left and right orbital region. These images will be used to assess measurements in periorbital volume.

REASON FOR CHANGE: To correct typographical errors and update image capture parameters.

**Amendment 2**

OLD VERSION:

6.4 Test Phase (Day 0)

**Amendments  
(continued):**

Instructions for Use: (Once Daily)

- Dip applicator into tube once for both eye applications.
- Apply once daily on a clean, dry upper eyelash line using a single stroke. (ex: apply like a liquid eyeliner)
- Allow 1-2 minutes for serum to dry

NEW VERSION:

6.4 Test Phase (Day 0)

Instructions for Use: (Once Daily)

- Apply once daily on a clean, dry upper eyelash line using a single stroke. (ex: apply like a liquid eyeliner)
- Allow 1-2 minutes for serum to dry before applying other products to your eye area.
- Use sparingly as dripping into the eye may cause irritation or other unwanted effects.
- If serum drips into the eye, immediately rinse thoroughly with cool water to completely remove serum from the eye.
- Apply every day for at least 3 months. After desired improvement is achieved, apply every other day for maintenance.
- The serum requires continued use to maintain benefits.

REASON FOR CHANGE: Per client request.

**Deviations:**

Subject #7 was enrolled in Schedule 1 of the trial. The subject deceptively presented as a new panelist at a later date and was enrolled a second time on the trial as subject # 51. On the medical history form as Subject # 51 the subject falsely stated she was not using an eyelash serum within the past 6 months. Due to the subject's deceptive behavior, Subject # 7/51 was removed from the trial by the Principal Investigator.

Per protocol, the environmentally controlled rooms were to be maintained at a relative humidity of  $40 \pm 5\%$ . However, the following excursions in relative humidity occurred:

- On 4/6/2023 - 10 minutes excursion with maximum RH of 48.3% for the AP room
- On 8/17/2023 - 30 minutes excursion with maximum RH of 49.5% for the AP room
- On 9/7/2023 - 122 minutes excursion with maximum RH of 50.8% for the AP room and 46% for the AEVA room.

The Principal Investigator deemed these excursions to have no impact on trial results.

**Deviations  
(continued):**

Subject #s 103, 116, and 117 ended the trial 8 days earlier than initially scheduled and Subject #s 95-102, 104-112, 114, 115, 118-121 ended the trial 6 days earlier than initially scheduled due to the Board-Certified Ophthalmologist's availability. It was the opinion of the Principal Investigator that a few days difference for a 8 month trial did not impact trial results.

**Adverse Events:**

Subject #83 complained of left eye swelling that started on 1/27/23. Itching occurred on both lids on 1/27/23 and swelling of the right lid started on 1/31/23. Symptoms were reported on 2/2/23 and the Board-Certified Ophthalmologist examined the Subject on this date. The Ophthalmologist reported the Subject had meibomian gland dysfunction in both eyes. No erythema was noted on lids or eyes. The Subject was removed from the trial and instructed to seek follow up with her ophthalmologist if symptoms persisted. A follow-up phone call with the Subject on 2/13/23 revealed that all symptoms had resolved, and she did not deem it necessary to follow-up with her doctor. It was the opinion of the Principal Investigator that this event was probably test material related.

Subject #36 complained of a "ball" on the upper left eyelid on 3/2/23. Upon observation by the Board-Certified Ophthalmologist, an early hordeolum/chalazion on the left upper lid was found. The Ophthalmologist recommended warm compresses to the area. The Subject followed up by telephone and sent images to the testing facility on 3/9/23. All symptoms were resolved per subject and ophthalmologist. No further complaints were noted, and the subject continued on the trial. This event is considered resolved. It was the opinion of the Principal Investigator that this event was possibly test material related.

Subject #38 stated on 8/17/23, Month 8 visit, that 2 weeks prior she had sand blown into her eyes which caused irritation. Upon observation, the Board-Certified Ophthalmologist reported probable conjunctivitis, right eye greater than left with no corneal abrasion or adenopathy noted. The subject was recommended to see her eye doctor for follow up. The subject visited her eye doctor on 8/18/23 and was prescribed Tobramycin eye drops twice a day. All symptoms resolved as of 8/21/23 per subject, per telephone conversation on 8/22/23. This event is considered resolved. It was the opinion of the Principal Investigator that this event was unlikely related to the test material.

Subject #113 was evaluated by the Ophthalmologist at her 8-week visit and was diagnosed with conjunctivitis of her right eye and removed from the trial. A follow-up phone conversation on 4/11/23 revealed that all symptoms resolved as of 4/10/23. The subject did not follow-up with her primary doctor and had no further complaints. This event is considered resolved. It was the opinion of the Principal Investigator that this event was possibly test material related.

**Statistical Analysis:**

Within-groups statistical analysis was performed on the mean calculated  $\Delta E$  values from the VISIA-CR<sup>®</sup> image analysis color data, and the periorbital volume measurements (total volume change) obtained from the Aeva3D-HE instrument. Prior to performing the analyses, diagnostic tests on the data was performed to determine whether normality and/or homogeneity of variances of the data are maintained. If the above conditions were maintained, a parametric Student's t-Test or Analysis of Variance was performed. If any of the above conditions were not maintained, a non-parametric equivalent to the above statistical tests was utilized. If statistical significance was observed and further statistical comparisons were required, multiple comparison testing was performed and appropriate adjustments to the  $p$ -values were made accordingly. For all of the above analyses, statistical significance was achieved at the 95% Confidence Level ( $p < 0.050$ ).

**Revisions:**

At the client's request, the comments recorded by the subject in the daily diary were removed from the body of the report. The diaries are provided under separate cover. In addition, the summary was updated to include the RGB color space results to the summary section of the report.

**Results:**

Subject demographics are presented in Table 1.

Dermatological evaluations at baseline and after 1, 2, 4, and 8 months of test material usage are presented in Table 2.

- Dermatological examinations remained within normal limits throughout the test interval.

Statistical Analysis of Aeva3D-HE Positive volume (mm<sup>3</sup>) values are presented in Table 3.

**Left Orbital Region:**

- When compared to baseline values for the left orbital side, there was a statistically significant decrease in volume after 1 month of test material use. There were no statistically significant differences in the left orbital volume after 2, 4, and 8 months of test material use.

**Right Orbital Region:**

- When compared to baseline values for the right orbital side, there was a statistically significant decrease in volume after 1 and 4 months of test material use. There were no statistically significant differences in the right orbital volume after 2 and 8 months of test material use.

VISIA-CR Image Analysis Color Data is presented in Table 4.



**Results  
(continued):****For the Left Iris:**

- When compared to baseline values, there were no statistically significant differences in R/RGB (red color), G/RGB (green color), or B/RGB (blue color) values after 1, 2, 4, and 8 months of test material use.

When compared to baseline values, there was a statistically significant increase in the overall color change ( $\Delta E$ ) of the iris after 1, 2, 4, and 8, months of test material use. There were no statistically significant differences in L\* (luminosity) values after 1, 2, 4, and 8, months of test material use. There were no statistically significant differences in a\* (redness) values after 1, 2, and 4 months of test material use.

However, there was a statistically significant increase in a\* (redness) values after 8 months of test material use. There were no statistically significant differences in b\* (yellowness) values after 1 and 2 months of test material use. However, there was a statistically significant increase in b\* (yellowness) values after 4 and 8 months of test material use.

**For the Right Iris:**

- When compared to baseline values, there were no statistically significant differences in R/RGB (red color) after 1, 2, 4, and 8 months of test material use. When compared to baseline values, there were no statistically significant differences in G/RGB (green color) or B/RGB (blue color) after 1, 2, and 8 months of test material use. However, there was a statistically significant decrease in G/RGB (green color) and B/RGB (blue color) after 4 months of test material use.
- When compared to baseline values, there was a statistically significant increase in the overall color change ( $\Delta E$ ) of the iris after 1, 2, 4, and 8, months of test material use. There were no statistically significant differences in L\* (luminosity) values after 1, 2, 4, and 8, months of test material use. There were no statistically significant differences in a\* (redness) values after 1 and 2 months of test material use. However, there was a statistically significant increase in a\* (redness) values after 4 and 8 months of test material use. There were no statistically significant differences in b\* (yellowness) values after 1, 2, and 4 months of test material use. However, there was a statistically significant increase in b\* (yellowness) values after 8 months of test material use.

Subject daily diaries are provided under separate cover.

**Results  
 (continued):**

Transcribed ophthalmologist examination records and comments are provided under separate cover.

The following are *observations made by the ophthalmologist* between different trial timepoints. Note: for details pertaining to Adverse Events, see the Adverse Events section of this report:

Subject #	Comment / Observation
<b>Baseline – 1 Month</b>	
83	Meibomian gland dysfunction in both eyes *AE*
113	Erythema right and left conjunctiva
<b>1 Month – 2 Months</b>	
6	Cornea: Punctate epithelial erosion right
8	Cornea: Punctate epithelial erosion right and left
9	Conjunctiva: Mild conjunctival erythema both eyes
10	Conjunctiva: Mild conjunctival erythema both eyes
19	Cornea: Punctate epithelial erosion left inferior
26	Started a new prescription for glasses which improved her visual acuity score from 50-1/50-1 to 25/20
30	Plus 1 right eye tarsal erythema
34	Plus 1 bilateral tarsal erythema
36	Left upper lid chalazion *AE*
50	Lids: Increased meibomian gland dysfunction right and left
52	Cornea: Right and left punctate epithelial erosion
93	Conjunctiva: Mild erythema right and left
103	Lids: Meibomian gland dysfunction right and left
113	Conjunctivitis: right eye *AE*
<b>2 Months – 4 Months</b>	
40	Conjunctiva: Mild conjunctival erythema
45	Tarsal follicles bilateral
53	Conjunctiva: Mild erythema right and left
64	Conjunctiva: Mild erythema right and left
101	Conjunctiva: Conjunctival erythema and papillae
111	Conjunctiva: Conjunctival erythema
115	Conjunctiva: erythema right greater than left
120	Conjunctiva: Mild erythema and papillae
<b>4 Months – 8 Months</b>	
38	Conjunctiva: erythema right greater than left Cornea: Punctate epitheliopathy right eye *AE*
93	Lids: Meibomian gland dysfunction right and left
101	Conjunctiva: Erythema conjunctiva bilateral

**Summary:**

Under the conditions of this trial, 8 months of once daily usage of test material, [REDACTED] Lash Enhancing Serum, the following conclusions can be made:

- Safe for contact lens and non-contact lens wearers.
- Slight potential for transient ophthalmologic irritation.
- The total color change ( $\Delta E$ ) from baseline indicated a change in the color of the iris. When evaluating the individual color components, there were increases in the  $a^*$  and  $b^*$  values, red and yellow, respectively, after 8 months of usage. Although these increases were statistically significant, they were not clinically relevant.
- After 8 months of usage there were no statistically significant changes in the RGB color space values of the iris.
- After 8 months of usage there was no change in periorbital volume from baseline.

**Table 1**  
**Subject Demographics**

<b>Subject #</b>	<b>Subject ID</b>	<b>Age</b>	<b>Contact Lens</b>
1	56135	53	No
2	87855	50	No
3	88888	18	No
4	86779	54	No
5	89104	52	No
6	88905	30	No
7	92956	54	No
8	92429	44	No
9	58976	31	No
10	91854	41	No
11	91927	54	No
12	75855	28	No
13	69699	37	No
14	66875	43	No
15	92592	41	No
16	87173	45	No
17	64690	18	No
18	92994	47	No
19	93102	35	No
20	25118	45	Yes (Soft)
21	72896	55	No
22	92978	22	No
23	85372	53	No
24	77457	39	No
25	89254	32	No
26	90669	53	No
27	68629	44	No
28	93146	41	No
29	47917	51	No
30	93150	40	No
31	93151	48	No
32	49868	55	Yes (Soft)
33	92615	40	No
34	76837	32	Yes (Soft)
35	89198	40	No

Did Not Complete: Subject #7, 58, 81, 83, 85 and 113

**Table 1**  
**(continued)****Subject Demographics**

<b>Subject #</b>	<b>Subject ID</b>	<b>Age</b>	<b>Contact Lens</b>
36	80522	39	No
37	92575	43	No
38	92096	53	No
39	63350	20	No
40	93162	30	No
41	91523	40	No
42	66549	42	No
43	84377	53	No
44	92895	44	No
45	93104	51	No
46	60209	47	Yes (Soft)
47	21096	55	No
48	93197	47	No
49	47949	41	No
50	92889	37	No
52	92706	25	No
53	39164	43	No
54	93153	35	No
55	71893	51	No
56	91393	37	No
57	90080	36	No
58	93083	26	No
59	91137	33	No
60	92158	52	No
61	93210	32	Yes (Soft)
62	88490	40	Yes (Soft)
63	87998	33	No
64	93160	37	No
65	46058	40	No
66	70499	29	No
67	93152	42	No
68	91812	41	No

Did Not Complete: Subject #7, 58, 81, 83, 85 and 113

\*Deviation: #51 – Subject # and data removed from the trial.

**Table 1**  
**(continued)****Subject Demographics**


<b>Subject #</b>	<b>Subject ID</b>	<b>Age</b>	<b>Contact Lens</b>
69	56034	41	No
70	80386	32	No
71	63555	29	No
72	93198	31	No
73	92065	40	No
74	91636	34	Yes (Soft)
75	93018	42	No
76	77962	39	Yes (Soft)
77	90494	54	No
78	60639	46	No
79	92756	50	No
80	90099	41	No
81	78294	47	No
82	93044	37	No
83	93196	27	No
84	91200	43	No
85	92803	29	No
86	71209	52	No
87	91745	44	No
88	58577	52	No
89	92282	23	No
90	4284	52	No
91	92854	40	No
92	48073	49	No
93	92836	45	No
94	45824	52	No
95	61969	54	No
96	84567	54	No
97	92840	33	No
98	76099	54	No
99	92770	22	No
100	93235	45	No
101	93229	46	No
102	66648	32	Yes (Soft)

Did Not Complete: Subject #7, 58, 81, 83, 85 and 113

**Table 1**  
**(continued)****Subject Demographics**

<b>Subject #</b>	<b>Subject ID</b>	<b>Age</b>	<b>Contact Lens</b>
103	75527	55	No
104	81232	51	No
105	92715	46	Yes (Soft)
106	47011	44	No
107	67311	54	No
108	62190	53	No
109	93213	53	No
110	93234	44	No
111	65407	55	No
112	42734	47	No
113	92456	38	No
114	91044	48	No
115	84560	55	No
116	87722	44	No
117	91445	44	No
118	72693	46	No
119	67863	42	No
120	92316	53	No
121	84404	51	Yes (Soft)

Did Not Complete: Subject #7, 58, 81, 83, 85 and 113

**Table 2****DERMATOLOGICAL EVALUATIONS – QUALIFICATION (DAY 0)****TEST SITE:** Eyelid (along upper lash line)**TEST MATERIAL:**  Lash Enhancing Serum**EVALUATION SCALE**

0 = NONE

0.5 = BARELY PERCEPTIBLE

1 = MILD

2 = MODERATE

3 = MARKED

4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

	Subject # & ID	ERYTHEMA		EDEMA		DRYNESS		COMMENTS
		Right	Left	Right	Left	Right	Left	
1.	56135	0	0	0	0	0	0	
2.	87855	0	0	0	0	0	0	
3.	88888	0	0	0	0	0	0	
4.	86779	0	0	0	0	0	0	
5.	89104	0	0	0	0	0	0	
6.	88905	0	0	0	0	0	0	
7.	92956	0	0	0	0	0	0	
8.	92429	0	0	0	0	0	0	
9.	58976	0	0	0	0	0	0	
10.	91854	0	0	0	0	0	0	
11.	91927	0	0	0	0	0	0	
12.	75855	0	0	0	0	0	0	
13.	69699	0	0	0	0	0	0	
14.	66875	0	0	0	0	0	0	



**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – QUALIFICATION (DAY 0)**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

0 = NONE

0.5 = BARELY PERCEPTIBLE

1 = MILD

2 = MODERATE

3 = MARKED

4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

	Subject # & ID	ERYTHEMA		EDEMA		DRYNESS		COMMENTS
		Right	Left	Right	Left	Right	Left	
15.	92592	0	0	0	0	0	0	
16.	87173	0	0	0	0	0	0	
17.	64690	0	0	0	0	0	0	
18.	92994	0	0	0	0	0	0	
19.	93102	0	0	0	0	0	0	
20.	25118	0	0	0	0	0	0	
21.	72896	1	1	0	0	0	0	
22.	92978	0	0	0	0	0	0	
23.	85372	0	0	0	0	0	0	
24.	77457	0	0	0	0	0	0	
25.	89254	0	0	0	0	0	0	
26.	90669	1	1	0	0	1	1	
27.	68629	0	0	0	0	0	0	
28.	93146	0	0	0	0	0	0	

**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – QUALIFICATION (DAY 0)**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

0 = NONE

0.5 = BARELY PERCEPTIBLE

1 = MILD

2 = MODERATE

3 = MARKED

4 = SEVERE


**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID	ERYTHEMA		EDEMA		DRYNESS		COMMENTS
	Right	Left	Right	Left	Right	Left	
29. 47917	0	0	0	0	0	0	
30. 93150	0	0	0	0	0	0	
31. 93151	0	0	0	0	0	0	
32. 49868	1	1	0	0	0	0	
33. 92615	0	0	0	0	0	0	
34. 76837	0	0	0	0	0	0	
35. 89198	0	0	0	0	1	1	
36. 80522	0	0	0	0	0	0	
37. 92575	0	0	0	0	0	0	
38. 92096	0	0	0	0	1	1	
39. 63350	0	0	0	0	0	0	
40. 93162	0	0	0	0	0	0	
41. 91523	0	0	0	0	0	0	
42. 66549	0	0	0	0	0	0	

**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS -- QUALIFICATION (DAY 0)**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

0 = NONE

0.5 = BARELY PERCEPTIBLE

1 = MILD

2 = MODERATE

3 = MARKED

4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID	ERYTHEMA		EDEMA		DRYNESS		COMMENTS
	Right	Left	Right	Left	Right	Left	
43. 84377	0	0	0	0	0	0	
44. 92895	0	0	0	0	0	0	
45. 93104	0	0	0	0	0	0	
46. 60209	0	0	0	0	1	1	
47. 21096	0	0	0	0	0	0	
48. 93197	0	0	0	0	0	0	
49. 47949	0	0	0	0	0	0	
50. 92889	0	0	0	0	0	0	
51. *	*	*	*	*	*	*	
52. 92706	0	0	0	0	0	0	
53. 39164	1	1	0	0	0	0	
54. 93153	0	0	0	0	0	0	
55. 71893	0	0	0	0	0	0	
56. 91393	0	0	0	0	0	0	

\*#51 will not be used – deviation\*

**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – QUALIFICATION (DAY 0)**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

- 0 = NONE  
 0.5 = BARELY PERCEPTIBLE  
 1 = MILD  
 2 = MODERATE  
 3 = MARKED  
 4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID		ERYTHEMA		EDEMA		DRYNESS		COMMENTS
		Right	Left	Right	Left	Right	Left	
57.	90080	1	1	0	0	0	0	
58.	93083	0	0	0	0	0	0	
59.	91137	0	0	0	0	0	0	
60.	92158	1	1	0	0	0	0	
61.	93210	0	0	0	0	0	0	
62.	88490	1	1	0	0	0	0	
63.	87998	0	0	0	0	0	0	
64.	93160	0	0	0	0	0	0	
65.	46058	0	0	0	0	0	0	
66.	70499	0	0	0	0	0	0	
67.	93152	0	0	0	0	0	0	
68.	91812	0	0	0	0	0	0	
69.	56034	0	0	0	0	0	0	
70.	80386	0	0	0	0	0	0	





**Table 2  
(continued)**

**DERMATOLOGICAL EVALUATIONS – QUALIFICATION (DAY 0)**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:** [Redacted] Lash Enhancing Serum

**EVALUATION SCALE**

- 0 = NONE
- 0.5 = BARELY PERCEPTIBLE
- 1 = MILD
- 2 = MODERATE
- 3 = MARKED
- 4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID		ERYTHEMA		EDEMA		DRYNESS		COMMENTS
		Right	Left	Right	Left	Right	Left	
85.	92803	0	0	0	0	0	0	
86.	71209	0	0	0	0	0	0	
87.	91745	0	0	0	0	0	0	
88.	58577	1	1	0	0	0	0	
89.	92282	0	0	0	0	0	0	
90.	4284	0	0	0	0	0	0	
91.	92854	0	0	0	0	0	0	
92.	48073	0	0	0	0	0	0	
93.	92836	1	1	0	0	0	0	
94.	45824	0	0	0	0	0	0	
95.	61969	0	0	0	0	0	0	
96.	84567	0	0	0	0	0	0	
97.	92840	0	0	0	0	0	0	
98.	76099	0	0	0	0	0	0	

**Table 2  
(continued)**

**DERMATOLOGICAL EVALUATIONS – QUALIFICATION (DAY 0)**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:** Lash Enhancing Serum

**EVALUATION SCALE**

- 0 = NONE
- 0.5 = BARELY PERCEPTIBLE
- 1 = MILD
- 2 = MODERATE
- 3 = MARKED
- 4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID		ERYTHEMA		EDEMA		DRYNESS		COMMENTS
		Right	Left	Right	Left	Right	Left	
99.	92770	0	0	0	0	0	0	
100.	93235	0	0	0	0	0	0	
101.	93229	0	0	0	0	0	0	
102.	66648	0	0	0	0	0	0	
103.	75527	0	0	0	0	0	0	
104.	81232	0	0	0	0	0	0	
105.	92715	0	0	0	0	0	0	
106.	47011	0	0	0	0	0	0	
107.	67311	0	0	0	0	0	0	
108.	62190	0	0	0	0	0	0	
109.	93213	0	0	0	0	0	0	
110.	93234	0	0	0	0	0	0	
111.	65407	0	0	0	0	0	0	
112.	42734	0	0	0	0	0	0	

**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – QUALIFICATION (DAY 0)**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

0 = NONE

0.5 = BARELY PERCEPTIBLE

1 = MILD

2 = MODERATE

3 = MARKED

4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID		ERYTHEMA		EDEMA		DRYNESS		COMMENTS
		Right	Left	Right	Left	Right	Left	
113.	92456	0	0	0	0	0	0	
114.	91044	0	0	0	0	0	0	
115.	84560	0	0	0	0	0	0	
116.	87722	0	0	0	0	0	0	
117.	91445	0	0	0	0	0	0	
118.	72693	0	0	0	0	0	0	
119.	67863	0	0	0	0	0	0	
120.	92316	0	0	0	0	0	0	
121.	84404	0	0	0	0	0	0	



**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – WEEK 4**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

0 = NONE

0.5 = BARELY PERCEPTIBLE

1 = MILD

2 = MODERATE

3 = MARKED

4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID	ERYTHEMA		EDEMA		DRYNESS		COMMENTS
	Right	Left	Right	Left	Right	Left	
1. 56135	0	0	0	0	0	0	
2. 87855	0	0	0	0	0	0	
3. 88888	0	0	0	0	0	0	
4. 86779	0	0	0	0	0	0	
5. 89104	0	0	0	0	0	0	
6. 88905	0	0	0	0	0	0	
7. 92956	-	-	-	-	-	-	Did Not Complete
8. 92429	0	0	0	0	0	0	
9. 58976	0	0	0	0	0	0	
10. 91854	0	0	0	0	0	0	
11. 91927	0	0	0	0	0	0	
12. 75855	0	0	0	0	0	0	
13. 69699	0	0	0	0	0	0	
14. 66875	0	0	0	0	0	0	



**Table 2  
(continued)**

**DERMATOLOGICAL EVALUATIONS – WEEK 4**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

- 0 = NONE
- 0.5 = BARELY PERCEPTIBLE
- 1 = MILD
- 2 = MODERATE
- 3 = MARKED
- 4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

	Subject # & ID	ERYTHEMA		EDEMA		DRYNESS		COMMENTS
		Right	Left	Right	Left	Right	Left	
15.	92592	0	0	0	0	0	0	
16.	87173	0	0	0	0	0	0	
17.	64690	1	1	0	0	0	0	
18.	92994	0	0	0	0	0	0	
19.	93102	0	0	0	0	0	0	
20.	25118	0	0	0	0	0	0	
21.	72896	0	0	0	0	0	0	
22.	92978	0	0	0	0	0	0	
23.	85372	0	0	0	0	0	0	
24.	77457	0	0	0	0	0	0	
25.	89254	0	0	0	0	0	0	
26.	90669	0	0	0	0	0	0	
27.	68629	0	0	0	0	0	0	
28.	93146	0	0	0	0	0	0	



**Table 2  
(continued)**

**DERMATOLOGICAL EVALUATIONS -- WEEK 4**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:** [Redacted] Lash Enhancing Serum

**EVALUATION SCALE**

- 0 = NONE
- 0.5 = BARELY PERCEPTIBLE
- 1 = MILD
- 2 = MODERATE
- 3 = MARKED
- 4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID		ERYTHEMA		EDEMA		DRYNESS		COMMENTS
		Right	Left	Right	Left	Right	Left	
29.	47917	0	0	0	0	0	0	
30.	93150	0	0	0	0	0	0	
31.	93151	0	0	0	0	0	0	
32.	49868	0	0	0	0	0	0	
33.	92615	0	0	0	0	0	0	
34.	76837	0	0	0	0	0	0	
35.	89198	0	0	0	0	0	0	
36.	80522	0	0	0	0	0	0	
37.	92575	0	0	0	0	0	0	
38.	92096	0	0	0	0	0	0	
39.	63350	0	0	0	0	0	0	
40.	93162	0	0	0	0	0	0	
41.	91523	0	0	0	0	0	0	
42.	66549	0	0	0	0	0	0	

**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – WEEK 4**

TEST SITE: Eyelid (along upper lash line)

TEST MATERIAL:  Lash Enhancing Serum

**EVALUATION SCALE**

- 0 = NONE
- 0.5 = BARELY PERCEPTIBLE
- 1 = MILD
- 2 = MODERATE
- 3 = MARKED
- 4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**


Subject # & ID	ERYTHEMA		EDEMA		DRYNESS		COMMENTS
	Right	Left	Right	Left	Right	Left	
43. 84377	0	0	0	0	0	0	
44. 92895	0	0	0	0	0	0	
45. 93104	0	0	0	0	0	0	
46. 60209	0	0	0	0	0	0	
47. 21096	0	0	0	0	0	0	
48. 93197	0	0	0	0	0	0	
49. 47949	0	0	0	0	0	0	
50. 92889	0	0	0	0	0	0	
51. *	*	*	*	*	*	*	
52. 92706	0	0	0	0	0	0	
53. 39164	0	0	0	0	0	0	
54. 93153	0	0	0	0	0	0	
55. 71893	0	0	0	0	0	0	
56. 91393	0	0	0	0	0	0	

\*#51 will not be used – deviation\*

**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – WEEK 4**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

0 = NONE

0.5 = BARELY PERCEPTIBLE

1 = MILD

2 = MODERATE

3 = MARKED

4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID		ERYTHEMA		EDEMA		DRYNESS		COMMENTS
		Right	Left	Right	Left	Right	Left	
57.	90080	0	0	0	0	0	0	
58.	93083	-	-	-	-	-	-	Did Not Complete
59.	91137	0	0	0	0	0	0	
60.	92158	0	0	0	0	0	0	
61.	93210	0	0	0	0	0	0	
62.	88490	0	0	0	0	0	0	
63.	87998	0	0	0	0	0	0	
64.	93160	0	0	0	0	0	0	
65.	46058	0	0	0	0	0	0	
66.	70499	0	0	0	0	0	0	
67.	93152	0	0	0	0	0	0	
68.	91812	0	0	0	0	0	0	
69.	56034	0	0	0	0	0	0	
70.	80386	0	0	0	0	0	0	



**Table 2  
(continued)**

**DERMATOLOGICAL EVALUATIONS – WEEK 4**

TEST SITE: Eyelid (along upper lash line)

TEST MATERIAL: [REDACTED] Lash Enhancing Serum

**EVALUATION SCALE**

- 0 = NONE
- 0.5 = BARELY PERCEPTIBLE
- 1 = MILD
- 2 = MODERATE
- 3 = MARKED
- 4 = SEVERE


**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID		ERYTHEMA		EDEMA		DRYNESS		COMMENTS
		Right	Left	Right	Left	Right	Left	
71.	63555	0	0	0	0	0	0	
72.	93198	0	0	0	0	0	0	
73.	92065	0	0	0	0	0	0	
74.	91636	0	0	0	0	0	0	
75.	93018	0	0	0	0	0	0	
76.	77962	0	0	0	0	0	0	
77.	90494	0	0	0	0	0	0	
78.	60639	0	0	0	0	0	0	
79.	92756	0	0	0	0	0	0	
80.	90099	0	0	0	0	0	0	
81.	78294	0	0	0	0	0	0	
82.	93044	0	0	0	0	0	0	
83.	93196	-	-	-	-	-	-	Did Not Complete
84.	91200	0	0	0	0	0	0	

**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – WEEK 4**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

0 = NONE

0.5 = BARELY PERCEPTIBLE

1 = MILD

2 = MODERATE

3 = MARKED

4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID		ERYTHEMA		EDEMA		DRYNESS		COMMENTS
		Right	Left	Right	Left	Right	Left	
85.	92803	-	-	-	-	-	-	Did Not Complete
86.	71209	0	0	0	0	0	0	
87.	91745	0	0	0	0	0	0	
88.	58577	0	0	0	0	0	0	
89.	92282	0	0	0	0	0	0	
90.	4284	0	0	0	0	0	0	
91.	92854	0	0	0	0	0	0	
92.	48073	0	0	0	0	0	0	
93.	92836	0	0	0	0	0	0	
94.	45824	0	0	0	0	0	0	
95.	61969	0	0	0	0	0	0	
96.	84567	0	0	0	0	0	0	
97.	92840	0	0	0	0	0	0	
98.	76099	0	0	0	0	0	0	



**Table 2  
(continued)**

**DERMATOLOGICAL EVALUATIONS – WEEK 4**

**TEST SITE:** eyelid (along upper lash line)  
**TEST MATERIAL:** [REDACTED] Lash Enhancing Serum

**EVALUATION SCALE**

- 0 = NONE
- 0.5 = BARELY PERCEPTIBLE
- 1 = MILD
- 2 = MODERATE
- 3 = MARKED
- 4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID		ERYTHEMA		EDEMA		DRYNESS		COMMENTS
		Right	Left	Right	Left	Right	Left	
99.	92770	0	0	0	0	0	0	
100.	93235	0	0	0	0	0	0	
101.	93229	0	0	0	0	0	0	
102.	66648	0	0	0	0	0	0	
103.	75527	0	0	0	0	0	0	
104.	81232	0	0	0	0	0	0	
105.	92715	0	0	0	0	0	0	
106.	47011	0	0	0	0	0	0	
107.	67311	0	0	0	0	0	0	
108.	62190	0	0	0	0	0	0	
109.	93213	0	0	0	0	0	0	
110.	93234	0	0	0	0	0	0	
111.	65407	0	0	0	0	0	0	
112.	42734	0	0	0	0	0	0	



**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – WEEK 4**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

0 = NONE

0.5 = BARELY PERCEPTIBLE

1 = MILD

2 = MODERATE

3 = MARKED

4 = SEVERE


**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID		ERYTHEMA		EDEMA		DRYNESS		COMMENTS
		Right	Left	Right	Left	Right	Left	
113.	92456	0	0	0	0	0	0	
114.	91044	0	0	0	0	0	0	
115.	84560	0	0	0	0	0	0	
116.	87722	0	0	0	0	0	0	
117.	91445	0	0	0	0	0	0	
118.	72693	0	0	0	0	0	0	
119.	67863	0	0	0	0	0	0	
120.	92316	0	0	0	0	0	0	
121.	84404	0	0	0	0	0	0	

**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – WEEK 8**

TEST SITE: Eyelid (along upper lash line)

TEST MATERIAL:  Lash Enhancing Serum

**EVALUATION SCALE**

0 = NONE

0.5 = BARELY PERCEPTIBLE

1 = MILD

2 = MODERATE

3 = MARKED

4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

	Subject # & ID	ERYTHEMA		EDEMA		DRYNESS		COMMENTS
		Right	Left	Right	Left	Right	Left	
1.	56135	0	0	0	0	0	0	
2.	87855	0	0	0	0	0	0	
3.	88888	0	0	0	0	0	0	
4.	86779	0	0	0	0	0	0	
5.	89104	0	0	0	0	0	0	
6.	88905	0	0	0	0	0	0	
7.	92956	-	-	-	-	-	-	Did Not Complete
8.	92429	0	0	0	0	0	0	
9.	58976	0	0	0	0	0	0	
10.	91854	0	0	0	0	0	0	
11.	91927	0	0	0	0	0	0	
12.	75855	0	0	0	0	0	0	
13.	69699	0	0	0	0	0	0	
14.	66875	0	0	0	0	0	0	

**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – WEEK 8**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

0 = NONE

0.5 = BARELY PERCEPTIBLE

1 = MILD

2 = MODERATE

3 = MARKED

4 = SEVERE


**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID	ERYTHEMA		EDEMA		DRYNESS		COMMENTS
	Right	Left	Right	Left	Right	Left	
15. 92592	0	0	0	0	0	0	
16. 87173	0	0	0	0	0	0	
17. 64690	1	1	0	0	0	0	
18. 92994	0	0	0	0	0	0	
19. 93102	0	0	0	0	0	0	
20. 25118	0	0	0	0	0	0	
21. 72896	0	0	0	0	0	0	
22. 92978	0	0	0	0	0	0	
23. 85372	0	0	0	0	0	0	
24. 77457	0	0	0	0	0	0	
25. 89254	0	0	0	0	0	0	
26. 90669	0	0	0	0	0	0	
27. 68629	0	0	0	0	0	0	
28. 93146	0	0	0	0	0	0	

**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – WEEK 8**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

0 = NONE

0.5 = BARELY PERCEPTIBLE

1 = MILD

2 = MODERATE

3 = MARKED

4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID	ERYTHEMA		EDEMA		DRYNESS		COMMENTS
	Right	Left	Right	Left	Right	Left	
29. 47917	0	0	0	0	0	0	
30. 93150	0	0	0	0	0	0	
31. 93151	0	0	0	0	0	0	
32. 49868	0	0	0	0	0	0	
33. 92615	0	0	0	0	0	0	
34. 76837	0	0	0	0	0	0	
35. 89198	0	0	0	0	0	0	
36. 80522	0	0	0	0	0	0	
37. 92575	0	0	0	0	0	0	
38. 92096	0	0	0	0	0	0	
39. 63350	0	0	0	0	0	0	
40. 93162	0	0	0	0	0	0	
41. 91523	0	0	0	0	0	0	
42. 66549	0	0	0	0	0	0	

**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – WEEK 8**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

0 = NONE

0.5 = BARELY PERCEPTIBLE

1 = MILD

2 = MODERATE

3 = MARKED

4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**


Subject # & ID	ERYTHEMA		EDEMA		DRYNESS		COMMENTS
	Right	Left	Right	Left	Right	Left	
43. 84377	0	0	0	0	0	0	
44. 92895	0	0	0	0	0	0	
45. 93104	0	0	0	0	0	0	
46. 60209	0	0	0	0	0	0	
47. 21096	0	0	0	0	0	0	
48. 93197	0	0	0	0	0	0	
49. 47949	0	0	0	0	0	0	
50. 92889	0	0	0	0	0	0	
51. *	*	*	*	*	*	*	
52. 92706	0	0	0	0	0	0	
53. 39164	0	0	0	0	0	0	
54. 93153	0	0	0	0	0	0	
55. 71893	0	0	0	0	0	0	
56. 91393	0	0	0	0	0	0	

\*#51 will not be used – deviation\*

**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS - WEEK 8**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

- 0 = NONE
- 0.5 = BARELY PERCEPTIBLE
- 1 = MILD
- 2 = MODERATE
- 3 = MARKED
- 4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID	ERYTHEMA		EDEMA		DRYNESS		COMMENTS
	Right	Left	Right	Left	Right	Left	
57. 90080	0	0	0	0	0	0	
58. 93083	-	-	-	-	-	-	Did Not Complete
59. 91137	0	0	0	0	0	0	
60. 92158	0	0	0	0	0	0	
61. 93210	0	0	0	0	0	0	
62. 88490	0	0	0	0	0	0	
63. 87998	0	0	0	0	0	0	
64. 93160	0	0	0	0	0	0	
65. 46058	0	0	0	0	0	0	
66. 70499	0	0	0	0	0	0	
67. 93152	0	0	0	0	0	0	
68. 91812	0	0	0	0	0	0	
69. 56034	0	0	0	0	0	0	
70. 80386	0	0	0	0	0	0	

**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – WEEK 8**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL** [REDACTED] Lash Enhancing Serum

**EVALUATION SCALE**

- 0 = NONE
- 0.5 = BARELY PERCEPTIBLE
- 1 = MILD
- 2 = MODERATE
- 3 = MARKED
- 4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID		ERYTHEMA		EDEMA		DRYNESS		COMMENTS
		Right	Left	Right	Left	Right	Left	
71.	63555	0	0	0	0	0	0	
72.	93198	0	0	0	0	0	0	
73.	92065	0	0	0	0	0	0	
74.	91636	0	0	0	0	0	0	
75.	93018	0	0	0	0	0	0	
76.	77962	0	0	0	0	0	0	
77.	90494	0	0	0	0	0	0	
78.	60639	0	0	0	0	0	0	
79.	92756	0	0	0	0	0	0	
80.	90099	0	0	0	0	0	0	
81.	78294	0	0	0	0	0	0	
82.	93044	0	0	0	0	0	0	
83.	93196	-	-	-	-	-	-	Did Not Complete
84.	91200	0	0	0	0	0	0	

**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – WEEK 8**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

0 = NONE

0.5 = BARELY PERCEPTIBLE

1 = MILD

2 = MODERATE

3 = MARKED

4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID	ERYTHEMA		EDEMA		DRYNESS		COMMENTS
	Right	Left	Right	Left	Right	Left	
85. 92803	-	-	-	-	-	-	Did Not Complete
86. 71209	0	0	0	0	0	0	
87. 91745	0	0	0	0	0	0	
88. 58577	0	0	0	0	0	0	
89. 92282	0	0	0	0	0	0	
90. 4284	0	0	0	0	0	0	
91. 92854	0	0	0	0	0	0	
92. 48073	0	0	0	0	0	0	
93. 92836	0	0	0	0	0	0	
94. 45824	0	0	0	0	0	0	
95. 61969	0	0	0	0	0	0	
96. 84567	0	0	0	0	0	0	
97. 92840	0	0	0	0	0	0	
98. 76099	0	0	0	0	0	0	



**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – WEEK 8**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

0 = NONE

0.5 = BARELY PERCEPTIBLE

1 = MILD

2 = MODERATE

3 = MARKED

4 = SEVERE


**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Any subject Subject # & ID		ERYTHEMA		EDEMA		DRYNESS		COMMENTS
		Right	Left	Right	Left	Right	Left	
99.	92770	0	0	0	0	0	0	
100.	93235	0	0	0	0	0	0	
101.	93229	0	0	0	0	0	0	
102.	66648	0	0	0	0	0	0	
103.	75527	0	0	0	0	0	0	
104.	81232	0	0	0	0	0	0	
105.	92715	0	0	0	0	0	0	
106.	47011	0	0	0	0	0	0	
107.	67311	0	0	0	0	0	0	
108.	62190	0	0	0	0	0	0	
109.	93213	0	0	0	0	0	0	
110.	93234	0	0	0	0	0	0	
111.	65407	0	0	0	0	0	0	
112.	42734	0	0	0	0	0	0	

**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – WEEK 8**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

0 = NONE

0.5 = BARELY PERCEPTIBLE

1 = MILD

2 = MODERATE

3 = MARKED

4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID		ERYTHEMA		EDEMA		DRYNESS		COMMENTS
		Right	Left	Right	Left	Right	Left	
113.	92456*	0	0	0	0	0	0	
114.	91044	0	0	0	0	0	0	
115.	84560	0	0	0	0	0	0	
116.	87722	0	0	0	0	0	0	
117.	91445	0	0	0	0	0	0	
118.	72693	0	0	0	0	0	0	
119.	67863	0	0	0	0	0	0	
120.	92316	0	0	0	0	0	0	
121.	84404	0	0	0	0	0	0	


\*Subject #113 removed from the trial after derm exam due to an adverse event.



**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – WEEK 16**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

- 0 = NONE
- 0.5 = BARELY PERCEPTIBLE
- 1 = MILD
- 2 = MODERATE
- 3 = MARKED
- 4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID	ERYTHEMA		EDEMA		DRYNESS		COMMENTS
	Right	Left	Right	Left	Right	Left	
1. 56135	0	0	0	0	0	0	
2. 87855	0	0	0	0	0	0	
3. 88888	0	0	0	0	0	0	
4. 86779	0	0	0	0	0	0	
5. 89104	0	0	0	0	0	0	
6. 88905	0	0	0	0	0	0	
7. 92956	-	-	-	-	-	-	Did Not Complete
8. 92429	0	0	0	0	0	0	
9. 58976	0	0	0	0	0	0	
10. 91854	0	0	0	0	0	0	
11. 91927	0	0	0	0	0	0	
12. 75855	0	0	0	0	0	0	
13. 69699	0	0	0	0	0	0	
14. 66875	0	0	0	0	0	0	



**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – WEEK 16**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

0 = NONE

0.5 = BARELY PERCEPTIBLE

1 = MILD

2 = MODERATE

3 = MARKED

4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID	ERYTHEMA		EDEMA		DRYNESS		COMMENTS	
	Right	Left	Right	Left	Right	Left		
29.	47917	0	0	0	0	0	0	
30.	93150	0	0	0	0	0	0	
31.	93151	0	0	0	0	0	0	
32.	49868	0	0	0	0	0	0	
33.	92615	0	0	0	0	0	0	
34.	76837	0	0	0	0	0	0	
35.	89198	0	0	0	0	0	0	
36.	80522	0	0	0	0	0	0	
37.	92575	0	0	0	0	0	0	
38.	92096	0	0	0	0	0	0	
39.	63350	0	0	0	0	0	0	
40.	93162	0	0	0	0	0	0	
41.	91523	0	0	0	0	0	0	
42.	66549	0	0	0	0	0	0	

**Table 2  
(continued)**

**DERMATOLOGICAL EVALUATIONS – WEEK 16**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

0 = NONE

0.5 = BARELY PERCEPTIBLE

1 = MILD

2 = MODERATE

3 = MARKED

4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**


Subject # & ID	ERYTHEMA		EDEMA		DRYNESS		COMMENTS
	Right	Left	Right	Left	Right	Left	
43. 84377	0	0	0	0	0	0	
44. 92895	0	0	0	0	0	0	
45. 93104	0	0	0	0	0	0	
46. 60209	0	0	0	0	0	0	
47. 21096	0	0	0	0	0	0	
48. 93197	0	0	0	0	0	0	
49. 47949	0	0	0	0	0	0	
50. 92889	0	0	0	0	0	0	
51. *	*	*	*	*	*	*	
52. 92706	0	0	0	0	0	0	
53. 39164	0	0	0	0	0	0	
54. 93153	0	0	0	0	0	0	
55. 71893	0	0	0	0	0	0	
56. 91393	0	0	0	0	0	0	

\*#51 will not be used – deviation\*

**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – WEEK 16**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

0 = NONE

0.5 = BARELY PERCEPTIBLE

1 = MILD

2 = MODERATE

3 = MARKED

4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID	ERYTHEMA		EDEMA		DRYNESS		COMMENTS
	Right	Left	Right	Left	Right	Left	
57. 90080	0	0	0	0	0	0	
58. 93083	-	-	-	-	-	-	Did Not Complete
59. 91137	0	0	0	0	0	0	
60. 92158	0	0	0	0	0	0	
61. 93210	0	0	0	0	0	0	
62. 88490	0	0	0	0	0	0	
63. 87998	0	0	0	0	0	0	
64. 93160	0	0	0	0	0	0	
65. 46058	0	0	0	0	0	0	
66. 70499	0	0	0	0	0	0	
67. 93152	0	0	0	0	0	0	
68. 91812	0	0	0	0	0	0	
69. 56034	0	0	0	0	0	0	
70. 80386	0	0	0	0	0	0	

**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – WEEK 16**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL**  Lash Enhancing Serum

**EVALUATION SCALE**

0 = NONE

0.5 = BARELY PERCEPTIBLE

1 = MILD

2 = MODERATE

3 = MARKED

4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**


Subject # & ID		ERYTHEMA		EDEMA		DRYNESS		COMMENTS
		Right	Left	Right	Left	Right	Left	
71.	63555	0	0	0	0	0	0	
72.	93198	0	0	0	0	0	0	
73.	92065	0	0	0	0	0	0	
74.	91636	0	0	0	0	0	0	
75.	93018	0	0	0	0	0	0	
76.	77962	0	0	0	0	0	0	
77.	90494	0	0	0	0	0	0	
78.	60639	0	0	0	0	0	0	
79.	92756	0	0	0	0	0	0	
80.	90099	0	0	0	0	0	0	
81.	78294	0	0	0	0	0	0	
82.	93044	0	0	0	0	0	0	
83.	93196	-	-	-	-	-	-	Did Not Complete
84.	91200	0	0	0	0	0	0	



**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – WEEK 16**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

0 = NONE

0.5 = BARELY PERCEPTIBLE

1 = MILD

2 = MODERATE

3 = MARKED

4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID		ERYTHEMA		EDEMA		DRYNESS		COMMENTS
		Right	Left	Right	Left	Right	Left	
85.	92803	-	-	-	-	-	-	Did Not Complete
86.	71209	0	0	0	0	0	0	
87.	91745	0	0	0	0	0	0	
88.	58577	0	0	0	0	0	0	
89.	92282	0	0	0	0	0	0	
90.	4284	0	0	0	0	0	0	
91.	92854	0	0	0	0	0	0	
92.	48073	0	0	0	0	0	0	
93.	92836	0	0	0	0	0	0	
94.	45824	0	0	0	0	0	0	
95.	61969	0	0	0	0	0	0	
96.	84567	0	0	0	0	0	0	
97.	92840	0	0	0	0	0	0	
98.	76099	0	0	0	0	0	0	

**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – WEEK 16**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

- 0 = NONE
- 0.5 = BARELY PERCEPTIBLE
- 1 = MILD
- 2 = MODERATE
- 3 = MARKED
- 4 = SEVERE


**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID		ERYTHEMA		EDEMA		DRYNESS		COMMENTS
		Right	Left	Right	Left	Right	Left	
99.	92770	0	0	0	0	0	0	
100.	93235	0	0	0	0	0	0	
101.	93229	0	0	0	0	0	0	
102.	66648	0	0	0	0	0	0	
103.	75527	0	0	0	0	0	0	
104.	81232	0	0	0	0	0	0	
105.	92715	0	0	0	0	0	0	
106.	47011	0	0	0	0	0	0	
107.	67311	0	0	0	0	0	0	
108.	62190	0	0	0	0	0	0	
109.	93213	0	0	0	0	0	0	
110.	93234	0	0	0	0	0	0	
111.	65407	0	0	0	0	0	0	
112.	42734	0	0	0	0	0	0	

**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – WEEK 16**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

- 0 = NONE  
 0.5 = BARELY PERCEPTIBLE  
 1 = MILD  
 2 = MODERATE  
 3 = MARKED  
 4 = SEVERE


**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID		ERYTHEMA		EDEMA		DRYNESS		COMMENTS
		Right	Left	Right	Left	Right	Left	
113.	92456	-	-	-	-	-	-	Did Not Complete
114.	91044	0	0	0	0	0	0	
115.	84560	0	0	0	0	0	0	
116.	87722	0	0	0	0	0	0	
117.	91445	0	0	0	0	0	0	
118.	72693	0	0	0	0	0	0	
119.	67863	0	0	0	0	0	0	
120.	92316	0	0	0	0	0	0	
121.	84404	0	0	0	0	0	0	

**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – FINAL WEEK 32**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

0 = NONE

0.5 = BARELY PERCEPTIBLE

1 = MILD

2 = MODERATE

3 = MARKED

4 = SEVERE


**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID	ERYTHEMA		EDEMA		DRYNESS		COMMENTS
	Right	Left	Right	Left	Right	Left	
1. 56135	0	0	0	0	0	0	
2. 87855	0	0	0	0	0	0	
3. 88888	0	0	0	0	0	0	
4. 86779	0	0	0	0	0	0	
5. 89104	0	0	0	0	0	0	
6. 88905	0	0	0	0	0	0	
7. 92956	-	-	-	-	-	-	Did Not Complete
8. 92429	0	0	0	0	0	0	
9. 58976	0	0	0	0	0	0	
10. 91854	0	0	0	0	0	0	
11. 91927	0	0	0	0	0	0	
12. 75855	0	0	0	0	0	0	
13. 69699	0	0	0	0	0	0	
14. 66875	0	0	0	0	0	0	

**Table 2  
(continued)**

**DERMATOLOGICAL EVALUATIONS – FINAL WEEK 32**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

0 = NONE

0.5 = BARELY PERCEPTIBLE

1 = MILD

2 = MODERATE

3 = MARKED

4 = SEVERE


**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID	ERYTHEMA		EDEMA		DRYNESS		COMMENTS	
	Right	Left	Right	Left	Right	Left		
15.	92592	0	0	0	0	0	0	
16.	87173	0	0	0	0	0	0	
17.	64690	0	0	0	0	0	0	
18.	92994	0	0	0	0	0	0	
19.	93102	0	0	0	0	0	0	
20.	25118	0	0	0	0	0	0	
21.	72896	0	0	0	0	0	0	
22.	92978	0	0	0	0	0	0	
23.	85372	0	0	0	0	0	0	
24.	77457	0	0	0	0	0	0	
25.	89254	0	0	0	0	0	0	
26.	90669	0	0	0	0	0	0	
27.	68629	0	0	0	0	0	0	
28.	93146	0	0	0	0	0	0	

**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – FINAL WEEK 32**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

- 0 = NONE
- 0.5 = BARELY PERCEPTIBLE
- 1 = MILD
- 2 = MODERATE
- 3 = MARKED
- 4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID	ERYTHEMA		EDEMA		DRYNESS		COMMENTS
	Right	Left	Right	Left	Right	Left	
29. 47917	0	0	0	0	0	0	
30. 93150	0	0	0	0	0	0	
31. 93151	0	0	0	0	0	0	
32. 49868	0	0	0	0	0	0	
33. 92615	0	0	0	0	0	0	
34. 76837	0	0	0	0	0	0	
35. 89198	0	0	0	0	0	0	
36. 80522	0	0	0	0	0	0	
37. 92575	0	0	0	0	0	0	
38. 92096	0	0	0	0	0	0	
39. 63350	0	0	0	0	0	0	
40. 93162	0	0	0	0	0	0	
41. 91523	0	0	0	0	0	0	
42. 66549	0	0	0	0	0	0	



**Table 2  
(continued)**

**DERMATOLOGICAL EVALUATIONS – FINAL WEEK 32**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:** [Redacted] Lash Enhancing Serum

**EVALUATION SCALE**

- 0 = NONE
- 0.5 = BARELY PERCEPTIBLE
- 1 = MILD
- 2 = MODERATE
- 3 = MARKED
- 4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID	ERYTHEMA		EDEMA		DRYNESS		COMMENTS
	Right	Left	Right	Left	Right	Left	
43. 84377	0	0	0	0	0	0	
44. 92895	0	0	0	0	0	0	
45. 93104	0	0	0	0	0	0	
46. 60209	0	0	0	0	0	0	
47. 21096	0	0	0	0	0	0	
48. 93197	0	0	0	0	0	0	
49. 47949	0	0	0	0	0	0	
50. 92889	0	0	0	0	0	0	
51. *	*	*	*	*	*	*	
52. 92706	0	0	0	0	0	0	
53. 39164	0	0	0	0	0	0	
54. 93153	0	0	0	0	0	0	
55. 71893	0	0	0	0	0	0	
56. 91393	0	0	0	0	0	0	

\*#51 will not be used – deviation\*

**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – FINAL WEEK 32**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

0 = NONE

0.5 = BARELY PERCEPTIBLE

1 = MILD

2 = MODERATE

3 = MARKED

4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID	ERYTHEMA		EDEMA		DRYNESS		COMMENTS
	Right	Left	Right	Left	Right	Left	
57. 90080	0	0	0	0	0	0	
58. 93083	-	-	-	-	-	-	Did Not Complete
59. 91137	0	0	0	0	0	0	
60. 92158	0	0	0	0	0	0	
61. 93210	0	0	0	0	0	0	
62. 88490	0	0	0	0	0	0	
63. 87998	0	0	0	0	0	0	
64. 93160	0	0	0	0	0	0	
65. 46058	0	0	0	0	0	0	
66. 70499	0	0	0	0	0	0	
67. 93152	0	0	0	0	0	0	
68. 91812	0	0	0	0	0	0	
69. 56034	0	0	0	0	0	0	
70. 80386	0	0	0	0	0	0	






**Table 2  
(continued)**

**DERMATOLOGICAL EVALUATIONS – FINAL WEEK 32**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL**  Lash Enhancing Serum

**EVALUATION SCALE**

- 0 = NONE
- 0.5 = BARELY PERCEPTIBLE
- 1 = MILD
- 2 = MODERATE
- 3 = MARKED
- 4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID		ERYTHEMA		EDEMA		DRYNESS		COMMENTS
		Right	Left	Right	Left	Right	Left	
71.	63555	0	0	0	0	0	0	
72.	93198	0	0	0	0	0	0	
73.	92065	0	0	0	0	0	0	
74.	91636	0	0	0	0	0	0	
75.	93018	0	0	0	0	0	0	
76.	77962	0	0	0	0	0	0	
77.	90494	0	0	0	0	0	0	
78.	60639	0	0	0	0	0	0	
79.	92756	0	0	0	0	0	0	
80.	90099	0	0	0	0	0	0	
81.	78294	-	-	-	-	-	-	Did Not Complete
82.	93044	0	0	0	0	0	0	
83.	93196	-	-	-	-	-	-	Did Not Complete
84.	91200	0	0	0	0	0	0	



**Table 2  
(continued)**

**DERMATOLOGICAL EVALUATIONS – FINAL WEEK 32**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:** [Redacted] Lash Enhancing Serum

**EVALUATION SCALE**

- 0 = NONE
- 0.5 = BARELY PERCEPTIBLE
- 1 = MILD
- 2 = MODERATE
- 3 = MARKED
- 4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID		ERYTHEMA		EDEMA		DRYNESS		COMMENTS
		Right	Left	Right	Left	Right	Left	
85.	92803	-	-	-	-	-	-	Did Not Complete
86.	71209	0	0	0	0	0	0	
87.	91745	0	0	0	0	0	0	
88.	58577	0	0	0	0	0	0	
89.	92282	0	0	0	0	0	0	
90.	4284	0	0	0	0	0	0	
91.	92854	0	0	0	0	0	0	
92.	48073	0	0	0	0	0	0	
93.	92836	0	0	0	0	0	0	
94.	45824	0	0	0	0	0	0	
95.	61969	0	0	0	0	0	0	
96.	84567	0	0	0	0	0	0	
97.	92840	0	0	0	0	0	0	
98.	76099	0	0	0	0	0	0	

**Table 2**  
**(continued)**

**DERMATOLOGICAL EVALUATIONS – FINAL WEEK 32**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:**  Lash Enhancing Serum

**EVALUATION SCALE**

0 = NONE

0.5 = BARELY PERCEPTIBLE

1 = MILD

2 = MODERATE

3 = MARKED

4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID		ERYTHEMA		EDEMA		DRYNESS		COMMENTS
		Right	Left	Right	Left	Right	Left	
99.	92770	0	0	0	0	0	0	
100.	93235	0	0	0	0	0	0	
101.	93229	0	0	0	0	0	0	
102.	66648	0	0	0	0	0	0	
103.	75527	0	0	0	0	0	0	
104.	81232	0	0	0	0	0	0	
105.	92715	0	0	0	0	0	0	
106.	47011	0	0	0	0	0	0	
107.	67311	0	0	0	0	0	0	
108.	62190	0	0	0	0	0	0	
109.	93213	0	0	0	0	0	0	
110.	93234	0	0	0	0	0	0	
111.	65407	0	0	0	0	0	0	
112.	42734	0	0	0	0	0	0	



**Table 2  
 (continued)**

**DERMATOLOGICAL EVALUATIONS – FINAL WEEK 32**

**TEST SITE:** Eyelid (along upper lash line)

**TEST MATERIAL:** [Redacted] Lash Enhancing Serum

**EVALUATION SCALE**

- 0 = NONE
- 0.5 = BARELY PERCEPTIBLE
- 1 = MILD
- 2 = MODERATE
- 3 = MARKED
- 4 = SEVERE

**Any subject exhibiting a score of  $\geq 2$  for any one parameter will be disqualified.**

Subject # & ID		ERYTHEMA		EDEMA		DRYNESS		COMMENTS
		Right	Left	Right	Left	Right	Left	
113.	92456	-	-	-	-	-	-	Did Not Complete
114.	91044	0	0	0	0	0	0	
115.	84560	0	0	0	0	0	0	
116.	87722	0	0	0	0	0	0	
117.	91445	0	0	0	0	0	0	
118.	72693	0	0	0	0	0	0	
119.	67863	0	0	0	0	0	0	
120.	92316	0	0	0	0	0	0	
121.	84404	0	0	0	0	0	0	

Table 3

Aeva3D-HE Positive volume (mm3) Left

[REDACTED] Lash Enhancing Serum

Subject #	Baseline	Month 1	Month 2	Month 4	Month 8	Difference From Baseline At:			
						Month 1	Month 2	Month 4	Month 8
1	192.7	378.9	270.0	227.5	269.0	186.2	77.3	34.8	76.4
2	275.0	248.1	222.6	231.1	236.6	-26.9	-52.4	-43.9	-38.4
3	228.7	216.5	269.9	256.4	260.1	-12.2	41.2	27.7	31.4
4	228.5	259.9	273.3	255.8	363.5	31.4	44.8	27.3	134.9
5	417.1	542.4	452.0	452.6	380.3	125.4	35.0	35.5	-36.7
6	225.4	123.6	189.6	249.8	189.9	-101.8	-35.8	24.5	-35.5
8	399.6	488.4	516.8	477.4	447.2	88.9	117.2	77.9	47.6
9	292.2	271.2	247.9	297.6	304.4	-21.0	-44.2	5.4	12.3
10	482.2	523.1	527.6	555.4	446.1	40.8	45.4	73.2	-36.2
11	215.5	145.3	84.9	155.7	23.2	-70.2	-130.6	-59.7	-192.2
12	212.5	252.6	273.6	402.8	270.1	40.1	61.2	190.4	57.7
13	337.8	350.7	341.7	381.5	283.7	12.9	3.9	43.7	-54.1
14	205.7	215.7	346.9	339.3	297.2	10.0	141.2	133.6	91.5
15	312.6	226.3	236.3	272.0	278.7	-86.2	-76.3	-40.6	-33.8
16	263.6	316.3	340.7	309.9	348.3	52.7	77.1	46.4	84.7
17	331.1	240.6	227.1	222.0	252.1	-90.4	-103.9	-109.0	-79.0
18	554.2	384.9	388.1	439.2	463.5	-169.3	-166.1	-115.6	-90.7
19	377.1	448.1	528.2	445.5	439.5	71.0	151.1	68.5	62.4
20	311.0	281.3	317.0	222.1	216.9	-29.8	6.0	-88.9	-94.1
21	381.2	298.3	302.7	376.3	442.8	-83.0	-78.6	-4.9	61.6
22	199.0	136.7	163.4	164.4	161.1	-62.3	-35.6	-34.6	-37.9
23	521.2	561.0	537.2	552.5	652.1	39.8	16.0	31.3	130.9
24	415.8	408.6	576.1	458.4	491.6	-7.3	160.2	42.5	75.8
25	195.4	121.6	108.3	133.9	318.7	-73.9	-87.1	-61.5	123.3
26	409.7	415.3	396.8	462.0	465.0	5.6	-12.9	52.3	55.3
27	410.3	467.7	388.5	372.0	408.3	57.4	-21.8	-38.3	-2.0
28	559.0	544.9	507.8	514.8	559.8	-14.1	-51.1	-44.1	0.8
30	331.8	405.8	493.8	448.0	406.3	74.1	162.0	116.2	74.6
31	269.4	309.4	327.4	269.5	364.4	39.9	57.9	0.1	95.0
32	146.6	174.1	196.5	193.7	189.1	27.5	49.9	47.1	42.5
33	200.8	165.8	134.2	148.3	127.4	-35.0	-66.6	-52.5	-73.4
34	353.4	156.2	239.0	198.9	490.7	-197.3	-114.4	-154.6	137.3
35	417.1	479.2	417.4	439.0	337.9	62.0	0.3	11.9	-79.2
36	348.4	316.7	296.8	355.1	315.9	-31.7	-51.6	6.7	-32.5
37	221.0	256.8	173.8	231.3	266.3	35.7	-47.3	10.2	45.2
38	460.3	381.8	349.0	420.3	386.4	-78.5	-111.4	-40.1	-74.0
39	326.9	324.3	306.1	334.6	316.1	-2.6	-20.8	7.7	-10.8
40	141.1	129.7	105.4	76.7	145.9	-11.4	-35.7	-64.4	4.8
41	102.2	106.1	137.4	242.8	196.9	3.9	35.2	140.6	94.7
42	366.2	335.6	334.6	375.4	284.4	-30.5	-31.6	9.3	-81.8
43	298.7	326.9	241.1	274.6	348.6	28.2	-57.6	-24.1	49.9
44	480.2	304.9	384.8	345.1	436.7	-175.3	-95.4	-135.2	-43.5
45	208.5	339.6	333.0	213.8	254.0	131.2	124.5	5.3	45.5
46	335.2	441.7	371.7	452.0	430.6	106.5	36.5	116.8	115.4
47	610.3	593.2	595.7	610.1	588.9	-17.1	-14.6	-0.2	-21.4
48	331.4	300.2	204.5	265.1	235.8	-31.2	-126.9	-66.3	-95.6
49	425.2	339.8	395.1	412.4	848.3	-85.4	-30.1	-12.7	423.1
50	514.0	440.5	448.6	442.8	501.5	-73.4	-65.3	-71.2	-12.4
52	375.5	303.1	385.3	377.1	364.0	-72.4	9.8	1.6	-11.5
53	351.0	293.7	307.6	373.9	398.8	-57.3	-43.4	23.0	47.8
54	362.4	297.9	374.7	356.2	434.8	-64.5	12.3	-6.2	72.4
55	274.2	91.4	124.6	192.6	220.3	-182.8	-149.6	-81.6	-53.9
56	171.7	121.4	219.0	164.0	127.1	-50.3	47.3	-7.7	-44.6
57	160.6	301.7	196.4	103.7	174.8	141.1	35.8	-56.9	14.2
59	379.7	373.7	392.8	390.7	351.0	-5.9	13.1	11.0	-28.7
60	270.6	245.2	243.7	248.6	372.8	-25.4	-26.8	-21.9	102.3
61	378.7	323.8	282.0	298.8	381.3	-55.0	-96.8	-80.0	2.6

**Table 3**  
**(continued)**  
**Aeva3D-HE Positive volume (mm<sup>3</sup>) Left**

	Lash Enhancing Serum									
62	304.7	294.7	367.8	340.5	255.3	-9.9	63.2	35.9	-49.3	
63	513.9	510.9	542.6	534.0	541.5	-3.0	28.7	20.1	27.6	
64	196.6	101.0	88.7	170.1	113.0	-95.6	-107.9	-26.5	-83.6	
65	285.7	242.2	276.3	319.1	288.7	-43.4	-9.3	33.5	3.0	
66	234.2	210.2	225.4	196.7	217.0	-24.0	-8.8	-37.5	-17.2	
67	387.8	326.8	362.6	307.5	359.7	-61.1	-25.3	-80.4	-28.2	
68	273.7	269.6	227.7	236.8	276.1	-4.1	-46.1	-36.9	2.4	
69	255.2	270.6	262.3	357.3	318.1	15.4	7.1	102.1	62.9	
70	439.3	366.3	433.7	427.8	384.9	-72.9	-5.5	-31.5	-54.4	
71	256.3	241.0	218.3	249.1	203.7	-153	-38.0	-7.2	-52.6	
72	167.1	179.1	88.2	157.7	136.5	12.0	-78.9	-9.3	-30.6	
73	303.5	261.9	364.1	282.3	270.8	-41.6	0.5	-21.3	-32.7	
74	274.4	270.9	265.2	394.1	272.9	-3.5	-9.2	119.7	-1.6	
75	420.8	360.3	423.0	400.3	402.3	-60.5	2.2	-20.5	-18.5	
76	389.0	411.1	689.5	390.1	365.6	22.1	300.5	1.1	-23.3	
77	557.5	653.7	1110.6	594.9	772.7	96.1	553.1	37.3	215.1	
78	385.6	364.5	346.9	385.8	407.6	-21.1	-38.7	0.1	22.0	
79	274.6	366.6	252.0	291.8	292.9	92.0	-22.5	17.3	18.3	
80	397.5	451.7	381.6	410.0	427.2	34.1	-15.9	12.5	29.6	
82	336.1	299.7	321.8	327.3	342.1	-36.5	-14.3	-8.9	5.9	
84	339.4	292.5	354.6	356.7	280.3	-46.9	15.3	17.4	-59.0	
86	398.1	391.2	323.6	343.5	340.2	-6.9	-74.5	-54.6	-57.9	
87	344.9	441.0	579.8	380.2	291.7	96.1	234.9	35.3	-53.2	
88	277.0	305.4	451.7	414.3	318.4	28.4	174.7	137.3	41.4	
89	393.0	378.0	398.1	374.4	391.0	-15.0	5.1	-18.6	-1.9	
90	237.8	225.9	228.1	256.0	246.4	-11.9	-9.7	18.1	8.6	
91	129.1	98.8	154.3	119.4	81.0	-30.3	25.2	-9.7	-48.2	
92	188.2	138.2	22.7	319.8	211.2	-50.0	-165.5	131.5	23.0	
93	274.1	269.8	281.2	290.1	231.9	-4.3	7.1	16.0	-22.2	
94	386.1	195.9	355.7	363.6	259.4	-190.2	-30.4	-2.5	-126.7	
95	280.3	317.5	279.4	272.2	229.9	37.4	-0.7	-7.8	-50.2	
96	444.8	434.3	475.9	486.9	451.8	-10.5	31.1	42.1	7.0	
97	215.5	249.9	95.9	84.3	0.0	34.5	-119.6	-131.2	-215.4	
98	338.8	320.2	431.4	325.6	385.9	-18.6	92.6	-13.2	47.1	
99	338.9	342.8	316.6	286.8	333.8	3.9	-22.3	-52.1	-5.1	
100	162.2	139.3	168.8	156.6	185.0	-22.9	6.6	-5.6	22.8	
101	382.4	361.3	357.6	388.0	727.7	-21.1	-24.8	5.7	345.3	
102	258.9	240.2	267.3	274.0	256.7	-18.6	8.5	15.1	-2.2	
103	274.5	12.4	8.5	83.2	6.5	-262.2	-266.0	-191.3	-268.0	
104	299.3	298.1	275.3	329.6	308.9	-1.3	-24.1	30.3	9.6	
105	562.9	565.2	622.8	604.7	533.7	2.3	59.9	41.8	-29.2	
106	432.2	321.4	111.2	518.5	399.0	-110.8	-320.9	86.3	-33.2	
107	445.9	429.1	485.8	366.9	360.9	-16.8	39.8	-79.0	-85.0	
108	662.0	631.9	684.1	703.3	682.9	-30.1	22.1	41.3	20.9	
109	355.8	411.7	340.3	426.6	340.0	55.9	-15.5	70.8	-15.8	
110	317.0	367.7	347.5	50.0	89.3	30.6	30.5	-267.0	-227.8	
111	263.5	220.0	248.4	204.9	266.7	-43.5	-15.1	-58.6	3.2	
112	382.8	366.6	349.8	300.0	333.4	-16.2	-33.0	-82.8	-49.4	
114	359.8	289.1	292.8	294.2	336.1	-70.7	-67.0	-65.6	-23.6	
115	460.8	364.6	434.5	381.7	358.0	-96.3	-26.3	-79.2	-102.8	
116	273.5	180.3	304.0	195.0	153.3	-93.3	30.5	-80.5	-120.2	
117	372.8	363.1	368.6	358.3	377.1	-9.7	-4.2	-14.5	4.3	
118	274.1	192.3	143.1	204.8	169.0	-81.8	-131.0	-69.3	-105.2	
119	249.9	273.7	286.8	290.9	287.0	23.9	36.9	41.0	37.1	
120	285.9	212.3	205.1	186.7	169.5	-73.6	-80.8	-99.1	-116.4	
121	349.5	440.4	388.3	350.3	423.6	90.9	18.9	0.8	74.1	
Mean =	329.5	313.1	324.6	323.8	328.1	-16.4	-4.9	-5.7	-1.4	
Median =	331.4	304.9	316.6	327.3	318.4	-15.3	-9.7	-0.2	-2.2	
Standard Deviation =	109.0	123.9	154.9	124.8	146.0	71.4	100.6	69.3	91.5	
Maximum =	662.0	653.7	1110.6	703.3	848.3	186.2	553.1	190.4	423.1	
Minimum =	102.2	12.4	8.5	50.0	0.0	-262.2	-320.9	-267.0	-268.0	

	Mean % Change From Baseline				Tallies & Percentages				
	Month 1	Month 2	Month 4	Month 8	Month 1	Month 2	Month 4	Month 8	
	-5.0%	-1.5%	-1.7%	-0.4%	Total	113	113	113	113
	Decrease	Decrease	Decrease	Decrease	Increased Values	39	50	56	53
					Decreased Values	74	63	57	60
					No Change	0	0	0	0
					Increased Values	34.51%	44.25%	49.56%	46.90%
					Decreased Values	65.49%	55.75%	50.44%	53.10%
					No Change	0.00%	0.00%	0.00%	0.00%

Did Not Complete Subjects: 7, 51, 58, 81, 83, 85, 113  
Note: Data for Subject #29 not included due to image noise

**Table 3**  
 (continued)  
 Aeva3D-HE Positive volume (mm<sup>3</sup>) Right

Lash Enhancing Serum

Subject #	Baseline	Month 1	Month 2	Month 4	Month 8	Difference From Baseline At :			
						Month 1	Month 2	Month 4	Month 8
1	312.2	411.1	328.4	320.6	296.5	98.9	16.2	8.5	-15.6
2	222.1	172.9	126.6	158.2	159.1	-49.2	-95.4	-63.9	-63.0
3	263.5	245.8	283.0	265.8	225.0	-17.7	19.5	2.3	-38.4
4	264.2	281.4	315.2	288.3	288.7	17.2	51.0	24.2	24.5
5	266.5	410.9	306.1	297.7	268.9	144.5	39.7	31.2	2.4
6	181.0	118.1	167.6	175.1	155.0	-62.9	-13.5	-5.9	-26.1
8	324.0	180.9	429.1	388.5	332.3	56.9	105.1	64.5	8.3
9	259.9	247.6	240.9	234.1	278.4	-12.3	-19.0	-25.8	18.5
10	307.2	349.3	458.3	475.7	337.0	42.1	151.1	168.5	29.8
11	193.3	134.8	87.3	207.6	30.6	-58.4	-106.0	14.3	-162.7
12	205.9	238.4	260.2	361.1	290.8	32.5	54.3	155.2	85.0
13	371.4	363.6	357.8	330.2	311.2	-7.8	-13.7	-41.2	-60.2
14	214.5	214.6	286.3	295.7	330.0	0.0	71.8	81.1	115.4
15	355.1	209.5	273.7	240.1	281.0	-145.6	-81.4	-115.0	-74.1
16	244.1	228.5	218.7	212.7	282.1	-15.6	-25.3	-31.4	38.1
17	310.5	251.3	254.3	223.5	258.5	-59.2	-56.2	-86.9	-52.0
18	308.2	141.9	183.7	148.4	212.8	-166.3	-124.5	-159.8	-95.4
19	329.3	415.1	490.4	432.4	433.4	85.8	170.1	103.1	104.1
20	366.1	284.9	282.0	248.6	205.7	-81.2	-84.1	-117.6	-160.5
21	462.3	231.3	334.5	294.9	644.8	-231.0	-127.8	-167.4	182.5
22	134.0	39.6	65.2	28.9	38.7	-94.4	-68.8	-105.1	-95.3
23	611.1	609.1	615.3	629.3	646.8	-2.0	4.3	18.2	35.8
24	346.1	255.9	423.7	329.0	406.2	-90.2	77.6	-17.1	60.1
25	123.7	61.2	55.8	59.9	229.3	-62.4	-67.9	-63.8	105.6
26	436.5	484.6	427.2	527.4	487.1	48.1	-9.3	90.9	50.6
27	407.0	438.5	443.7	366.5	316.0	31.5	36.7	-40.5	-91.0
28	316.6	332.2	385.4	308.9	341.1	15.6	-11.2	-7.7	24.5
30	197.0	285.5	348.7	318.8	261.9	88.5	151.7	121.7	64.9
31	140.5	156.3	174.5	147.2	181.9	15.8	34.0	6.7	41.4
32	360.3	310.2	335.1	269.0	300.4	9.8	34.7	-31.3	0.1
33	126.6	87.5	64.5	98.9	74.3	-39.0	-62.1	-27.7	-52.3
34	279.2	67.4	73.3	59.9	402.0	-211.7	-205.9	-219.3	122.8
35	329.3	339.9	325.6	325.2	278.1	10.6	-3.7	-4.1	-51.2
36	223.9	189.9	182.5	212.8	175.2	-34.0	-41.4	-11.1	-48.7
37	185.4	208.2	81.2	190.4	83.0	22.8	-104.1	5.0	-102.4
38	428.6	305.0	324.7	372.4	417.0	-123.6	-103.9	-56.2	-11.6
39	241.8	225.7	238.1	223.0	247.7	-16.0	-3.7	-18.8	5.9
40	151.6	114.8	116.1	84.7	164.7	-36.8	-35.5	-66.9	13.1
41	131.4	120.5	151.3	311.0	208.6	-10.9	19.9	179.6	77.2
42	352.2	354.4	348.8	367.0	312.7	2.2	-3.4	14.8	-39.5
43	183.1	239.6	135.4	207.1	314.5	56.5	-47.7	24.0	131.4
44	446.0	326.5	353.7	417.8	424.7	-119.4	-92.2	-28.2	-21.3
45	141.3	274.1	275.5	163.1	179.6	132.8	134.2	21.8	38.3
46	440.3	597.9	507.1	573.8	576.7	157.6	66.7	193.5	136.4
47	450.2	450.1	441.7	498.0	449.1	0.0	-8.5	47.8	-1.1
48	424.9	308.3	114.1	375.8	284.7	-116.6	-310.8	-49.2	-140.3
49	307.5	184.7	266.9	274.0	649.7	-122.8	-40.6	-33.5	342.2
50	388.4	366.5	346.8	381.0	395.3	-21.9	-41.6	-7.4	6.9
52	358.5	299.8	385.3	335.3	336.4	-58.7	26.7	-23.2	-22.2
53	366.9	200.4	215.2	220.1	260.7	-166.5	-151.6	-146.8	-106.2
54	306.0	244.1	278.7	273.8	389.1	-61.9	-27.3	-32.3	83.1
55	278.5	164.6	190.7	188.7	274.0	-114.0	-87.8	-89.8	-4.5
56	176.3	179.5	257.1	155.1	168.3	3.2	80.8	-21.2	-8.0
57	181.1	247.9	249.0	138.7	188.1	66.8	67.9	-42.4	7.0
59	249.3	240.6	246.0	219.1	142.7	-8.7	-3.3	-30.2	-106.6
60	336.0	294.6	289.6	288.3	437.0	-41.4	-46.4	-47.8	101.0

**Table 3**  
**(continued)**  
**Aeva3D-HE Positive volume (mm3) Right**  
**Lash Enhancing Serum**

61	359.9	305.3	270.5	295.3	328.1	-54.5	-89.4	-61.6	-31.8
62	306.2	316.2	375.0	353.9	264.0	10.0	68.7	47.7	-42.2
63	413.3	413.5	418.5	396.8	421.9	0.1	5.2	-16.5	8.5
64	353.5	269.1	266.6	271.7	299.9	-84.3	-86.9	-81.7	-53.5
65	374.0	337.3	366.5	357.6	396.8	-36.8	-7.5	-16.4	22.7
66	210.5	191.6	194.8	180.5	197.9	-18.9	-15.6	-30.0	-12.6
67	230.8	219.1	266.5	199.7	221.6	-31.7	15.7	-51.1	-29.2
68	217.4	171.1	165.8	217.9	198.2	-46.3	-51.6	0.5	-19.3
69	235.0	19.1	7.6	17.4	24.7	-215.9	-227.4	-217.5	-210.2
70	302.1	209.6	408.3	280.9	274.2	-92.5	106.2	-21.2	-27.9
71	207.5	225.9	229.2	213.8	183.1	18.4	21.7	6.3	-24.4
72	192.4	180.6	177.5	146.9	173.6	-11.8	-15.0	-45.5	-18.8
73	357.2	348.4	363.4	321.7	320.3	-8.7	6.2	-35.5	-36.9
74	202.6	236.4	188.0	186.3	197.0	33.8	-14.6	-16.3	-5.6
75	261.6	169.5	206.7	276.4	175.4	-92.1	-54.9	14.8	-86.2
76	350.9	366.0	696.5	394.6	352.5	15.1	345.7	43.7	1.6
77	444.6	527.9	995.1	381.0	506.0	83.3	550.5	-63.6	61.4
78	258.5	255.8	221.0	237.3	235.6	-2.7	-37.5	-21.2	-22.9
79	173.9	662.8	176.0	197.9	213.0	488.9	2.1	24.0	39.1
80	335.7	518.3	334.3	391.6	380.2	182.6	-1.4	55.9	44.5
82	335.5	303.2	326.0	342.1	364.0	-32.3	-9.5	6.7	28.5
84	300.0	266.3	293.7	347.4	247.4	-33.7	-6.3	47.4	-52.6
86	331.4	315.6	245.3	275.1	242.1	-15.8	-86.1	-56.3	-89.3
87	331.5	340.7	433.2	310.1	310.9	9.2	101.7	-21.4	-20.6
88	253.9	497.9	511.1	480.8	314.5	244.1	257.3	226.9	60.6
89	351.7	394.4	378.7	340.8	363.5	42.7	27.0	-10.8	11.8
90	251.5	222.7	255.0	249.4	235.8	-28.8	3.5	-2.1	-15.7
91	171.7	24.2	320.6	75.3	40.6	-147.5	148.9	-96.4	-131.1
92	165.0	106.9	25.8	269.4	220.1	-58.2	-139.2	104.4	55.1
93	218.5	210.7	175.8	217.1	156.9	-7.8	-42.6	-1.4	-61.6
94	247.4	0.3	184.2	60.3	0.0	-247.2	-63.2	-187.1	-247.4
95	315.0	346.0	313.7	300.6	249.0	31.0	-1.3	-14.4	-6.0
96	297.1	234.1	267.9	260.1	231.6	27.0	60.8	53.0	24.5
97	302.2	306.6	147.2	66.5	2.3	4.5	-155.0	-235.6	-299.9
98	357.8	349.8	349.5	268.1	321.2	-8.0	-8.3	-89.6	-36.6
99	496.1	443.3	421.1	440.2	442.3	-52.8	-75.0	-55.9	-53.8
100	278.9	238.3	260.1	235.6	334.2	-40.6	-18.8	-43.3	55.3
101	221.3	180.8	149.3	247.5	455.5	-40.5	-72.0	26.2	234.2
102	187.3	159.3	201.0	208.6	208.1	-27.9	13.7	21.3	20.8
103	111.9	35.2	11.8	15.9	0.0	-76.7	-100.1	-96.0	-111.9
104	287.0	286.4	281.2	360.2	278.8	-0.6	-5.8	73.2	-8.2
105	443.9	448.1	483.1	487.6	445.4	4.2	39.2	43.7	1.4
106	389.5	337.0	170.3	497.1	359.5	-52.4	-219.2	107.7	-30.0
107	373.0	370.5	452.4	354.6	317.3	-2.5	79.4	-18.4	-55.7
108	356.1	360.4	497.4	337.6	390.5	4.3	141.3	-18.5	34.4
109	316.5	358.3	310.4	368.0	335.9	41.7	-6.1	51.5	19.4
110	479.7	500.1	516.1	578.7	422.2	20.5	36.5	99.0	-57.5
111	157.4	164.0	146.3	152.9	179.5	6.6	-11.1	-4.4	22.1
112	257.6	216.7	262.0	227.9	231.8	-40.8	4.4	-29.7	-25.8
114	322.9	262.3	269.6	271.9	299.6	-60.6	-53.3	-51.0	-23.4
115	419.6	351.6	458.3	356.3	351.2	-68.0	38.7	-63.4	-68.5
116	277.7	230.9	315.9	131.0	225.5	-46.9	38.2	-146.8	-52.3
117	318.6	288.1	298.9	273.5	304.7	-30.5	-19.6	-45.1	-13.8
118	250.0	168.8	185.4	218.6	225.1	-81.1	-64.6	-31.4	-24.8
119	232.0	270.8	246.6	294.4	204.1	38.7	14.6	62.4	-27.9
120	361.1	265.3	248.1	160.0	136.6	-95.8	-113.0	-201.1	-224.5
121	358.7	450.2	420.0	377.3	408.6	91.6	61.3	18.7	49.9
Mean =	292.9	276.0	287.7	277.1	282.2	-16.9	-5.3	-15.8	-10.8
Median =	302.1	265.3	273.7	273.8	278.8	-15.6	-8.3	-18.4	-13.8
Standard Deviation =	95.0	126.1	143.9	120.9	128.1	91.9	105.0	80.1	87.0
Maximum =	611.1	662.8	995.1	629.3	649.7	488.9	550.5	226.9	342.1
Minimum =	111.9	0.3	7.6	15.9	0.0	-247.2	-310.8	-235.6	-299.9

	<i>Mean % Change From Baseline</i>				<i>Total</i>	<i>Tallies &amp; Percentages</i>			
	<i>Month 1</i>	<i>Month 2</i>	<i>Month 4</i>	<i>Month 8</i>		<i>Month 1</i>	<i>Month 2</i>	<i>Month 4</i>	<i>Month 8</i>
	-5.8%	-4.4%	-5.4%	-3.7%		113	113	113	113
	Decrease	Decrease	Decrease	Decrease	Increased Values	43	46	42	49
					Decreased Values	70	67	71	64
					No Change	0	0	0	0
					Increased Values	38.05%	40.71%	37.17%	43.36%
					Decreased Values	61.95%	59.29%	62.83%	56.64%
					No Change	0.00%	0.00%	0.00%	0.00%

Did Not Complete Subjects: 7, 51, 58, 81, 83, 85, 113  
Note: Data for Subject #29 not included due to image noise



**Table 3**  
(continued)

**Statistical Analysis of Aeva3D-HE Positive volume (mm3)**

**Within-Groups Analysis For :**

***Lash Enhancing Serum (Left)***

Pre-Test	Normality	Brown-Forsythe	Friedman ANOVA
P-Value	< 0.050	Not Required	0.01

**Pairwise Comparisons**

Difference from Baseline	Test Type	P-value	Significance	Direction (Mean)
Month 1	Dunn's Method	0.006	Yes	Decrease
Month 2	Dunn's Method	0.610	No	Decrease
Month 4	Dunn's Method	1.000	No	Decrease
Month 8	Dunn's Method	1.000	No	Decrease

**Within-Groups Analysis For :**

***Lash Enhancing Serum (Right)***

Pre-Test	Normality	Brown-Forsythe	Friedman ANOVA
P-Value	< 0.050	Not Required	0.02

**Pairwise Comparisons**

Difference from Baseline	Test Type	P-value	Significance	Direction (Mean)
Month 1	Dunn's Method	0.019	Yes	Decrease
Month 2	Dunn's Method	0.370	No	Decrease
Month 4	Dunn's Method	0.013	Yes	Decrease
Month 8	Dunn's Method	0.103	No	Decrease

\* = ANOVA (RM) compares the means across groups (the non-parametric version is Friedman). The null hypothesis is all means are equivalent and the alternative is that the mean of at least one group differs. If ANOVA is significant further pairwise comparisons can be made, if not then it is assumed there is no statistically significant difference among the mean (or ranks) and no further testing is done due to risk of type one error. It is possible that Friedman or RM ANOVA may be significant, but when running post-hoc test may not show any statistically significant difference due to only examining the comparisons to baseline, post-hoc test, small sample size, lack of power, or if there is borderline significance.

\* = Dunn's method is a post-hoc test commonly run after Friedman RM ANOVA. It allows for comparisons between a control group, and it is a robust, non-parametric test that adjusts for multiple comparisons.

The images obtained from the Aeva<sup>3d</sup>-HE instrument were used to measure the periorbital volume, the higher the value, the greater the volume.

**Summary:**


For subjects using the  Lash Enhancing Serum, when compared to baseline, there was a statistically significant decrease in the periorbital volume measurements after 1 month of test material usage on the left side. There was also a statistically significant decrease from baseline after month 1 and month 4 of test material usage on the right side.

Table 4

VISIA-CR Image Analysis Color Data-R/RGB \* Left Iris

.01 -- [REDACTED] Last Enhancing Serum

Subject #	Baseline	Month 1	Month 2	Month 4	Month 8	Difference From Baseline At :			
						Month 1	Month 2	Month 4	Month 8
1	67.47	74.50	66.40	65.49	71.91	7.0	-1.1	-2.0	4.4
2	87.30	80.34	83.49	80.80	82.48	-7.0	-3.8	-6.5	-4.8
3	82.14	82.96	80.54	83.33	92.05	0.8	-1.6	1.2	9.9
4	86.45	85.06	91.32	83.16	82.08	-1.4	5.1	-3.3	-4.4
5	32.87	33.00	30.75	27.54	31.98	0.1	-2.1	-5.3	-0.9
6	32.62	31.49	26.52	26.78	31.54	-1.1	-6.1	-5.8	-1.1
8	30.98	29.39	30.49	31.25	28.08	-1.6	-0.5	0.3	-2.9
9	99.91	102.36	97.06	95.15	90.15	2.5	-2.8	-4.8	-9.8
10	83.35	91.31	81.81	86.71	82.72	8.0	-1.5	3.4	-0.6
11	24.15	23.34	25.65	32.66	25.00	-0.8	1.5	8.5	0.9
12	89.31	88.24	86.06	89.73	93.21	-1.1	-3.2	0.4	3.9
13	33.48	33.20	28.79	29.12	29.38	-0.3	-4.7	-4.4	-4.1
14	31.34	35.65	31.74	31.61	32.62	4.3	0.4	0.3	1.3
15	22.39	27.44	30.79	27.43	29.04	5.1	8.4	5.0	6.7
16	42.44	37.53	39.92	42.18	42.87	-4.9	-2.5	-0.3	0.4
17	67.49	65.45	72.73	69.41	68.01	-2.0	5.2	1.9	0.5
18	54.64	57.17	46.53	55.55	52.08	2.5	-8.1	0.9	-2.6
19	55.53	47.29	58.91	50.99	50.01	-8.3	3.4	-4.6	-5.5
20	78.09	89.03	79.31	76.23	73.72	10.9	1.2	-1.9	-4.4
21	77.35	79.31	86.82	86.91	89.20	2.0	9.5	9.6	11.9
22	52.34	54.28	53.25	53.02	54.50	1.9	0.9	0.7	2.2
23	81.68	84.73	82.21	78.26	77.36	3.0	8.5	-3.4	-4.3
24	28.84	26.10	27.03	29.55	23.94	-2.7	-1.8	0.7	-4.9
25	26.84	22.98	33.89	25.80	26.45	-3.9	7.0	-1.0	-0.4
26	83.50	88.69	84.77	84.91	83.73	5.2	1.3	1.4	0.2
27	51.46	48.60	48.38	53.60	53.94	-2.9	-3.1	2.1	2.5
28	45.83	46.19	48.33	50.29	46.75	0.4	2.5	4.5	0.9
29	61.72	67.98	71.45	75.03	72.82	6.3	9.7	13.3	11.1
30	19.45	20.89	22.31	26.36	20.64	1.4	2.9	6.9	1.2
31	26.28	24.78	21.86	24.72	25.66	-1.5	-4.4	-1.6	-0.6
32	59.27	57.60	55.75	59.61	59.51	-1.7	-3.5	0.3	0.2
33	47.32	44.71	48.45	43.14	46.71	-2.6	1.1	-4.2	-0.6
34	54.33	58.59	59.64	61.62	60.46	4.3	5.3	7.3	6.1
35	64.59	62.65	72.42	52.27	67.64	-1.9	7.8	-12.3	3.0
36	47.17	48.07	50.57	49.03	53.01	0.9	3.4	1.9	5.8
37	32.39	32.61	29.56	31.88	30.31	0.2	-2.8	-0.5	-2.1
38	92.66	88.70	93.49	99.24	86.80	-4.0	0.8	6.6	-5.9
39	89.05	87.15	91.51	91.50	90.72	-1.9	2.5	2.5	4.7
40	26.27	27.70	30.98	30.43	23.89	1.4	4.7	4.2	-2.4
41	30.16	29.28	27.53	30.91	28.76	-0.9	-2.6	0.7	-3.4
42	54.50	49.80	58.47	60.51	61.55	-4.7	4.0	6.0	7.0
43	36.72	33.60	33.93	34.43	34.23	-3.1	-2.8	-2.3	-2.5
44	67.58	70.78	65.39	65.73	71.57	3.2	-2.2	-1.9	4.0
45	27.49	31.40	33.43	32.98	30.40	3.9	5.9	5.5	2.9
46	55.43	66.64	59.80	64.53	75.03	11.2	4.4	9.1	19.6
47	61.11	43.72	52.38	50.89	47.01	-17.4	-8.7	-10.2	-14.1
48	31.08	32.31	26.63	30.17	29.50	1.2	-4.4	-0.9	-1.6
49	46.97	43.60	51.51	49.84	50.06	-3.4	4.5	2.9	3.1
50	78.50	76.81	73.86	74.91	79.60	-1.7	-4.6	-3.6	1.1
52	41.35	53.37	53.25	49.32	52.69	12.0	11.9	8.0	11.3
53	87.23	89.95	100.19	96.34	90.70	2.7	13.0	9.1	3.5
54	29.88	28.01	29.40	26.24	28.50	-1.9	-0.5	-3.6	-1.4
55	33.88	30.42	28.07	35.03	33.88	-3.5	-5.8	1.1	0.0
56	76.00	71.65	79.58	75.21	76.42	-4.4	3.6	-0.8	0.4
57	42.81	40.31	43.68	39.97	37.57	-2.5	0.9	-2.8	-5.2
59	30.39	30.25	33.01	35.75	44.31	-0.1	2.6	5.4	13.9
60	86.58	83.15	88.11	90.08	90.86	-3.4	1.5	3.5	4.3
61	46.74	48.81	53.12	45.11	46.91	2.1	6.4	-1.6	0.2
62	36.74	39.11	40.29	36.63	43.58	2.4	3.6	-0.1	6.8
63	71.46	71.79	67.54	68.42	78.21	0.3	-3.9	-3.0	6.7
64	47.06	47.99	46.70	46.66	44.88	0.9	-0.4	-0.4	-2.2
65	45.40	42.79	42.85	44.03	42.94	-2.6	-2.5	-1.4	-2.5
66	63.62	64.89	63.56	65.27	60.44	1.3	-0.1	1.6	-3.2
67	40.98	38.41	40.31	41.27	37.38	-2.6	-0.7	0.3	-3.6

Table 4  
(continued)

VISIA-CR Image Analysis Color Data- R/RGB\* Left Iris

.01 = [redacted] Lash Enhancing Serum

68	63.29	63.84	63.14	59.82	61.85	0.6	-0.1	-3.5	-1.4
69	70.99	72.41	73.30	72.13	70.24	1.4	2.3	1.1	-0.8
70	32.72	39.54	36.48	38.10	35.84	6.8	3.8	5.4	3.1
71	52.52	49.88	43.17	51.07	54.77	-2.6	-9.3	-1.4	2.3
72	47.14	53.46	49.96	51.82	56.83	6.3	2.8	4.7	9.7
73	37.16	37.86	33.07	35.33	34.76	0.7	-4.1	-1.8	-2.4
74	30.46	26.49	22.52	24.70	33.61	-4.0	-7.9	-5.8	3.2
75	43.15	38.01	38.85	40.22	41.29	-5.1	-4.3	-2.9	-1.9
76	58.60	58.17	60.26	59.78	59.84	-0.4	1.7	1.2	1.2
77	50.12	57.06	54.01	50.26	57.04	6.9	3.9	0.1	6.9
78	69.72	72.18	72.46	71.77	71.71	2.5	2.7	2.1	2.0
79	54.32	52.01	56.31	54.74	52.10	-2.3	2.5	0.4	-2.2
80	42.92	38.99	39.57	38.73	38.11	-3.9	-3.4	-4.2	-4.8
82	42.14	44.57	46.08	47.85	47.54	2.4	3.9	5.7	5.4
84	28.27	34.73	26.50	28.09	30.86	6.5	-1.8	-0.2	2.6
86	45.64	49.71	52.15	47.46	52.97	4.1	6.5	1.8	7.3
87	36.77	36.23	41.09	40.42	42.53	-0.5	4.3	3.6	5.8
88	102.87	111.34	100.48	107.96	110.92	8.5	-2.4	5.1	8.1
89	73.50	76.11	76.84	79.61	77.54	2.6	3.3	6.1	4.0
90	91.16	88.05	92.17	89.90	92.71	-3.1	1.0	-1.3	1.6
91	45.04	43.54	46.29	42.53	49.33	-1.5	1.3	-2.5	4.3
92	73.06	64.68	62.15	62.25	60.95	-8.4	-10.9	-10.8	-12.1
93	71.30	63.78	66.91	63.75	65.59	-7.5	-4.4	-7.5	-5.7
94	95.65	95.39	80.10	91.66	99.82	-0.3	-15.6	-4.0	4.2
95	77.24	73.10	74.82	77.22	75.99	-4.1	-2.4	0.0	-1.3
96	77.50	77.39	74.24	79.98	74.18	-0.1	-3.3	2.5	-3.3
97	20.06	25.23	19.63	20.63	24.44	5.2	-0.4	0.6	4.4
98	72.65	64.03	65.82	77.04	69.05	-8.6	-6.8	4.4	-3.6
99	49.68	47.76	52.14	51.59	52.14	-1.9	2.5	1.9	2.5
100	64.13	64.22	64.29	66.67	64.29	0.1	0.2	2.5	0.2
102	54.83	55.65	57.28	59.86	53.26	0.8	2.4	5.0	-1.6
102	72.55	64.95	66.04	57.02	69.24	-7.6	-6.5	-15.5	-3.3
103	56.10	53.49	61.66	57.06	56.07	-2.6	5.6	1.0	0.0
104	59.66	57.31	61.04	60.66	64.70	-2.4	1.4	1.0	5.0
105	98.67	92.65	91.95	102.30	98.59	-6.0	-6.7	3.6	-0.1
106	47.06	50.02	52.98	54.76	55.54	3.0	5.9	7.7	8.5
107	44.51	46.82	42.55	45.71	39.31	2.3	-2.0	1.2	-5.2
108	91.56	88.48	88.45	90.07	84.49	-3.1	-3.1	-1.5	-7.1
109	91.42	93.24	96.72	93.85	84.67	1.8	5.3	2.4	-6.7
110	90.20	89.53	92.55	92.16	94.25	-0.7	2.4	2.0	4.1
111	52.14	51.47	58.00	48.79	51.89	-0.7	5.9	-3.3	-0.2
112	35.77	34.57	38.19	35.24	36.05	-1.2	2.4	-0.5	0.3
114	51.19	52.87	57.15	53.66	54.03	1.7	6.0	2.5	2.8
115	47.38	45.53	46.75	48.35	46.72	-1.8	-0.6	1.0	-0.7
116	66.42	62.56	67.42	64.99	68.95	-3.9	1.0	-1.4	2.5
117	58.75	55.81	53.45	60.23	52.91	-2.9	-5.3	1.5	-5.8
118	78.21	82.76	78.86	81.72	86.36	4.6	0.6	3.5	8.2
119	50.12	49.89	50.80	48.38	49.97	-0.2	0.7	-1.7	-0.1
120	59.10	53.69	58.48	51.89	61.73	-5.4	-0.6	-7.2	2.6
121	34.90	39.65	32.81	40.88	46.04	4.8	-2.1	6.0	11.1
<b>Mean =</b>	<b>56.14</b>	<b>56.02</b>	<b>56.43</b>	<b>56.61</b>	<b>57.16</b>	<b>-0.12</b>	<b>0.29</b>	<b>0.46</b>	<b>1.02</b>
<b>Median =</b>	<b>53.42</b>	<b>53.12</b>	<b>53.73</b>	<b>52.64</b>	<b>53.98</b>	<b>-0.36</b>	<b>0.67</b>	<b>0.62</b>	<b>0.35</b>
<b>Standard Deviation =</b>	<b>21.30</b>	<b>21.39</b>	<b>21.35</b>	<b>21.51</b>	<b>21.45</b>	<b>4.41</b>	<b>4.74</b>	<b>4.61</b>	<b>5.25</b>
<b>Maximum =</b>	<b>102.87</b>	<b>111.34</b>	<b>100.48</b>	<b>107.96</b>	<b>110.92</b>	<b>12.01</b>	<b>12.96</b>	<b>13.31</b>	<b>19.61</b>
<b>Minimum =</b>	<b>19.45</b>	<b>20.89</b>	<b>19.63</b>	<b>20.63</b>	<b>20.64</b>	<b>-17.38</b>	<b>-15.55</b>	<b>-15.53</b>	<b>-14.10</b>

Mean % Change From Baseline

Month 1	Month 2	Month 4	Month 8
-0.2%	0.5%	0.8%	1.8%
Decrease	Increase	Increase	Increase

Tallies & Percentages

Total	Month 1	Month 2	Month 4	Month 8
Increased Values	52	61	65	62
Decreased Values	62	53	49	52
No Change	0	0	0	0
Increased Values	45.61%	53.51%	57.02%	54.39%
Decreased Values	54.39%	46.49%	42.98%	45.61%
No Change	0.00%	0.00%	0.00%	0.00%

Did Not Complete. Subjects#s 7, 51, 58, 81, 83, 85, 113

Mean R/RGB = Mean red value from the RGB color space, for the detected features within the masked region of interest (ROI)

Table 4  
 (continued)

VISIA-CR Image Analysis Color Data- R/RGB Right Iris

.01 [REDACTED] Lash Enhancing Serum

Subject #	Baseline	Month 1	Month 2	Month 4	Month 8	Difference From Baseline At:			
						Month 1	Month 2	Month 4	Month 8
1	66.42	68.49	67.52	66.47	67.39	2.1	1.1	0.1	1.0
2	90.23	83.50	90.87	85.20	91.79	-6.7	0.6	-5.0	1.6
3	76.63	83.66	73.37	86.50	81.11	7.0	-3.3	9.9	4.5
4	82.80	82.23	84.83	84.36	84.85	-0.6	2.0	1.6	2.1
5	36.65	34.97	30.08	31.51	33.49	-1.7	-6.6	-5.1	-3.2
6	26.79	26.24	27.86	23.59	25.59	-0.6	1.1	-3.2	-1.2
8	32.75	27.59	31.24	30.27	25.63	-5.2	-1.5	-2.5	-7.1
9	87.67	93.58	88.77	86.73	89.53	5.9	1.1	-0.9	1.9
10	77.76	82.67	79.62	76.72	83.65	4.9	1.9	-1.0	5.9
11	26.96	26.22	23.98	28.53	27.37	-0.7	-3.0	1.6	0.4
12	90.96	88.81	86.36	99.65	96.40	-2.1	-4.6	8.7	5.4
13	28.89	29.32	27.31	27.02	27.91	0.4	-1.6	-1.9	-1.0
14	37.30	38.40	34.45	29.82	27.44	1.1	-2.9	-7.5	-9.9
15	21.96	31.52	31.46	22.87	27.30	9.6	9.5	0.9	5.3
16	39.83	36.57	37.65	39.07	39.16	-3.3	-2.2	-0.8	-0.7
17	69.88	66.44	74.82	75.98	73.07	-3.4	4.9	6.1	3.2
18	56.58	55.52	43.08	52.76	52.92	-1.1	-13.5	-3.8	-3.7
19	62.45	49.69	55.06	53.45	54.70	-12.8	-7.4	-9.0	-7.8
20	72.71	80.71	87.86	76.45	67.97	8.0	15.2	3.7	-4.7
21	82.42	88.30	96.43	101.73	99.14	5.9	14.0	19.3	16.7
22	54.18	54.06	54.68	54.73	54.96	-0.1	0.5	0.5	0.8
23	68.57	80.16	75.60	69.26	71.67	11.6	7.0	0.7	3.1
24	25.58	26.92	24.24	25.33	26.70	1.3	-1.3	-0.2	1.1
25	57.58	20.12	31.08	23.60	40.57	-37.5	-26.5	-34.0	-17.0
26	82.69	83.86	85.21	88.57	89.46	1.2	2.5	5.9	6.8
27	58.21	54.80	59.11	56.13	61.15	-3.4	0.9	-2.1	2.9
28	45.91	53.63	57.17	52.51	50.15	7.7	11.3	6.6	4.2
29	52.46	72.50	44.50	52.41	50.83	20.0	-8.0	-0.1	-1.6
30	22.06	21.17	23.43	23.17	22.17	-0.9	1.4	1.1	0.1
31	23.46	22.84	25.61	23.95	22.68	-0.6	2.1	0.5	-0.8
32	69.17	61.60	59.54	61.32	63.36	-7.6	-9.6	-7.8	-5.8
33	53.55	55.77	53.06	49.16	54.41	2.2	-0.5	-4.4	0.9
34	57.55	55.36	60.82	62.79	58.23	-2.2	3.3	5.2	0.7
35	72.71	75.21	74.06	59.09	77.59	2.5	1.4	-13.6	4.9
36	46.89	48.75	47.33	50.34	49.79	1.9	0.4	3.4	-3.1
37	29.31	30.87	27.92	29.55	30.38	1.6	-1.4	0.2	1.1
38	86.40	82.17	88.30	87.69	85.21	-4.2	1.9	1.3	-1.2
39	86.92	85.56	86.23	86.52	89.90	-1.4	-0.7	-0.4	3.0
40	27.56	27.13	29.09	27.74	25.05	-0.4	1.5	0.2	-2.5
41	27.90	35.52	25.13	27.17	25.47	7.6	-2.8	-0.7	-2.4
42	49.90	47.68	56.92	56.61	65.27	-2.2	7.0	6.7	15.4
43	33.24	30.19	32.14	32.02	31.65	-3.1	-1.1	-1.2	-1.6
44	75.63	75.92	69.05	73.00	74.07	0.3	-6.6	-2.6	-1.6
45	28.25	36.21	28.55	30.21	26.96	8.0	0.3	2.0	-1.3
46	72.21	87.16	63.41	61.92	93.00	15.0	-8.8	-10.3	20.8
47	64.27	59.15	62.66	59.38	53.76	-5.1	-1.6	-4.9	-10.5
48	30.74	27.52	28.88	28.15	31.90	-3.2	-1.9	-2.6	1.2
49	46.71	42.40	47.35	43.26	45.38	-4.3	0.6	-3.5	-1.3
50	71.61	70.97	70.34	68.54	72.80	-0.6	-1.3	-3.1	1.2
52	42.72	40.64	41.92	37.49	44.39	-2.1	-0.8	-5.2	1.7
53	72.21	79.35	75.26	76.67	78.32	7.1	3.0	4.5	6.1
54	27.39	26.76	27.82	25.24	27.16	-0.6	0.4	-2.1	-0.2
55	34.06	30.85	25.32	32.95	27.96	-3.2	-8.7	-1.1	-6.1
56	68.13	66.24	80.07	72.17	72.83	-1.9	11.9	4.0	4.7
57	30.79	31.43	34.08	33.04	29.73	0.6	3.3	2.2	-1.1
59	27.78	29.75	26.98	28.27	30.46	2.0	-0.8	0.5	2.7
60	78.87	82.63	74.94	80.68	77.92	3.8	-3.9	1.8	-0.9
61	42.96	44.76	47.79	42.32	42.49	1.8	4.8	-0.6	-0.5
62	33.13	31.46	31.15	32.30	34.95	-1.7	-2.0	-0.8	1.8
63	72.70	70.82	67.25	67.51	71.25	-1.9	-5.5	-5.2	-1.4
64	43.04	43.46	43.34	43.88	41.22	0.4	0.3	0.8	-1.8
65	41.15	37.29	37.47	38.82	39.33	-3.9	-3.7	-2.3	-1.8
66	57.25	61.76	60.01	60.15	60.44	4.5	2.8	2.9	3.2
67	36.66	37.15	34.58	36.69	36.16	0.5	-2.1	0.0	-0.5

Table 4  
(continued)

VISA-CR Image Analysis Color Data- R/RGB Right Iris

.01 - [REDACTED] Lash Enhancing Serum

68	50.98	56.33	49.27	50.86	53.08	5.3	-1.7	-0.1	2.1
69	73.94	73.79	73.38	74.95	72.30	-0.1	-0.6	1.0	-1.6
70	30.12	31.99	33.25	30.63	31.21	1.9	3.1	0.5	1.1
71	46.94	48.87	48.60	51.72	50.15	1.9	1.7	4.8	3.2
72	47.84	51.03	49.09	45.75	51.32	3.2	1.2	-2.1	3.5
73	36.57	38.28	36.67	36.09	37.24	1.7	0.1	-0.5	0.7
74	25.83	21.67	22.18	24.63	25.31	-4.2	-3.6	-1.2	-0.5
75	35.82	38.40	35.78	35.11	36.26	2.6	0.0	-0.7	0.4
76	50.72	55.92	53.30	53.80	51.29	5.2	2.6	3.1	0.6
77	52.66	47.45	54.28	51.37	48.66	-5.2	1.6	-1.3	-4.0
78	61.28	67.45	65.13	67.22	70.83	6.2	3.9	5.9	9.5
79	68.43	57.78	66.66	67.29	61.78	-10.7	-1.8	-1.1	-6.6
80	40.77	38.91	39.93	35.83	38.78	-1.9	-0.8	-4.9	-2.0
82	41.59	37.99	36.84	40.41	41.06	-3.6	-4.7	-1.2	-0.5
84	22.54	32.84	23.04	24.43	28.63	10.3	0.5	1.9	6.1
86	43.52	40.64	38.15	48.47	43.53	-2.9	-5.4	4.9	0.0
87	31.69	35.10	34.85	36.39	36.51	3.4	3.2	4.7	4.8
88	108.80	106.37	103.05	100.93	104.98	-8.4	-5.7	-7.9	-3.8
89	72.49	73.89	74.16	73.77	75.56	1.4	1.7	1.3	3.1
90	88.33	90.68	94.12	92.21	90.06	2.3	5.8	3.9	1.7
91	34.83	39.01	33.65	35.31	38.34	4.2	-1.2	0.5	3.5
92	68.25	64.29	57.75	72.12	54.33	-4.0	-10.5	3.9	-13.9
93	85.53	80.30	69.05	77.73	81.03	-5.2	-16.5	-7.8	-4.5
94	106.79	107.77	91.91	107.72	110.43	1.0	-14.9	0.9	3.6
95	80.77	77.16	87.32	82.11	83.32	-3.6	6.6	1.3	2.6
96	69.12	70.17	70.45	74.01	70.93	1.0	1.3	4.9	1.8
97	20.92	20.38	16.90	18.97	21.58	-0.5	-4.2	-1.9	0.7
98	61.33	61.05	69.89	55.26	64.72	-0.3	8.6	-6.1	3.4
99	47.38	49.72	51.95	49.76	52.56	2.3	4.6	2.4	5.2
100	55.73	48.54	54.53	51.13	50.40	-7.2	-1.2	-4.6	-5.3
101	55.42	52.67	58.00	55.77	53.41	-2.8	2.6	0.1	-2.0
102	70.45	67.35	72.67	50.87	66.85	-3.1	2.2	-19.6	-3.6
103	60.16	65.09	71.29	64.01	68.20	4.9	11.1	3.8	8.0
104	53.05	53.08	51.48	51.26	55.60	0.0	-1.6	-1.8	2.6
105	101.73	94.32	92.30	101.14	95.25	-7.4	-9.4	-0.6	-6.5
106	52.12	50.23	52.48	57.97	57.10	-1.9	0.4	5.9	5.0
107	41.78	41.78	45.42	39.89	37.03	0.0	3.6	-1.9	-4.7
108	84.39	85.78	91.30	91.22	90.34	1.4	6.9	6.8	5.9
109	94.44	85.84	85.06	79.23	88.85	-8.6	-9.4	-15.2	-5.6
110	88.26	89.07	88.50	89.77	90.45	0.8	0.2	1.5	2.2
111	48.58	58.09	54.08	48.00	53.33	9.5	5.5	-0.6	4.7
112	36.78	35.27	36.76	33.84	32.62	-1.5	0.0	-2.9	-4.2
114	55.06	57.73	55.45	59.13	60.02	2.7	0.4	4.1	5.0
115	52.66	53.21	54.80	44.85	44.17	0.5	2.1	-7.8	-8.5
116	64.41	63.68	64.76	66.12	67.79	-0.7	0.3	1.7	3.4
117	58.23	61.79	60.76	59.01	63.22	3.6	2.5	0.8	5.0
118	70.31	75.29	71.84	71.52	78.55	5.0	1.5	1.2	8.2
119	48.38	48.19	48.04	48.26	49.17	-0.2	-0.3	-0.1	0.8
120	57.31	55.42	54.25	51.25	58.14	-1.9	-3.1	-6.1	0.8
121	36.28	41.46	31.76	47.70	52.94	5.2	-4.5	11.4	16.7
Mean =	55.17	55.33	54.81	54.63	55.87	0.16	-0.36	-0.54	0.70
Median =	53.30	53.85	54.27	52.06	53.37	-0.06	0.30	-0.09	0.78
Standard Deviation =	21.35	21.50	21.70	22.07	22.44	6.10	5.86	5.99	5.46
Maximum =	108.80	107.77	103.05	107.72	110.43	20.04	15.15	19.31	20.79
Minimum =	20.92	20.12	16.70	18.97	21.58	-37.45	-26.50	-33.98	-17.01

Mean % Change From Baseline

Month 1	Month 2	Month 4	Month 8
0.3%	-0.7%	-1.0%	1.3%
Increase	Decrease	Decrease	Increase

Totals & Percentages

	Month 1	Month 2	Month 4	Month 8
Total	114	114	114	114
Increased Values	57	60	56	66
Decreased Values	57	54	58	48
No Change	0	0	0	0
Increased Values	50.00%	52.63%	49.12%	57.89%
Decreased Values	50.00%	47.37%	50.88%	42.11%
No Change	0.00%	0.00%	0.00%	0.00%

Did Not Complete Subject#s 7, 51, 58, 81, 83, 85, 113

Mean R/RGB = Mean red value from the RGB color space, for the detected features within the masked region of interest (ROI)

**Table 4**  
(continued)

.01 [REDACTED] Lash Enhancing Serum

Within-Groups Analysis For :  
VISIA-CR Image Analysis Color Data- R/RGB \* Left Iris

Pre-Test	Normality	Brown-Forsythe	Friedman ANOVA
P-Value	P < 0.050	Not Required	0.092

Within-Groups Analysis For :  
VISIA-CR Image Analysis Color Data- R/RGB \* Right Iris

Pre-Test	Normality	Brown-Forsythe	Friedman ANOVA
P-Value	P < 0.050	Not Required	0.045

**Pairwise Comparisons**

Difference from Baseline	Test Type	P-value	Significance	Direction (Mean)
Month 1	Dunn's Method	1.000	No	Increase
Month 2	Dunn's Method	1.000	No	Decrease
Month 4	Dunn's Method	1.000	No	Decrease
Month 8	Dunn's Method	0.068	No	Increase

\* = ANOVA (RM) compares the means across groups (the non-parametric version is Friedman). The null hypothesis is all means are equivalent and the alternative is that the mean of at least one group differs. If ANOVA is significant further pairwise comparisons can be made, if not then it is assumed there is no statistically significant difference among the mean (or ranks) and no further testing is done due to risk of type one error. It is possible that Friedman or RM ANOVA may be significant, but when running post-hoc test may not show any statistically significant difference due to only examining the comparisons to baseline, post-hoc test, small sample size, lack of power, or if there is borderline significance.

Mean R/RGB = Mean red value from the RGB color space, for the detected features within the masked region of interest (ROI)

**Summary:**

For subjects using [REDACTED] Lash Enhancing Serum, there were no statistically significant changes in the R/RGB values in either the left or the right eye when compared to baseline R/RGB values.

Table 4  
(continued)

VISIA-CR Image Analysis Color Data - G/RGB \* Value Left Iris

.01 = [REDACTED] Lash Enhancing Serum

Subject #	Baseline	Month 1	Month 2	Month 4	Month 8	Difference From Baseline At :			
						Month 1	Month 2	Month 4	Month 8
1	43.07	45.54	44.42	40.40	46.46	2.5	1.4	-2.7	3.4
2	100.75	90.78	94.44	90.07	89.86	-10.0	-6.3	-10.7	-10.9
3	86.85	89.44	84.57	88.31	96.19	2.6	-2.3	1.5	9.3
4	75.69	76.50	82.46	72.01	70.88	0.8	6.8	-3.7	-4.8
5	28.48	27.27	25.02	20.63	25.62	-1.2	-3.5	-7.9	-2.9
6	25.62	25.45	19.20	20.13	24.92	-0.2	-6.4	-5.5	-0.7
8	23.83	25.41	28.99	28.69	24.17	1.6	5.2	4.9	0.3
9	101.06	102.23	95.68	92.21	86.95	1.2	-5.4	-8.9	-14.1
10	48.03	101.63	86.23	93.32	90.16	13.6	-1.8	5.3	2.1
11	19.79	18.55	21.46	27.27	19.85	-1.2	1.7	7.5	0.1
12	97.19	91.59	93.12	96.12	99.82	-5.7	-4.1	-1.1	2.6
13	31.00	31.67	24.06	24.39	25.61	0.7	-6.9	-6.6	-5.4
14	21.71	29.93	23.27	22.82	24.54	8.2	1.6	1.1	2.8
15	15.99	24.78	26.84	22.16	25.56	8.8	10.8	6.2	9.6
16	30.49	25.26	27.01	29.13	29.95	-5.2	-3.5	-1.4	-0.5
17	42.39	42.90	50.05	44.60	41.15	0.5	7.7	2.2	-1.2
18	33.85	37.05	24.58	37.61	32.60	3.2	-9.3	3.8	-1.2
19	38.56	28.81	41.67	33.83	33.06	-9.8	3.1	-4.7	-5.5
20	87.65	103.24	93.13	87.62	84.36	15.6	5.5	0.0	-3.3
21	60.45	72.10	82.64	81.62	82.41	11.7	22.2	21.2	22.0
22	29.35	31.89	30.14	29.77	30.78	2.5	0.8	0.4	1.4
23	92.00	95.21	92.23	87.71	82.51	3.2	0.2	-4.3	-9.5
24	24.73	21.49	21.94	25.16	18.60	-3.2	-2.8	0.4	-6.1
25	22.61	18.79	31.16	22.10	21.51	-3.8	8.5	-0.5	-1.1
26	86.27	90.07	82.87	81.49	83.61	3.8	-3.4	-4.8	-2.7
27	31.11	29.31	29.17	35.36	33.55	-1.8	-1.9	4.2	2.4
28	31.43	34.58	35.56	35.56	27.34	3.1	4.1	4.1	-4.1
29	62.85	68.16	71.69	51.41	71.32	5.3	8.8	-11.4	8.5
30	17.70	18.17	20.27	25.26	18.25	0.5	2.6	7.6	0.5
31	24.77	23.50	19.77	22.68	23.01	-1.3	-5.0	-2.1	-1.8
32	35.90	33.10	31.10	34.94	34.06	-2.8	-4.8	-1.0	-1.8
33	28.63	27.37	29.86	25.35	26.82	-1.3	1.2	-3.3	-1.8
34	34.40	38.73	38.36	42.43	38.32	4.3	4.0	8.0	3.9
35	72.86	71.54	84.31	54.60	77.76	-1.3	11.4	-18.3	4.9
36	28.41	30.34	31.79	30.19	32.39	1.9	3.4	1.8	4.0
37	23.06	24.51	19.95	22.10	21.40	1.5	-3.1	-1.0	-1.7
38	103.44	98.82	103.39	109.38	95.80	-4.6	0.0	5.9	-7.6
39	71.14	72.27	77.26	76.18	75.09	1.1	6.1	5.0	3.9
40	20.78	23.77	27.18	27.46	17.33	3.0	6.4	6.7	-3.4
41	22.85	23.12	18.36	21.80	19.59	0.3	-4.5	-1.1	-3.3
42	34.69	29.05	36.39	35.79	39.18	-5.6	1.7	1.1	4.5
43	27.84	22.09	22.56	23.88	23.42	-5.7	-5.3	-4.0	-4.4
44	41.71	44.78	44.61	40.15	46.82	3.1	2.9	-1.6	5.1
45	23.41	30.40	29.45	29.87	27.88	7.0	6.0	6.5	4.5
46	34.84	47.03	38.78	40.56	48.11	12.2	3.9	5.7	13.3
47	63.00	43.30	56.06	53.67	49.34	-19.7	-6.9	-9.3	-13.7
48	27.74	27.72	22.67	27.21	26.38	0.0	-5.1	-0.5	-1.4
49	28.56	24.96	30.98	29.94	30.10	-3.6	2.4	1.4	1.5
50	70.75	70.68	68.18	67.09	70.41	-0.1	-2.6	-3.7	-0.3
52	29.11	34.74	31.92	31.87	31.58	5.6	2.8	2.8	2.5
53	85.43	82.39	95.28	90.14	80.58	-3.0	9.8	4.7	-4.8
54	25.96	21.79	24.20	20.15	22.23	-4.2	-1.8	-5.8	-3.7
55	29.27	25.18	19.88	31.81	28.28	-4.1	-9.4	2.5	-1.0
56	82.05	75.05	86.04	81.18	81.82	-7.0	4.0	-0.9	-0.2
57	35.80	32.92	38.02	30.30	30.13	-2.9	2.2	-5.5	-5.7
59	24.07	23.06	26.34	30.08	38.29	-1.0	2.3	6.0	14.2
60	84.32	82.42	85.77	88.83	87.09	-1.9	1.4	4.5	2.8
61	28.26	29.06	36.77	27.12	27.41	0.8	8.5	-1.1	-0.9
62	27.08	29.68	31.02	27.83	35.05	2.6	3.9	0.8	8.0
63	46.38	47.71	44.79	45.92	51.27	1.3	-1.6	-0.5	4.9
64	29.00	28.89	29.28	27.07	27.00	-0.1	0.3	-1.9	-2.0
65	28.94	26.92	26.77	26.12	26.26	-2.0	-2.2	-2.8	-2.7
66	52.23	49.16	48.67	46.26	48.55	-3.1	-3.6	-6.0	-3.7
67	24.55	25.12	30.15	30.22	21.84	0.6	5.6	5.7	-2.7

Table 4  
(continued)  
VISIA-CR Image Analysis Color Data - G/RGB \* Value Left Iris

	.01 - [REDACTED] Lash Enhancing Serum								
68	41.01	45.83	40.81	37.20	39.84	4.8	-0.2	-3.8	-1.2
69	42.12	43.72	43.61	43.63	41.30	1.6	1.5	1.5	-0.8
70	22.46	30.70	27.33	27.86	24.70	8.2	4.9	5.4	2.2
71	37.67	33.74	28.15	35.24	35.82	-3.9	-9.5	-2.4	-1.9
72	29.30	34.29	31.06	32.44	38.16	5.0	1.8	3.1	8.9
73	27.28	25.48	22.11	23.71	23.68	-1.8	-5.2	-3.6	-3.6
74	27.84	21.04	17.28	19.72	29.45	-6.8	-10.6	-8.1	1.6
75	31.42	24.57	26.70	26.50	29.03	-6.9	-4.7	-4.9	-2.4
76	41.27	42.36	38.88	38.64	41.66	1.1	-2.4	-2.6	0.4
77	29.89	35.35	35.06	32.06	36.67	5.5	5.2	2.2	6.8
78	75.52	80.53	81.37	78.89	78.89	5.0	5.8	3.4	3.4
79	39.30	35.66	41.04	38.82	36.11	-3.6	1.7	-0.5	-3.2
80	32.38	26.57	26.38	25.35	24.67	-5.8	-6.0	-7.0	-7.7
82	26.54	30.57	31.13	32.35	31.66	4.0	4.6	5.8	5.1
84	22.66	33.98	20.47	23.22	26.50	11.3	-2.2	0.6	3.8
86	29.07	33.63	36.83	33.41	35.42	4.6	7.8	4.3	6.4
87	27.56	24.14	29.21	30.00	32.25	-3.4	1.6	2.4	4.7
88	101.81	113.64	100.20	105.39	112.34	11.8	-1.6	3.6	10.5
89	42.26	43.33	47.46	47.04	43.65	1.1	5.2	4.8	1.4
90	106.08	101.13	104.89	103.01	106.11	-4.9	-1.2	-3.1	0.0
91	29.43	29.53	28.18	27.06	31.28	0.1	-1.3	-2.4	1.8
92	51.00	46.13	41.75	39.34	37.90	-4.9	-9.3	-11.7	-13.1
93	75.01	62.07	67.45	64.31	65.89	-12.9	-7.6	-10.7	-9.1
94	68.23	67.14	57.57	62.61	69.86	-1.1	-10.7	-5.6	1.6
95	68.70	68.78	65.91	67.18	69.36	0.1	-2.8	-1.5	0.7
96	87.36	89.59	86.59	93.12	85.91	2.2	-0.4	5.8	-1.5
97	18.77	24.19	17.58	18.24	21.77	5.4	-1.2	-0.5	3.0
98	54.69	42.08	43.26	59.71	48.54	-12.6	-11.4	5.0	-6.1
99	41.04	39.83	43.70	43.20	42.33	-1.2	2.7	2.2	1.3
100	46.27	42.43	41.86	45.71	44.75	-3.8	-4.4	-0.6	-1.5
101	34.90	34.43	36.69	37.01	31.92	-0.5	1.8	2.1	-3.0
102	39.39	38.10	39.76	28.18	40.98	-1.3	0.4	-11.2	1.6
103	37.55	33.78	39.95	36.57	35.13	-3.8	2.4	-1.0	-2.4
104	40.37	38.20	43.17	40.36	46.35	-2.2	2.8	0.0	6.0
105	86.31	89.06	88.92	82.64	92.55	2.7	2.6	-3.7	6.2
106	26.71	32.40	31.39	30.81	32.06	5.7	4.7	4.1	5.4
107	25.49	29.66	26.82	28.03	27.27	4.2	1.3	2.5	1.8
108	99.96	97.78	98.62	99.25	93.17	-2.2	-1.3	-0.7	-6.8
109	91.22	94.93	97.34	93.86	84.91	3.7	6.1	2.6	-6.3
110	97.16	95.18	100.97	99.04	99.60	-2.0	3.8	1.9	2.4
111	30.51	32.46	38.52	28.51	34.85	1.9	8.0	-2.0	4.3
112	27.04	25.72	30.76	27.33	27.15	-1.3	3.7	0.3	0.1
114	31.55	36.16	37.45	35.67	34.57	4.6	5.9	4.1	3.0
115	34.18	30.47	31.82	34.31	32.98	-3.7	-2.4	0.1	-1.2
116	40.53	39.48	44.24	40.97	45.68	-1.1	3.7	0.4	5.1
117	62.57	60.89	56.91	62.21	55.97	-1.7	-5.7	-0.4	-6.6
118	55.88	59.72	55.49	60.04	65.78	3.8	-0.4	4.2	9.9
119	30.67	31.19	32.18	29.22	30.42	0.5	1.5	-1.4	-0.2
120	37.83	33.55	38.66	31.72	42.02	-4.3	0.8	-6.1	4.2
121	22.49	24.44	22.20	26.88	31.70	1.9	-0.3	4.4	9.2
Mean =	45.86	46.04	46.37	45.65	46.25	0.18	0.51	-0.21	0.39
Median =	34.77	34.36	37.14	35.30	35.62	0.09	1.28	-0.20	0.85
Standard Deviation =	25.26	25.53	25.61	25.01	24.82	5.36	5.41	5.31	5.67
Maximum =	106.88	113.64	104.89	109.38	112.34	15.59	22.19	21.17	21.97
Minimum =	15.99	18.17	17.28	18.24	17.33	-19.69	-11.42	-18.26	-14.11

Mean % Change From Baseline

	Month 1	Month 2	Month 4	Month 8
	0.4%	1.1%	-0.4%	0.9%
Increase	Increase	Increase	Decrease	Increase

Totals & Percentages

	Month 1	Month 2	Month 4	Month 8
Total	114	114	114	114
Increased Values	58	63	55	58
Decreased Values	56	51	59	56
No Change	0	0	0	0
Increased Values	50.88%	55.26%	48.25%	50.88%
Decreased Values	49.12%	44.74%	51.75%	49.12%
No Change	0.00%	0.00%	0.00%	0.00%

Did Not Complete Subject#s 7, 51, 58, 81, 83, 85, 113

Mean G/RGB = Mean Green value from the RGB color space, for the detected features within the masked region of interest (ROI)



Table 4  
 (continued)

VISIA-CR Image Analysis Color Data- G/RGB Values Right Iris

.01 [REDACTED] Lash Enhancing Serum

Subject #	Baseline	Month 1	Month 2	Month 4	Month 8	Difference From Baseline At :			
						Month 1	Month 2	Month 4	Month 8
1	38.06	37.42	40.37	37.54	38.77	-0.6	2.3	-0.5	0.7
2	102.60	92.81	103.61	94.69	102.10	-9.8	1.0	-7.9	-0.5
3	82.82	92.48	78.63	94.57	87.30	9.7	-4.2	11.7	4.5
4	73.44	71.55	74.21	73.21	73.37	-1.9	0.8	-0.2	-0.1
5	30.87	26.63	23.55	22.97	25.91	-4.2	-7.3	-7.9	-5.0
6	19.38	19.03	18.98	15.23	17.70	-0.3	-0.4	-4.1	-1.7
8	30.05	21.71	27.79	25.66	21.26	-8.3	-2.3	-4.4	-8.8
9	89.58	95.38	88.07	84.04	88.89	5.8	-1.5	-5.5	-0.7
10	82.92	91.68	85.92	83.35	90.73	8.8	3.0	0.4	7.8
11	21.92	21.03	18.60	21.24	21.22	-0.9	-3.3	-0.7	-0.7
12	96.31	91.64	90.99	105.14	100.93	-4.7	-5.3	8.8	4.6
13	26.86	27.49	23.30	23.05	24.61	0.6	-3.6	-3.8	-2.2
14	28.84	32.43	27.27	21.91	19.95	3.6	-1.6	-6.9	-8.9
15	16.46	28.41	25.46	16.06	21.12	11.9	9.0	-0.4	4.7
16	27.63	24.49	24.35	26.41	26.41	-3.1	-3.3	-1.2	-1.2
17	47.57	45.75	56.60	53.53	49.87	-1.8	9.0	6.0	2.3
18	31.62	31.19	22.89	29.06	31.39	-0.4	-8.7	-2.6	-0.2
19	43.39	28.14	33.18	35.18	34.32	-15.3	-10.2	-8.2	-9.1
20	79.47	93.86	102.91	87.90	76.92	14.4	23.4	8.4	-2.6
21	60.01	75.83	90.23	97.66	88.59	15.8	30.2	37.6	28.6
22	27.91	27.65	29.99	28.12	27.71	-0.3	2.1	0.2	-0.2
23	74.35	88.86	84.81	76.98	75.70	14.5	10.5	2.6	1.4
24	21.31	22.81	19.68	21.24	22.19	1.5	-1.6	-0.1	0.9
25	31.35	16.34	26.43	19.83	24.09	-15.0	-4.9	-11.5	-7.3
26	84.12	84.81	85.62	88.58	89.16	0.7	1.5	4.5	5.0
27	37.09	33.22	38.44	35.08	39.01	-3.9	1.4	-2.0	1.9
28	27.30	39.50	39.16	30.67	30.27	12.2	11.9	3.4	3.0
29	51.55	71.55	45.09	47.41	50.13	20.0	-6.5	-4.1	-1.4
30	17.08	14.91	18.88	18.44	16.40	-2.2	1.8	1.4	-0.7
31	19.81	19.86	22.66	20.39	19.03	0.0	2.9	0.6	-0.8
32	49.65	35.60	33.45	35.18	36.92	-14.1	-16.2	-14.5	-12.7
33	30.04	30.35	29.77	27.29	29.26	0.3	-0.3	-2.8	-0.8
34	39.76	33.61	39.27	41.07	35.20	-6.2	-0.5	1.3	-4.6
35	77.96	85.88	85.51	63.15	89.06	7.9	7.6	-14.8	11.1
36	28.76	28.62	25.86	31.91	24.04	-0.1	-2.9	3.1	-4.7
37	19.34	23.27	18.43	19.30	21.16	3.9	-0.9	0.0	1.8
38	95.84	91.54	99.02	96.36	94.55	-4.3	3.2	0.5	-1.3
39	69.68	67.78	69.14	68.17	72.11	-1.9	-0.5	-1.5	2.4
40	20.66	21.05	21.78	19.60	17.11	0.4	1.1	-1.1	-3.6
41	20.49	30.19	16.44	20.20	17.15	9.7	-4.0	-0.3	-3.3
42	30.02	27.70	33.98	32.39	41.55	-2.3	4.0	2.4	11.5
43	23.44	18.46	20.61	21.17	20.53	-5.0	-2.8	-2.3	-2.9
44	52.50	51.60	46.68	47.72	50.15	-0.9	-5.8	-4.8	-2.3
45	25.56	35.82	24.84	27.72	22.97	10.3	-0.7	2.2	-2.6
46	43.35	56.69	37.73	36.96	57.72	13.3	-5.6	-6.4	14.4
47	68.29	61.51	66.79	61.54	54.09	-6.8	-1.5	-6.7	-14.2
48	28.16	22.64	25.56	23.84	29.33	-5.5	-2.6	-4.3	1.2
49	27.62	24.66	27.43	25.87	26.00	-3.0	-0.2	-1.8	-1.6
50	69.94	68.78	68.66	63.95	69.93	-1.2	-1.3	-6.0	0.0
52	28.77	26.82	24.95	24.39	26.21	-2.0	-3.8	-4.4	-2.6
53	67.61	68.32	63.13	66.53	63.10	0.7	-4.5	-1.1	-4.5
54	22.71	21.75	22.75	18.91	21.22	-1.0	0.0	-3.8	-1.5
55	29.31	26.70	17.94	28.79	20.91	-2.6	-11.4	-0.5	-8.4
56	74.44	69.12	87.36	78.69	78.31	-5.3	12.9	4.2	3.9
57	24.57	25.11	30.27	25.85	22.03	0.5	5.7	1.3	-2.5
59	21.04	23.65	19.46	20.49	23.64	2.6	-1.6	-0.5	2.6
60	67.07	70.34	61.70	69.00	64.74	3.3	-5.4	1.9	-2.3
61	26.22	28.55	32.03	26.30	24.73	2.3	5.8	0.1	-1.5
62	23.68	21.68	21.39	23.20	26.52	-2.0	-2.3	-0.5	2.8
63	42.69	42.73	39.88	39.46	42.17	0.0	-2.8	-3.2	-0.5
64	27.52	27.30	28.20	27.31	25.35	-0.2	0.7	-0.2	-2.2
65	25.18	21.84	22.38	23.20	23.01	-3.3	-2.8	-2.0	-2.2
66	43.89	48.98	44.32	43.76	47.75	5.1	0.4	-0.1	3.9

Table 4  
 (continued)

VISIA-CR Image Analysis Color Data - G/RGB Values Right Iris

.01 = [redacted] Lash Enhancing Serum

67	24.50	26.14	21.74	22.33	22.65	1.6	-2.8	-2.2	-1.9
68	30.32	37.33	28.73	28.83	32.03	7.0	-1.6	-1.5	1.7
69	43.80	43.76	42.14	46.84	42.40	0.0	-1.7	3.0	-1.4
70	20.08	23.86	24.49	21.13	21.96	3.8	4.4	1.0	1.9
71	32.53	33.97	31.92	34.75	30.46	1.4	-0.6	2.2	-2.1
72	27.37	31.44	29.08	26.15	30.84	4.1	1.7	-1.2	3.5
73	23.74	24.77	22.93	22.11	23.07	1.0	-0.8	-1.6	-0.7
74	20.24	15.21	16.42	17.91	18.52	-5.0	-3.8	-2.3	-1.7
75	24.58	24.09	23.47	22.25	24.77	-0.5	-1.1	-2.3	0.2
76	36.31	42.36	35.24	34.07	35.42	6.0	-1.1	-2.2	-0.9
77	33.05	27.92	34.59	34.22	32.06	-5.1	1.5	1.2	-1.0
78	56.87	73.70	69.74	73.35	76.00	16.8	12.9	14.5	19.1
79	48.32	36.95	49.31	44.93	41.75	-11.4	1.0	-3.4	-6.6
80	25.10	23.22	23.86	20.61	22.14	-1.9	-1.2	-4.5	-3.0
82	24.98	24.46	23.97	26.00	24.58	-0.5	-3.0	1.0	-0.4
84	17.29	32.17	17.94	18.13	25.18	14.9	0.6	0.8	7.9
86	24.52	27.41	25.27	33.33	27.37	2.9	0.7	8.8	2.9
87	24.01	22.51	22.41	23.35	24.19	-1.5	-1.6	-0.7	0.2
88	110.82	102.59	104.77	97.80	105.37	-8.2	-6.0	-13.0	-5.4
89	39.07	38.91	43.60	38.43	38.93	-0.2	4.5	-8.6	-0.1
90	100.72	104.15	105.74	104.77	102.74	3.4	5.0	4.1	2.0
91	21.09	27.84	20.30	21.70	24.71	6.8	-0.8	0.6	3.6
92	40.28	41.47	33.82	45.46	32.69	1.2	-6.5	5.2	-7.6
93	93.14	81.26	70.94	80.88	83.61	-11.9	-22.2	-12.3	-9.5
94	81.51	84.10	64.32	82.50	86.01	2.6	-17.2	1.0	4.5
95	71.00	69.19	76.90	68.14	73.06	-1.8	5.9	-2.9	2.1
96	79.90	81.44	80.44	86.52	81.02	1.5	0.5	6.6	1.1
97	20.28	19.49	16.24	17.36	19.79	-0.8	-4.0	-2.9	-0.5
98	57.64	56.35	63.69	47.73	57.63	-1.3	6.1	-9.9	0.0
99	38.04	39.46	42.62	40.59	42.35	1.4	4.6	2.5	4.3
100	44.53	31.11	38.30	36.73	36.99	-13.4	-6.2	-7.8	-7.5
101	34.08	30.80	35.19	33.59	31.38	-3.3	1.1	-0.5	-2.7
102	35.91	34.33	36.32	24.31	37.55	-1.6	0.4	-11.6	1.6
103	37.74	43.71	49.77	41.35	46.07	6.0	12.0	3.6	8.3
104	33.16	32.74	31.92	30.79	36.21	-0.4	-1.2	-2.4	3.0
105	88.90	85.84	87.45	84.78	85.20	-3.1	-1.4	-4.1	-3.7
106	27.69	28.09	27.94	31.07	31.79	0.4	0.3	3.4	4.1
107	26.29	24.07	34.48	24.36	25.12	-2.2	8.2	-1.9	-0.2
108	85.00	93.30	95.98	97.36	98.08	8.3	11.0	12.4	13.1
109	95.01	85.25	84.27	72.90	90.34	-9.8	-10.7	-22.1	-4.7
110	91.42	92.48	93.04	93.58	94.29	1.1	1.6	2.2	2.9
111	25.75	40.71	33.92	26.27	35.88	15.0	8.2	0.5	10.1
112	29.48	26.30	28.33	25.40	23.30	-3.2	-1.1	-4.1	-6.2
114	41.63	45.58	39.88	43.76	42.59	3.9	-1.7	2.1	1.0
115	35.26	39.49	42.83	32.50	29.62	4.2	7.6	-2.8	-5.6
116	38.49	42.26	41.81	42.90	45.88	3.8	3.3	4.4	7.4
117	58.71	62.41	60.28	58.87	63.16	3.7	1.6	0.2	4.4
118	48.15	48.27	46.74	47.78	52.34	0.1	-1.4	-0.4	4.2
119	27.85	28.27	26.59	27.61	27.98	0.4	-1.3	-0.2	0.1
120	33.82	35.27	31.21	28.71	35.59	1.4	-2.6	-5.1	1.8
121	23.50	27.83	20.01	32.51	38.05	4.3	-3.5	9.0	14.5
Mean =	44.04	44.76	44.08	43.26	44.43	0.72	0.84	-0.78	0.39
Median =	33.49	33.79	33.95	32.92	34.76	0.00	-0.80	-0.53	-0.31
Standard Deviation =	24.86	25.07	25.62	25.34	25.69	6.65	6.74	6.55	5.97
Maximum =	110.82	104.15	105.74	105.14	105.37	20.00	30.22	37.65	28.58
Minimum =	16.46	14.91	16.24	15.23	16.40	-15.26	-22.20	-22.11	-14.20

Mean % Change From Baseline

	Month 1	Month 2	Month 4	Month 8
	1.6%	0.1%	-1.8%	0.9%
	Increase	Increase	Decrease	Increase

Tallies & Percentages

	Month 1	Month 2	Month 4	Month 8
Total	114	114	114	114
Increased Values	57	49	44	50
Decreased Values	57	65	70	64
No Change	0	0	0	0
Increased Values	50.00%	42.98%	38.60%	43.86%
Decreased Values	50.00%	57.02%	61.40%	56.14%
No Change	0.00%	0.00%	0.00%	0.00%

Did Not Complete Subject#s 7, 51, 58, 81, 83, 85, 113

Mean G/RGB = Mean Green value from the RGB color space, for the detected features within the masked region of interest (ROI)

**Table 4**  
(continued)

.01 [REDACTED] Lash Enhancing Serum

Within-Groups Analysis For :  
*VISIA-CR Image Analysis Color Data - G/RGB \* Value Left Iris*

Pre-Test	Normality	Brown-Forsythe	Friedman ANOVA
P-Value	P < 0.050	Not Required	0.710

Within-Groups Analysis For :  
*VISIA-CR Image Analysis Color Data - G/RGB \* Value Right Iris*

Pre-Test	Normality	Brown-Forsythe	Friedman ANOVA
P-Value	P < 0.050	Not Required	0.036

**Pairwise Comparisons**

Difference from Baseline	Test Type	P-value	Significance	Direction (Mean)
Month 1	Dunn's Method	1.000	No	Increase
Month 2	Dunn's Method	0.314	No	Increase
Month 4	Dunn's Method	<b>0.018</b>	<b>Yes</b>	<b>Decrease</b>
Month 8	Dunn's Method	1.000	No	Increase

\* = ANOVA (RM) compares the means across groups (the non-parametric version is Friedman). The null hypothesis is all means are equivalent and the alternative is that the mean of at least one group differs. If ANOVA is significant further pairwise comparisons can be made, if not then it is assumed there is no statistically significant difference among the mean (or ranks) and no further testing is done due to risk of type one error. It is possible that Friedman or RM ANOVA may be significant, but when running post-hoc test may not show any statistically significant difference due to only examining the comparisons to baseline, post-hoc test, small sample size, lack of power, or if there is borderline significance.

Mean G/RGB = Mean Green value from the RGB color space, for the detected features within the masked region of interest (ROI)

**Summary:**

For subjects using [REDACTED] Lash Enhancing Serum, there was no statistically significant change in the G/RGB values in the left eye when compared to baseline. There was a statistically significant increase in the right eye at month 4 indicating an increase in the mean green value in the RGB color space; however, there was then no difference when comparing baseline to month 8.

Table 4  
 (continued)

VISIA-CR Image Analysis Color Data- B/R/G/B \* Value Left Iris

.01 - [REDACTED] Lash Enhancing Serum

Subject #	Baseline	Month 1	Month 2	Month 4	Month 8	Difference From Baseline At :			
						Month 1	Month 2	Month 4	Month 8
1	31.73	30.58	33.86	29.01	33.77	-1.1	2.1	-2.7	2.0
2	109.60	97.04	101.64	96.70	94.99	-12.6	-8.0	-12.9	-14.6
3	83.34	87.07	83.22	85.27	89.92	3.7	-0.1	1.9	6.6
4	55.11	57.32	61.19	52.56	53.13	2.2	6.1	-2.6	-2.0
5	25.23	23.86	21.67	17.20	22.06	-1.4	-3.6	-8.0	-3.2
6	21.23	21.29	15.28	16.60	20.81	0.1	-5.9	-4.6	-0.4
8	18.97	22.01	25.79	26.72	20.50	3.0	6.8	7.8	1.5
9	85.18	84.59	79.42	76.95	73.55	-0.6	-5.8	-8.2	-11.6
10	88.56	102.69	86.85	93.85	91.92	14.1	-1.7	5.3	3.4
11	16.73	15.43	18.50	22.24	16.83	-1.3	1.8	5.5	0.1
12	93.44	86.14	89.33	91.80	95.27	-7.3	-4.1	-1.6	1.8
13	27.97	28.68	20.86	21.10	22.28	0.7	-7.1	-6.9	-5.7
14	18.05	27.76	20.08	19.43	21.44	9.7	2.0	1.4	3.4
15	12.12	22.24	23.30	18.66	22.20	10.1	11.2	6.5	10.1
16	26.59	21.88	22.70	24.73	25.08	-4.7	-3.9	-1.9	-1.5
17	28.64	30.48	38.65	31.31	28.82	1.8	10.0	2.7	0.2
18	25.68	29.41	17.06	30.38	24.55	3.7	-8.6	4.7	-1.1
19	29.43	19.98	32.41	24.58	24.28	-9.5	3.0	-4.9	-5.1
20	93.89	109.64	101.54	94.80	91.35	15.8	7.7	0.9	-2.5
21	41.96	55.15	66.69	65.41	65.12	13.2	24.7	23.4	23.2
22	20.73	23.82	21.52	20.83	22.03	3.1	0.8	0.1	1.3
23	96.73	99.99	96.99	93.69	85.47	3.3	0.3	-3.0	-11.3
24	21.34	18.09	18.39	21.98	15.29	-3.3	-3.0	0.6	-6.0
25	19.19	15.48	27.65	18.75	17.84	-3.7	8.5	-0.4	-1.3
26	80.23	80.61	70.59	68.67	73.40	0.4	-9.6	-11.6	-6.8
27	22.52	22.51	22.50	28.56	24.06	0.0	0.6	6.0	1.5
28	26.68	30.08	29.74	30.29	19.91	3.4	3.1	3.6	-6.8
29	54.71	54.95	59.64	39.89	58.27	0.2	4.9	-14.8	3.6
30	14.54	14.93	17.12	22.03	14.68	0.4	2.6	7.5	0.1
31	21.22	21.01	16.89	19.11	19.59	-0.2	-4.3	-2.1	-1.6
32	24.99	22.45	19.85	24.16	22.57	-2.5	-5.1	-0.8	-2.4
33	21.09	20.54	22.54	17.88	19.01	-0.6	1.5	-3.2	-2.1
34	23.88	28.49	28.16	33.51	28.25	4.6	4.3	9.6	4.4
35	80.18	79.49	90.80	57.78	85.89	-0.7	10.6	-22.4	5.7
36	20.65	24.12	24.97	22.92	24.27	3.5	4.3	2.3	3.6
37	18.38	20.79	15.53	17.54	17.07	2.4	-2.9	-0.8	-1.3
38	103.71	97.69	101.58	106.73	94.34	-6.0	-2.1	3.0	-9.4
39	47.98	50.67	55.42	53.22	51.31	2.7	7.4	5.2	3.3
40	17.63	20.57	24.14	23.97	13.44	2.9	6.5	6.3	-4.2
41	19.61	19.72	14.60	17.74	15.46	0.1	-5.0	-1.9	-4.1
42	24.35	18.51	25.18	23.01	25.68	-5.8	0.8	-1.3	1.3
43	23.83	17.10	17.83	19.54	18.40	-6.7	-6.0	-4.3	-5.4
44	26.50	29.10	31.37	25.74	29.21	2.6	4.9	-0.8	2.7
45	20.20	27.48	24.51	24.98	24.58	7.3	4.3	4.8	4.4
46	30.35	41.87	32.35	31.19	41.38	11.5	2.0	0.8	11.0
47	60.71	43.17	58.04	54.77	50.49	-17.5	-2.7	-5.9	-10.2
48	24.66	23.99	19.31	23.82	22.89	-0.7	-5.4	-0.8	-1.8
49	21.17	18.03	23.16	21.70	22.08	-3.1	2.0	0.5	0.9
50	55.70	56.42	55.60	53.14	54.10	0.7	-0.1	-2.6	-1.6
52	23.72	26.72	23.14	23.97	22.11	3.0	-0.6	0.3	-1.6
53	69.15	64.76	77.42	71.71	63.54	-4.4	8.3	2.6	-5.6
54	22.91	18.74	20.89	16.76	19.07	-4.2	-2.0	-6.1	-3.8
55	26.44	21.88	16.08	28.38	25.10	-4.6	-10.4	1.9	-1.3
56	83.82	76.44	87.57	82.66	83.08	-7.4	3.8	-1.2	-0.7
57	30.94	28.15	32.82	25.73	26.92	-2.8	1.9	-5.2	-4.0
59	20.58	19.45	22.98	26.65	30.82	-1.1	2.4	6.1	10.2
60	72.26	72.60	71.11	75.18	70.37	0.3	-1.1	2.9	-1.9
61	20.62	20.98	29.69	19.84	19.79	0.4	9.1	-0.8	-0.8
62	23.38	26.46	27.75	24.26	31.25	3.1	4.4	0.9	7.9
63	29.44	30.47	29.45	28.72	33.48	1.0	0.0	-0.7	4.0
64	21.84	20.89	22.16	18.88	20.21	-0.9	0.3	-3.0	-1.6
65	19.97	18.66	16.92	16.92	17.31	-1.3	-1.6	-3.0	-2.7
66	39.15	34.99	34.37	30.18	36.82	-4.2	-4.8	-9.0	-2.1

**Table 4**  
(continued)  
**VISIA-CR Image Analysis Color Data- B/RGB \* Value Left Iris**

.01 - [Redacted] Lash Enhancing Serum

67	17.62	19.12	25.09	25.04	14.93	1.5	7.5	7.4	-2.7
68	28.67	35.73	28.14	24.64	27.37	7.1	-0.5	-4.0	-1.3
69	26.52	26.31	25.70	27.15	24.73	-0.2	-0.8	0.6	-1.8
70	19.19	27.29	23.53	23.76	20.43	8.1	4.3	4.6	1.2
71	31.88	27.11	21.75	28.67	25.38	-4.8	-10.1	-3.2	-6.5
72	22.23	27.48	24.52	25.51	31.02	5.2	2.3	3.3	8.8
73	22.73	20.23	18.20	18.47	18.70	-2.5	-4.5	-4.3	-4.0
74	24.48	17.31	14.16	15.87	25.76	-7.2	-10.3	-8.6	1.3
75	26.76	19.10	21.95	20.65	24.01	-7.7	-4.8	-6.1	-2.7
76	29.19	31.32	26.42	26.72	29.09	2.1	-2.8	-2.5	-0.1
77	20.54	25.36	26.49	23.90	27.38	4.8	6.0	3.4	6.8
78	83.32	88.64	89.82	85.82	86.30	5.3	6.5	2.5	3.0
79	27.80	24.99	29.95	27.69	25.07	-2.8	2.1	-0.1	-2.7
80	27.79	22.77	22.25	21.09	19.87	-5.0	-5.5	-6.7	-7.9
82	21.49	25.52	25.64	26.35	25.40	4.0	4.2	4.9	3.9
84	17.91	30.73	16.13	19.31	22.71	12.8	-1.8	1.4	4.8
86	23.04	27.31	29.50	27.94	28.48	4.3	6.5	4.9	5.4
87	24.36	20.55	24.19	26.38	28.41	-3.8	-0.2	2.0	4.1
88	89.92	101.34	89.77	92.58	100.15	11.4	-0.2	2.7	10.2
89	25.95	25.75	31.15	27.59	24.93	-0.2	5.2	1.6	-1.0
90	112.51	105.46	109.14	108.25	110.98	-7.1	-3.4	-4.3	-1.5
91	22.39	23.69	20.27	20.03	23.45	1.3	-2.1	-2.4	1.1
92	34.25	31.14	27.06	25.14	24.04	-3.1	-7.2	-9.1	-10.2
93	73.99	59.99	65.71	61.81	63.55	-14.0	-8.3	-12.2	-10.4
94	38.90	39.20	41.10	37.14	39.08	0.3	2.2	-1.8	0.2
95	54.27	55.58	50.37	51.45	54.94	1.3	-3.9	-2.8	0.7
96	96.85	100.06	98.58	103.50	96.91	3.2	1.7	6.6	0.1
97	16.14	21.61	14.71	14.90	18.38	5.5	-1.4	-1.2	2.2
98	42.57	29.87	32.94	45.08	35.71	-13.7	-9.6	2.5	-6.9
99	32.57	30.86	33.76	33.89	34.04	-1.7	1.2	1.3	1.5
100	32.83	27.05	26.58	29.98	30.96	-5.8	-6.2	-2.8	-1.9
101	25.93	24.37	26.04	25.25	21.70	-1.6	0.1	-0.7	-4.2
102	24.25	27.75	29.93	18.55	29.48	3.5	5.7	-5.7	5.2
103	28.53	23.20	28.30	25.42	23.56	-5.3	-0.2	-3.1	-5.0
104	30.71	28.33	34.46	28.75	35.80	-2.4	3.8	-2.0	5.1
105	62.79	70.70	71.60	55.50	72.15	7.9	8.8	-7.3	9.4
106	19.31	26.47	23.73	22.16	23.89	7.2	4.4	2.8	4.6
107	18.18	22.46	19.78	20.99	21.86	4.3	1.6	2.8	3.7
108	98.86	97.67	98.85	99.45	93.87	-1.2	0.0	0.6	-5.0
109	81.47	86.88	86.65	83.01	78.45	5.4	5.2	1.5	-3.0
110	94.60	91.95	97.78	95.60	96.27	-2.6	3.2	1.0	1.7
111	21.76	22.38	27.62	19.25	27.44	0.6	5.9	-2.5	5.7
112	23.27	21.94	27.23	23.50	23.16	-1.3	4.0	0.2	-0.1
114	22.61	27.37	27.83	27.10	24.71	4.8	5.2	4.5	2.1
115	28.46	23.88	24.70	27.23	26.91	-4.6	-3.8	-1.2	-1.6
116	25.30	23.98	27.86	23.99	28.27	-1.3	2.6	-1.3	3.0
117	67.82	67.11	62.60	65.55	62.01	-0.7	-5.2	-2.3	-5.8
118	37.01	40.25	35.00	39.41	45.82	3.2	-2.0	2.4	8.8
119	23.78	25.24	25.64	21.71	23.28	1.5	1.9	-2.1	-0.5
120	27.48	24.81	28.97	22.73	31.88	-2.7	1.5	-4.7	4.4
121	18.82	19.89	19.12	22.24	25.26	1.1	0.3	3.4	6.4
<b>Mean =</b>	<b>38.87</b>	<b>39.13</b>	<b>39.46</b>	<b>38.25</b>	<b>38.83</b>	<b>0.27</b>	<b>0.59</b>	<b>-0.62</b>	<b>-0.04</b>
<b>Median =</b>	<b>26.51</b>	<b>27.20</b>	<b>27.63</b>	<b>26.36</b>	<b>26.33</b>	<b>0.17</b>	<b>0.55</b>	<b>-0.75</b>	<b>-0.46</b>
<b>Standard Deviation =</b>	<b>26.39</b>	<b>26.45</b>	<b>26.58</b>	<b>25.82</b>	<b>25.65</b>	<b>5.64</b>	<b>5.50</b>	<b>5.56</b>	<b>5.50</b>
<b>Maximum =</b>	<b>112.51</b>	<b>109.64</b>	<b>109.14</b>	<b>108.25</b>	<b>110.98</b>	<b>15.75</b>	<b>24.73</b>	<b>23.45</b>	<b>23.16</b>
<b>Minimum =</b>	<b>12.12</b>	<b>14.93</b>	<b>14.16</b>	<b>14.90</b>	<b>13.44</b>	<b>-17.54</b>	<b>-10.35</b>	<b>-22.40</b>	<b>-14.61</b>

*Mean % Change From Baseline*

Month 1	Month 2	Month 4	Month 8
0.7%	1.5%	-1.6%	-0.1%
Increase	Increase	Decrease	Decrease

*Tallies & Percentages*

	Month 1	Month 2	Month 4	Month 8
<b>Total</b>	<b>114</b>	<b>114</b>	<b>114</b>	<b>114</b>
<b>Increased Values</b>	<b>59</b>	<b>62</b>	<b>53</b>	<b>54</b>
<b>Decreased Values</b>	<b>55</b>	<b>52</b>	<b>61</b>	<b>60</b>
<b>No Change</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Increased Values</b>	<b>51.75%</b>	<b>54.39%</b>	<b>46.49%</b>	<b>47.37%</b>
<b>Decreased Values</b>	<b>48.25%</b>	<b>45.61%</b>	<b>53.51%</b>	<b>52.63%</b>
<b>No Change</b>	<b>0.00%</b>	<b>0.00%</b>	<b>0.00%</b>	<b>0.00%</b>

Did Not Complete: Subject#s 7, 51, 58, 81, 85 and 113

Mean B/RGB = Mean Blue value from the RGB color space, for the detected features within the masked region of interest (ROI)

**Table 4**  
 (continued)  
 VISIA-CR Image Analysis Color Data - B/R/G Values Right Iris

.01 = [REDACTED] Lash Enhancing Serum

Subject #	Baseline	Month 1	Month 2	Month 4	Month 8	Difference From Baseline At :			
						Month 1	Month 2	Month 4	Month 8
1	24.91	22.83	27.94	24.00	25.29	-2.1	3.0	-0.9	0.4
2	108.87	97.84	109.74	100.46	107.27	-11.0	0.9	-8.4	-1.6
3	82.22	92.96	80.08	93.65	86.10	10.7	-2.1	11.4	3.9
4	53.15	52.00	54.00	53.42	54.52	-1.1	0.8	0.3	1.4
5	27.91	22.91	20.33	19.16	22.18	-5.0	-7.6	-8.8	-5.7
6	15.73	15.68	15.34	11.79	14.12	-0.1	-0.4	-3.9	-1.6
8	26.66	17.33	23.74	20.91	17.36	-9.3	-2.9	-5.8	-9.3
9	77.61	82.55	74.55	69.93	75.59	4.9	-3.1	-7.7	-2.0
10	86.94	94.52	89.19	87.48	94.21	7.6	2.2	0.5	7.3
11	19.28	18.04	15.61	16.67	18.29	-1.2	-3.7	-2.6	-1.0
12	89.21	84.19	84.07	98.06	93.57	-5.0	-5.1	8.9	4.4
13	23.89	24.94	20.17	20.15	21.48	1.1	-3.7	-3.7	-2.4
14	23.14	29.34	24.04	19.19	17.22	6.2	0.9	-4.0	-5.9
15	13.57	25.77	23.47	12.64	17.85	12.2	7.9	-0.9	4.3
16	24.08	20.57	20.27	22.67	21.91	-3.5	-3.8	-1.4	-2.2
17	32.77	31.78	44.31	38.98	34.99	-1.0	11.5	6.2	2.2
18	21.90	21.47	15.79	20.14	22.88	-0.4	-6.1	-1.8	1.0
19	33.13	18.36	23.06	26.33	24.02	-14.8	-10.1	-6.8	-9.1
20	85.19	100.74	110.30	95.34	83.79	15.5	25.1	10.1	-1.4
21	38.73	55.26	71.68	79.97	66.16	16.5	33.0	41.2	27.4
22	17.92	18.13	21.29	17.98	17.30	0.2	3.4	0.1	-0.6
23	77.63	94.94	90.94	83.12	77.52	17.3	13.3	5.5	-0.1
24	18.33	19.81	16.55	18.10	18.83	1.5	-1.8	-0.2	0.5
25	19.27	13.00	22.48	16.77	16.31	-6.3	3.2	-2.5	-3.0
26	75.20	75.64	73.94	76.23	76.58	0.4	-1.3	1.0	1.4
27	27.67	24.30	28.53	26.11	27.57	-3.4	0.9	-1.6	-0.1
28	20.38	34.13	33.23	21.99	23.28	13.7	12.8	1.6	2.9
29	45.08	65.68	41.14	39.68	44.56	20.6	-3.9	-5.4	-0.5
30	13.68	11.33	15.43	15.01	12.57	-2.3	1.8	1.3	-1.1
31	16.69	17.49	19.52	17.09	15.89	0.8	2.8	0.4	-0.8
32	39.77	23.02	20.91	23.10	23.82	-16.8	-18.9	-16.7	-15.9
33	21.31	21.13	21.48	18.78	19.78	-0.2	0.2	-2.5	-1.5
34	30.43	22.87	28.37	29.99	24.42	-7.6	-2.1	-0.4	-6.0
35	77.03	89.40	89.09	66.40	90.78	12.4	12.1	-10.6	13.7
36	21.31	20.84	17.86	24.85	16.44	-0.5	-3.5	3.5	-4.9
37	15.33	19.91	14.78	15.33	17.52	4.6	-0.5	0.0	2.2
38	97.09	93.72	99.84	96.58	95.90	-3.4	2.8	-0.5	-1.2
39	47.57	46.71	48.91	45.98	49.71	-0.9	1.3	-1.6	2.1
40	17.34	17.96	18.39	15.49	13.14	0.6	1.0	-1.9	-4.2
41	17.17	26.28	12.94	16.41	13.05	9.1	-4.2	-0.8	-4.1
42	20.38	17.40	22.07	19.81	28.24	-3.0	1.7	-0.6	7.9
43	19.64	13.87	16.35	16.97	16.08	-5.8	-3.3	-2.7	-3.6
44	33.89	32.21	28.56	28.70	30.55	-1.7	-5.3	-5.2	-3.3
45	22.61	34.36	21.34	23.65	19.98	11.8	-1.3	1.0	-2.6
46	35.79	46.12	30.13	28.50	44.91	10.3	-5.7	-7.3	9.1
47	67.30	60.08	67.04	60.35	52.00	-7.2	-0.3	-7.0	-15.3
48	25.60	18.99	22.25	20.32	26.11	-6.6	-3.4	-5.3	0.5
49	20.75	17.82	20.62	19.27	18.61	-2.9	-0.1	-1.5	-2.1
50	60.36	59.49	59.42	54.15	59.21	-0.9	-0.9	-6.2	-1.2
52	22.82	21.09	17.69	18.83	18.39	-1.7	-5.1	-4.0	-4.4
53	54.12	51.49	46.63	49.29	45.98	-2.6	-7.5	-4.8	-8.1
54	19.93	18.65	19.54	16.01	18.19	-1.3	-0.4	-3.9	-1.7
55	26.36	23.81	14.23	25.70	17.22	-2.5	-12.1	-0.7	-9.1
56	76.73	72.07	88.31	79.99	80.39	-4.7	11.6	3.3	3.7
57	21.26	21.26	26.13	21.70	18.97	0.0	4.9	0.4	-2.3
59	17.84	20.56	16.07	16.67	20.03	2.7	-1.8	-1.2	2.2
60	50.25	51.00	42.90	50.11	44.82	0.7	-7.3	-0.1	-5.4
61	19.47	21.87	24.92	19.39	17.66	2.4	5.4	-0.1	-1.8
62	21.13	19.25	18.40	19.44	23.30	-1.9	-2.7	-1.7	2.2
63	27.47	28.32	25.87	24.75	26.61	0.9	-1.6	-2.7	-0.9
64	21.55	21.00	22.62	20.61	19.08	-0.6	1.1	-0.9	-2.5
65	18.61	15.10	16.31	16.32	16.13	-3.5	-2.3	-2.3	-2.5
66	31.33	35.23	30.26	29.18	35.07	3.9	-1.1	-2.2	3.7
67	19.43	21.58	16.02	16.15	16.89	2.1	-3.4	-3.3	-2.5

**Table 4**  
(continued)  
VISA-CR Image Analysis Color Data - B/RGB Values Right Iris

.01 = [REDACTED] Lash Enhancing Serum

68	21.55	28.65	19.19	18.16	22.46	7.1	-2.4	-3.4	0.9
69	24.78	23.88	22.17	29.95	24.13	-0.9	-2.6	5.2	-0.7
70	16.82	20.62	20.35	17.27	18.42	3.8	3.5	0.4	1.6
71	27.36	27.41	24.29	25.54	21.05	0.0	-3.1	-1.8	-6.3
72	19.93	24.56	22.04	19.60	22.88	4.6	2.1	-0.3	3.0
73	17.96	19.16	17.38	16.44	16.91	1.2	-0.6	-1.5	-1.0
74	17.06	12.24	13.38	14.21	15.34	-4.8	-3.7	-2.8	-1.7
75	20.82	18.35	19.37	17.50	20.02	-2.5	-1.4	-3.3	-0.8
76	26.93	32.01	24.81	23.69	25.50	5.1	-2.1	-3.2	-1.4
77	24.77	19.39	25.94	26.72	24.39	-5.4	1.2	2.0	-0.4
78	58.65	80.17	75.10	76.75	80.99	21.5	16.5	18.1	22.3
79	31.73	24.00	36.86	27.94	25.52	-7.7	5.1	-3.8	-6.2
80	19.69	18.29	17.51	15.33	16.63	-1.4	-2.2	-4.4	-3.1
82	18.83	19.83	16.39	21.13	18.36	1.0	-2.4	2.3	-0.5
84	13.46	28.97	14.02	14.29	21.52	15.5	0.6	0.8	8.1
86	19.00	23.62	21.26	28.44	22.06	4.6	2.3	9.4	3.1
87	21.07	18.77	18.74	19.95	20.70	-2.3	-2.3	-1.1	-0.4
88	98.83	90.33	93.39	82.98	90.06	-8.5	-5.4	-15.8	-8.8
89	23.39	22.45	28.95	21.27	21.28	-0.9	5.6	-2.1	-2.1
90	103.14	107.14	106.55	107.32	105.88	4.0	3.4	4.2	2.7
91	15.38	23.68	14.70	16.25	18.20	8.3	-0.7	0.9	2.8
92	24.64	26.85	20.73	28.77	22.87	2.2	-3.9	4.1	-1.8
93	93.56	78.62	70.43	80.19	81.40	-14.9	-23.1	-13.4	-12.2
94	48.69	52.77	40.85	50.35	52.82	4.1	-7.8	1.7	4.1
95	52.85	52.40	55.18	47.27	53.36	-0.4	2.3	-5.6	0.5
96	89.68	92.05	90.16	96.82	90.76	2.4	0.5	7.1	1.1
97	18.13	17.08	13.91	14.20	16.58	-1.0	-4.2	-3.9	-1.6
98	49.89	47.77	53.76	37.15	48.07	-2.1	3.9	-12.7	-1.8
99	28.98	28.80	31.59	30.56	32.36	-0.2	2.6	1.6	3.4
100	35.47	21.10	27.23	25.32	27.34	-14.4	-8.2	-10.2	-8.1
101	24.29	21.32	23.98	23.08	20.63	-3.0	-0.3	-1.2	-3.7
102	21.57	21.47	20.99	16.36	25.89	-0.1	-0.6	-5.2	4.3
109	27.08	31.47	37.84	29.38	34.84	4.4	10.8	2.3	7.8
104	24.74	23.67	24.08	21.74	25.66	-1.1	-0.7	-3.0	0.9
105	64.67	66.03	68.33	58.77	64.56	1.4	3.7	-5.9	-0.1
106	18.63	20.67	19.25	20.84	22.79	2.0	0.6	2.2	4.2
107	20.15	17.05	28.41	17.98	21.54	-3.1	8.3	-2.2	1.4
108	76.14	90.39	89.20	94.16	94.63	14.3	13.1	18.0	18.5
109	82.81	74.45	73.44	59.48	79.13	-8.4	-9.4	-23.3	-3.7
110	83.36	83.54	84.88	85.13	85.85	0.2	1.5	1.8	2.5
111	17.66	31.09	23.28	17.21	28.30	13.4	5.6	-0.5	10.6
112	26.26	22.26	24.02	21.69	18.99	-4.0	-2.2	-4.6	-7.3
114	36.44	39.34	32.81	37.15	32.39	2.9	-3.6	0.7	-4.1
115	27.87	31.60	36.34	27.67	23.86	3.7	8.5	-0.2	-4.0
116	22.14	25.38	25.55	26.98	28.35	3.2	3.4	4.8	6.2
117	54.16	59.26	57.21	54.28	60.07	5.1	3.0	0.1	5.9
118	30.93	30.24	28.57	28.48	32.08	-0.7	-2.4	-2.4	1.2
119	20.14	22.21	19.03	19.70	19.72	2.1	-1.1	-0.4	-0.4
120	23.95	27.18	22.40	20.19	25.59	3.2	-1.6	-3.8	1.6
121	19.12	22.12	15.97	26.04	30.65	3.0	-3.2	6.9	11.5
<b>Mean =</b>	<b>36.71</b>	<b>37.63</b>	<b>36.90</b>	<b>35.70</b>	<b>36.68</b>	<b>0.92</b>	<b>0.19</b>	<b>-1.01</b>	<b>-0.03</b>
<b>Median =</b>	<b>24.78</b>	<b>24.43</b>	<b>24.06</b>	<b>23.85</b>	<b>24.07</b>	<b>-0.08</b>	<b>-0.62</b>	<b>-1.31</b>	<b>-0.73</b>
<b>Standard Deviation =</b>	<b>24.82</b>	<b>25.77</b>	<b>26.32</b>	<b>25.69</b>	<b>25.90</b>	<b>7.01</b>	<b>7.00</b>	<b>6.99</b>	<b>6.17</b>
<b>Maximum =</b>	<b>108.87</b>	<b>107.14</b>	<b>110.30</b>	<b>107.32</b>	<b>107.27</b>	<b>21.52</b>	<b>32.95</b>	<b>41.24</b>	<b>27.43</b>
<b>Minimum =</b>	<b>13.46</b>	<b>11.33</b>	<b>12.94</b>	<b>11.79</b>	<b>12.57</b>	<b>-16.75</b>	<b>-13.14</b>	<b>-23.33</b>	<b>-15.95</b>

*Mean % Change From Baseline*

Month 1	Month 2	Month 4	Month 8
2.5%	0.5%	-2.8%	-0.1%
Increase	Increase	Decrease	Decrease

*Taffes & Percentages*

	Month 1	Month 2	Month 4	Month 8
<b>Total</b>	<b>114</b>	<b>114</b>	<b>114</b>	<b>114</b>
<b>Increased Values</b>	<b>56</b>	<b>49</b>	<b>39</b>	<b>47</b>
<b>Decreased Values</b>	<b>58</b>	<b>65</b>	<b>75</b>	<b>67</b>
<b>No Change</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Increased Values</b>	<b>49.12%</b>	<b>42.98%</b>	<b>34.21%</b>	<b>41.23%</b>
<b>Decreased Values</b>	<b>50.88%</b>	<b>57.02%</b>	<b>65.79%</b>	<b>58.77%</b>
<b>No Change</b>	<b>0.00%</b>	<b>0.00%</b>	<b>0.00%</b>	<b>0.00%</b>

Did Not Complete Subject#s 7, 51, 58, 81, 85 and 113

Mean B/RGB = Mean Blue value from the RGB color space, for the detected features within the masked region of interest (ROI)

**Table 4**  
(continued)

.01 [REDACTED] Lash Enhancing Serum

**Within-Groups Analysis For :**  
*VISIA-CR Image Analysis Color Data - B/RGB \* Value Left Iris*

<b>Pre-Test</b>	<b>Normality</b>	<b>Brown-Forsythe</b>	<b>Friedman ANOVA</b>
P-Value	P < 0.050	Not Required	0.368

**Within-Groups Analysis For :**  
*VISIA-CR Image Analysis Color Data - B/RGB \* Value Right Iris*

<b>Pre-Test</b>	<b>Normality</b>	<b>Brown-Forsythe</b>	<b>Friedman ANOVA</b>
P-Value	<0.050	Not Required	0.003

**Pairwise Comparisons**

Difference from Baseline	Test Type	P-value	Significance	Direction (Mean)
Month 1	Dunn's Method	1.000	No	Increase
Month 2	Dunn's Method	0.131	No	Increase
Month 4	Dunn's Method	0.001	Yes	Decrease
Month 8	Dunn's Method	0.668	No	Decrease

\* = ANOVA (RM) compares the means across groups (the non-parametric version is Friedman). The null hypothesis is all means are equivalent and the alternative is that the mean of at least one group differs. If ANOVA is significant further pairwise comparisons can be made, if not then it is assumed there is no statistically significant difference among the mean (or ranks) and no further testing is done due to risk of type one error. It is possible that Friedman or RM ANOVA may be significant, but when running post-hoc test may not show any statistically significant difference due to only examining the comparisons to baseline, post-hoc test, small sample size, lack of power, or if there is borderline significance.

Mean B/RGB = Mean Blue value from the RGB color space, for the detected features within the masked region of interest (ROI)

**Summary:**

For subjects using [REDACTED] Lash Enhancing Serum, there was no statistically significant change in the B/RGB values in the left eye when compared to baseline. In the right eye, there was a statistically significant decrease at month 4 indicating a decrease in the mean blue value within the ROI.



Table 4  
 (continued)  
 VISIA-CR Image Analysis Color Data - Delta E Value Left Iris

.01 = [REDACTED] Last Enhancing Serum

Subject #	Month 1	Month 2	Month 4	Month 8
1	3.98	1.58	1.19	1.98
2	4.15	2.63	4.40	4.84
3	1.28	1.61	0.65	4.40
4	1.52	2.82	1.70	2.63
5	0.82	1.67	3.81	1.52
6	0.65	3.58	3.25	0.60
8	1.78	3.41	3.09	1.95
9	1.32	2.26	3.76	5.98
10	5.54	0.77	2.17	1.50
11	0.56	0.84	4.70	0.51
12	2.79	1.64	0.73	1.45
13	0.54	3.36	3.21	2.59
14	3.88	0.73	0.53	1.37
15	3.90	4.94	2.82	4.34
16	2.68	1.64	0.83	0.81
17	1.74	3.70	1.00	1.19
18	1.49	4.49	2.19	1.16
19	4.57	1.48	2.23	2.65
20	6.33	2.64	0.95	1.69
21	6.36	10.23	9.75	9.59
22	1.17	0.42	0.40	0.98
23	1.33	0.19	1.95	4.09
24	1.59	1.31	0.31	3.01
25	2.01	3.91	0.55	0.65
26	2.76	4.16	4.91	2.73
27	1.77	1.90	2.32	1.34
28	1.89	2.08	2.12	3.48
29	4.00	4.71	13.38	5.30
30	0.58	1.32	3.59	0.54
31	1.30	2.62	1.00	0.94
32	1.30	2.18	0.90	1.54
33	1.38	0.59	1.99	0.96
34	2.01	2.20	3.68	2.44
35	0.83	4.83	8.06	2.04
36	1.28	1.66	0.89	2.58
37	0.83	1.68	0.50	1.15
38	1.93	1.19	3.10	3.09
39	1.94	3.03	2.30	1.83
40	1.54	3.09	3.28	1.52
41	0.70	2.11	1.03	1.55
42	2.52	2.01	4.01	4.03
43	2.82	2.59	1.93	2.17
44	1.44	3.35	0.93	2.67
45	3.37	3.49	3.50	2.21
46	5.29	2.33	5.12	7.69
47	9.03	4.50	5.01	6.81
48	1.00	2.46	0.41	0.73
49	1.92	2.10	1.44	1.57
50	1.00	2.37	1.76	1.07
52	5.79	6.71	4.27	6.66
53	2.95	4.93	3.65	4.19
54	2.08	0.95	2.80	1.94
55	1.94	4.51	1.45	0.66
56	2.95	1.67	0.38	0.40
57	1.39	1.17	2.73	3.06
59	0.58	1.24	2.98	7.85
60	1.83	1.57	2.06	3.06
61	1.07	3.93	0.88	0.64
62	1.27	1.91	0.65	3.80
63	0.73	2.04	1.49	2.71
64	0.97	0.35	1.27	1.14
65	1.36	1.33	1.41	1.36
66	2.67	2.43	5.08	1.80

**Table 4**  
 (continued)  
**VISIA-CR Image Analysis Color Data - Delta E Value Left Iris**

	<b>.01 - [REDACTED] Lash Enhancing Serum</b>			
67	2.03	4.05	3.67	1.87
68	3.32	0.23	1.71	0.57
69	1.24	1.69	0.82	0.65
70	4.05	2.48	2.97	1.71
71	1.87	4.58	1.22	3.83
72	2.71	1.18	1.96	4.41
73	1.48	2.65	1.77	1.72
74	3.23	5.08	3.84	1.49
75	3.25	2.32	2.39	1.13
76	1.16	2.40	2.23	0.67
77	3.11	2.38	1.53	3.27
78	2.17	2.54	1.57	1.50
79	1.87	1.01	0.55	1.54
80	2.84	2.96	3.45	3.72
82	1.96	2.24	2.90	2.78
84	5.40	1.15	0.57	1.76
86	2.26	3.79	2.20	3.55
87	2.08	2.60	1.74	2.77
88	4.67	1.22	1.86	4.15
89	1.46	2.35	3.13	2.50
90	2.18	1.45	1.37	1.04
91	1.36	1.62	1.27	2.15
92	3.57	4.73	5.47	6.20
93	5.57	3.23	4.53	3.92
94	0.88	9.78	3.10	1.84
95	2.30	1.30	1.09	1.07
96	1.23	1.71	2.44	1.43
97	2.65	0.55	0.53	2.02
98	5.59	5.23	2.66	2.84
99	0.79	1.54	1.13	0.99
100	2.99	3.28	2.54	1.13
101	0.99	1.50	3.02	1.58
102	5.21	5.48	7.71	3.87
103	1.96	3.15	1.91	2.39
104	1.03	1.50	1.42	2.73
105	5.55	6.09	4.55	4.11
106	2.82	2.69	3.72	3.85
107	2.03	1.96	1.28	4.38
108	1.25	1.34	0.92	3.13
109	1.79	2.60	1.30	3.41
110	0.93	1.59	0.96	1.47
111	1.63	3.91	1.42	3.14
112	0.64	1.78	0.49	0.17
114	2.41	2.90	1.94	1.65
115	1.88	1.52	0.98	0.64
116	1.75	2.07	1.32	2.72
117	1.27	2.58	1.36	3.00
118	1.86	1.18	2.03	4.26
119	0.72	0.81	0.75	0.14
120	2.62	0.99	3.36	1.96
121	2.48	1.19	3.11	6.00
Mean =	2.33	2.56	2.42	2.52
Median =	1.90	2.22	1.95	2.00
Standard Deviation =	1.55	1.67	1.94	1.75
Maximum =	9.03	10.23	13.38	9.59
Minimum =	0.54	0.19	0.31	0.14

Did Not Complete Subject#s 7, 51, 58, 81, 83, 85, 113

L\* values are a measure of the luminosity of the test site. The higher the value, the greater the lightness of the test site.  
 a\* values are a measure of the redness of the test site. The higher the value, the greater the redness of the test site.  
 b\* values are a measure of the yellowness of the test site. The higher the value, the greater the yellowness of the test site.

Table 4  
 (continued)  
 VISIA-CR Image Analysis Color Data - L\* Value Left Iris

.01 [REDACTED] Lash Enhancing Serum

Subject #	Baseline	Month 1	Month 2	Month 4	Month 8	Difference From Baseline At:			
						Month 1	Month 2	Month 4	Month 8
1	20.38	22.07	20.63	19.27	22.01	1.7	0.2	-1.1	1.6
2	41.73	37.76	39.26	37.57	37.61	-4.0	-2.5	-4.2	-4.1
3	36.35	37.31	35.49	36.96	40.23	1.0	-0.9	0.6	3.9
4	32.83	32.94	35.47	31.32	30.86	0.1	2.6	-1.5	-2.0
5	10.91	10.48	9.38	7.38	9.75	-0.4	-1.5	-3.5	-1.2
6	9.82	9.62	6.79	7.22	9.42	-0.2	-3.0	-2.6	-0.4
8	8.96	9.34	10.84	10.87	8.73	0.4	1.9	1.9	-0.2
9	42.30	42.85	40.31	39.01	36.88	0.6	-2.0	-3.3	-5.4
10	36.93	42.08	36.19	38.96	37.62	5.1	-0.7	2.0	0.7
11	6.73	6.21	7.47	10.38	6.83	-0.5	0.7	3.7	0.1
12	40.38	38.44	38.77	40.07	41.56	-1.9	-1.6	-0.3	1.2
13	11.94	12.14	8.78	8.93	9.42	0.2	-3.2	-3.0	-2.5
14	8.30	11.81	8.88	8.71	9.48	3.5	0.6	0.4	1.2
15	5.41	8.99	10.07	8.02	9.45	3.6	4.7	2.6	4.0
16	12.89	10.40	11.33	12.37	12.74	-2.5	-1.6	-0.5	-0.1
17	20.13	20.03	23.21	21.09	19.85	-0.1	3.1	1.0	-0.3
18	15.67	17.09	11.52	17.03	14.89	1.4	-4.1	1.4	-0.8
19	17.29	12.92	18.74	15.09	14.71	-4.4	1.5	-2.2	-2.6
20	36.50	42.61	38.47	36.35	35.04	6.1	2.0	-0.2	-1.5
21	27.00	30.97	35.13	34.84	35.28	4.0	8.1	7.8	8.3
22	13.92	15.03	14.31	14.16	14.72	1.1	0.4	0.2	0.8
23	38.23	39.55	38.36	36.54	34.64	1.3	0.1	-1.7	-3.6
24	9.03	7.55	7.83	9.31	6.25	-1.5	-1.2	0.3	-2.8
25	8.29	6.48	12.02	7.95	7.70	-1.8	3.7	-0.3	-0.6
26	36.23	37.89	35.14	34.70	35.29	1.7	-1.1	-1.5	-0.9
27	14.34	13.36	13.28	16.06	15.48	-1.0	-1.1	1.7	1.1
28	13.65	14.77	15.34	15.63	12.40	1.1	1.7	2.0	-1.3
29	26.17	28.53	30.03	23.92	30.05	2.4	3.9	-2.3	3.9
30	5.66	5.93	6.84	9.06	5.93	0.3	1.2	3.4	0.3
31	8.77	8.19	6.57	7.84	8.05	-0.6	-2.2	-0.9	-0.7
32	16.97	15.89	14.98	16.77	16.47	-1.1	-2.0	-0.2	-0.5
33	12.92	12.12	13.50	11.20	12.24	-0.8	0.6	-1.7	-0.7
34	15.74	17.74	17.80	19.35	17.88	2.0	2.1	3.6	2.1
35	30.38	29.75	34.92	22.65	32.33	-0.6	4.5	-7.7	2.0
36	12.82	13.63	14.47	13.70	15.00	0.8	1.7	0.9	2.2
37	8.87	9.43	7.42	8.47	8.05	0.6	-1.5	-0.4	-0.8
38	42.80	40.94	42.80	45.19	39.79	-1.9	0.0	2.4	-3.0
39	31.66	31.80	33.83	33.48	33.39	0.1	2.2	1.8	1.7
40	7.29	8.57	10.20	10.24	5.83	1.3	2.9	2.9	-1.5
41	8.53	8.53	6.62	8.22	7.17	0.0	-1.9	-0.3	-1.4
42	15.78	13.34	16.92	17.07	18.25	-2.4	1.1	1.3	2.5
43	11.17	8.69	8.91	9.45	9.24	-2.5	-2.3	-1.7	-1.9
44	19.93	21.32	20.53	19.20	22.04	1.4	0.6	-0.7	2.1
45	8.42	11.48	11.32	11.43	10.44	3.1	2.9	3.0	2.0
46	16.18	21.34	18.04	19.26	22.86	5.2	1.9	3.1	6.7
47	26.38	17.69	23.21	22.16	20.26	-8.7	-3.2	-4.2	-6.1
48	10.42	10.55	8.01	10.11	9.74	0.1	-2.4	-0.3	-0.7
49	12.83	11.16	14.31	13.69	13.79	-1.7	1.5	0.9	1.0
50	30.47	30.28	29.16	28.90	30.46	-0.2	-1.3	-1.6	0.0
52	12.25	15.79	14.85	14.27	14.64	3.5	2.6	2.0	2.4
53	35.98	35.35	40.43	38.43	34.91	-0.6	4.5	2.5	-1.1
54	9.69	7.92	8.97	7.09	8.13	-1.8	-0.7	-2.6	-1.6
55	11.33	9.41	7.15	12.41	10.97	-1.9	-4.2	1.1	-0.4
56	34.33	31.54	35.96	33.97	34.28	-2.8	1.6	-0.4	-0.1
57	14.73	13.39	15.63	12.43	12.09	-1.3	0.9	-2.3	-2.6
59	9.03	8.65	10.19	11.87	15.75	-0.4	1.2	2.8	6.7
60	35.73	34.83	36.29	37.48	36.94	-0.9	0.6	1.7	1.2
61	12.71	13.28	16.43	12.09	12.46	0.6	3.7	-0.6	-0.2
62	10.89	12.15	12.78	11.15	14.58	1.3	1.9	0.3	3.7
63	21.86	22.31	20.83	21.28	24.29	0.4	-1.0	-0.6	2.4
64	12.96	13.08	13.01	12.29	11.99	0.1	0.1	-0.7	-1.0
65	12.66	11.62	11.59	11.55	11.42	-1.0	-1.1	-1.1	-1.2
66	22.73	21.91	21.59	21.01	21.19	-0.8	-1.1	-1.7	-1.5

**Table 4**  
(continued)  
VISIA-CR Image Analysis Color Data - L\* Value Left Iris

	.01 - [REDACTED] Lash Enhancing Serum									
67	10.61	10.44	12.46	12.64	9.16	-0.2	1.9	2.0	-1.4	
68	19.08	20.73	18.99	17.39	18.51	1.7	-0.1	-1.7	-0.6	
69	20.58	21.23	21.33	21.19	20.20	0.6	0.7	0.6	-0.4	
70	8.72	12.56	10.96	11.35	9.94	3.8	2.2	2.6	1.2	
71	16.66	14.97	12.15	15.62	16.26	-1.7	-4.5	-1.0	-0.4	
72	13.11	15.66	14.12	14.83	17.39	2.6	1.0	1.7	4.3	
73	11.00	10.46	8.64	9.49	9.40	-0.5	-2.4	-1.5	-1.6	
74	10.40	7.44	5.67	6.75	11.33	-3.0	-4.7	-3.7	0.9	
75	13.28	10.18	11.05	11.15	12.19	-3.1	-2.2	-2.1	-1.1	
76	18.54	18.88	18.03	17.84	18.82	0.3	-0.5	-0.7	0.3	
77	13.72	16.49	15.96	14.45	16.91	2.8	2.2	0.7	3.2	
78	31.64	33.59	33.91	32.96	32.98	1.9	2.3	1.3	1.3	
79	17.32	15.83	18.23	17.21	15.96	-1.5	0.9	-0.1	-1.4	
80	13.58	11.05	11.06	10.58	10.24	-2.5	-2.5	-3.0	-3.3	
82	11.49	13.20	13.59	14.22	13.97	1.7	2.1	2.7	2.5	
84	8.21	13.19	7.22	8.41	9.92	5.0	-1.0	0.2	1.7	
86	12.80	14.88	16.24	14.53	15.93	2.1	3.4	1.7	3.1	
87	11.08	9.80	12.21	12.41	13.47	-1.3	1.1	1.3	2.4	
88	42.91	47.37	42.15	44.46	46.93	4.5	-0.8	1.6	4.0	
89	20.98	21.68	22.99	23.25	21.99	0.7	2.0	2.3	1.0	
90	43.74	41.81	43.39	42.60	43.84	-1.9	-0.4	-1.1	0.1	
91	12.84	12.65	12.61	11.68	14.08	-0.2	-0.2	-1.2	1.2	
92	23.52	20.88	19.16	18.45	17.79	-2.6	-4.4	-5.1	-5.7	
93	31.44	26.30	28.45	27.06	27.75	-5.1	-3.0	-4.4	-3.7	
94	31.53	31.18	26.47	29.39	32.53	-0.4	-5.1	-2.1	1.0	
95	29.69	29.23	28.50	29.16	29.76	-0.5	-1.2	-0.5	0.1	
96	36.50	37.27	36.18	38.67	35.79	0.8	-0.3	2.2	-0.7	
97	6.06	8.49	5.65	5.90	7.50	2.4	-0.4	-0.2	1.4	
98	24.66	19.58	20.24	26.75	22.24	-5.1	-4.4	2.1	-2.4	
99	17.37	16.71	18.55	18.33	18.13	-0.7	1.2	1.0	0.8	
100	20.78	19.64	19.48	20.99	20.40	-1.1	-1.3	0.2	-0.4	
101	16.03	15.98	16.93	17.39	14.84	0.0	0.9	1.4	-1.2	
102	20.04	18.57	19.26	14.34	20.05	-1.5	-0.8	-5.7	0.0	
103	17.03	15.44	18.56	18.84	16.24	-1.6	1.5	-0.2	-0.8	
104	18.46	17.43	19.57	18.57	21.04	-1.0	1.1	0.1	2.6	
105	37.52	37.76	37.67	36.76	39.46	0.2	0.1	-0.8	1.9	
106	12.29	14.59	14.69	14.78	15.29	2.3	2.4	2.5	3.0	
107	11.47	13.18	11.59	12.48	11.29	1.7	0.1	1.0	-0.2	
108	41.56	40.62	40.91	41.24	38.79	-0.9	-0.7	-0.3	-2.8	
109	38.46	39.87	40.92	39.52	35.82	1.4	2.5	1.1	-2.6	
110	40.40	39.67	41.82	41.16	41.51	-0.7	1.4	0.8	1.1	
111	14.23	14.70	17.57	13.06	15.58	0.5	3.3	-1.2	1.3	
112	10.75	10.13	12.39	10.78	10.82	-0.6	1.6	0.0	0.1	
114	14.38	16.11	17.11	16.07	15.74	1.7	2.7	1.7	1.4	
115	14.78	13.25	13.86	14.91	14.29	-1.5	-0.9	0.1	-0.5	
116	19.40	18.50	20.64	19.29	21.28	-0.9	1.2	-0.1	1.9	
117	26.21	25.36	23.71	26.17	23.36	-0.9	-2.5	0.0	-2.9	
118	25.65	27.41	25.59	27.34	29.70	1.8	-0.1	1.7	4.1	
119	14.02	14.17	14.61	13.28	13.92	0.2	0.6	-0.7	-0.1	
120	17.57	15.44	17.75	14.58	19.27	-2.1	0.2	-3.0	1.7	
121	9.08	10.43	8.71	11.39	13.73	1.3	-0.4	2.3	4.7	
Mean =	19.62	19.66	19.81	19.60	19.87	0.04	0.20	-0.02	0.25	
Median =	15.76	15.73	16.92	15.84	16.10	-0.08	0.21	-0.07	-0.03	
Standard Deviation =	10.76	10.84	10.89	10.67	10.61	2.26	2.30	2.24	2.44	
Maximum =	43.74	47.37	43.39	45.19	46.93	6.11	5.13	7.84	8.28	
Minimum =	5.41	5.93	5.65	5.90	5.83	-8.69	-5.06	-7.72	-6.12	

*Mean % Change From Baseline*

	Month 1	Month 2	Month 4	Month 8
0.2%			-0.1%	1.3%
Increase	Increase		Decrease	Increase

*Totals & Percentages*

	Month 1	Month 2	Month 4	Month 8
Total	114	114	114	114
Increased Values	56	63	56	56
Decreased Values	58	51	58	58
No Change	0	0	0	0
Increased Values	49.12%	55.26%	49.12%	49.12%
Decreased Values	50.88%	44.74%	50.88%	50.88%
No Change	0.00%	0.00%	0.00%	0.00%

Did Not Complete Subjects 7, 51, 58, 81, 83, 85, 113

L\* values are a measure of the luminosity of the test site. The higher the value, the greater the lightness of the test site  
 a\* values are a measure of the redness of the test site. The higher the value, the greater the redness of the test site  
 b\* values are a measure of the yellowness of the test site. The higher the value, the greater the yellowness of the test site.

**Table 4**  
 (continued)  
 VISIA-CR Image Analysis Color Data - a\* Values Left Iris

.01 = [REDACTED] Lash Enhancing Serum

Subject #	Baseline	Month 1	Month 2	Month 4	Month 8	Difference From Baseline At:			
						Month 1	Month 2	Month 4	Month 8
1	11.38	13.19	10.17	11.80	11.64	1.8	-1.2	0.4	0.3
2	-2.51	-1.92	-1.93	-1.43	-0.91	0.6	0.6	1.1	1.6
3	-1.38	-1.89	-0.78	-1.42	-1.45	-0.5	0.6	0.0	-0.1
4	3.28	2.30	2.32	3.34	3.72	-1.0	-1.0	0.3	0.4
5	2.24	2.92	2.90	3.41	3.22	0.7	0.7	1.2	1.0
6	3.49	3.01	3.45	3.13	3.31	-0.5	0.0	-0.4	-0.2
8	3.32	1.94	0.74	1.47	1.80	-1.4	-2.6	-1.9	-1.5
9	-1.51	-1.15	-0.50	0.30	0.66	0.4	1.0	1.8	2.2
10	-0.61	-2.66	-0.55	-1.38	-1.57	-2.1	0.1	-0.8	-1.0
11	1.96	2.09	2.03	2.50	2.42	0.1	0.1	0.5	0.5
12	-2.57	-0.96	-2.31	-2.07	-2.15	1.6	0.3	0.5	0.4
13	1.30	0.83	2.38	2.38	1.87	-0.5	1.1	1.1	0.6
14	4.75	3.10	4.33	4.42	4.05	-1.6	-0.4	-0.3	-0.7
15	2.76	1.30	1.87	2.42	1.57	-1.5	-0.9	-0.3	-1.2
16	6.13	6.47	6.64	6.67	6.52	0.3	0.5	0.5	0.4
17	11.49	10.30	10.25	11.30	12.55	-1.2	-1.2	-0.2	1.1
18	10.13	9.77	11.20	8.72	9.53	-0.4	1.1	-1.4	-0.6
19	7.97	9.04	7.96	8.16	8.11	1.1	0.0	0.2	0.1
20	-1.63	-3.23	-2.82	-2.17	-1.96	-1.6	-1.2	-0.5	-0.3
21	6.56	2.04	0.91	1.27	1.94	-4.5	-5.6	-5.3	-4.6
22	11.42	11.06	11.45	11.51	11.74	-0.4	0.0	0.1	0.3
23	-2.18	-2.19	-2.05	-1.65	-0.49	0.0	0.1	0.5	1.7
24	1.99	2.15	2.38	2.13	2.41	0.2	0.4	0.1	0.4
25	1.96	1.76	1.33	1.67	2.24	-0.2	-0.6	-0.3	0.3
26	-0.99	-0.82	0.21	0.82	-0.34	0.2	1.2	1.8	0.6
27	9.99	9.68	9.65	8.97	9.84	-0.3	-0.3	-1.0	-0.1
28	7.32	5.88	6.26	7.33	9.75	-1.4	-1.1	0.0	2.4
29	-0.86	-1.09	-0.91	10.79	-0.20	-0.2	0.0	11.7	0.7
30	0.62	1.04	0.78	0.42	0.83	0.4	0.2	-0.2	0.2
31	0.61	0.64	0.81	0.79	1.18	0.0	0.2	0.2	0.6
32	11.16	11.87	11.99	11.87	12.25	0.7	0.8	0.7	1.1
33	9.31	8.73	9.24	8.96	9.99	-0.6	-0.1	-0.3	0.7
34	9.45	9.35	10.10	9.01	10.47	-0.1	0.7	-0.4	1.0
35	-1.10	-1.24	-2.54	0.41	-1.62	-0.1	-1.4	1.5	-0.5
36	9.32	8.92	9.36	9.38	10.15	-0.4	0.0	0.1	0.8
37	4.64	4.11	4.71	4.88	4.32	-0.5	0.1	0.2	-0.3
38	-2.99	-3.04	-2.99	-3.14	-2.69	-0.1	0.0	-0.1	0.3
39	6.40	5.06	4.67	5.08	6.61	-1.3	-1.7	-1.3	0.2
40	2.63	1.88	1.97	1.47	2.86	-0.7	-0.7	-1.2	0.2
41	3.76	3.11	4.44	4.60	4.51	-0.7	0.7	0.8	0.7
42	9.36	10.00	10.43	11.66	10.28	0.6	1.1	2.3	0.9
43	4.55	5.88	5.83	5.42	5.50	1.3	1.3	0.9	1.0
44	11.81	11.72	9.28	11.79	10.85	-0.1	-2.5	0.0	-1.0
45	1.93	0.54	1.68	1.26	1.16	-1.4	-0.2	-0.7	-0.8
46	10.38	9.36	10.26	11.41	12.63	-1.0	-0.1	1.0	2.3
47	-0.17	0.96	-0.43	-0.22	-0.08	1.1	-0.3	0.0	0.1
48	1.70	2.27	1.88	1.46	1.48	0.6	0.2	-0.2	-0.2
49	9.15	9.47	10.15	9.81	9.85	0.3	1.0	0.7	0.7
50	2.41	1.74	1.72	2.55	2.95	-0.7	-0.7	0.1	0.5
52	6.09	9.00	10.42	8.50	10.26	2.9	4.3	2.4	4.2
53	-0.35	2.10	0.88	1.40	3.37	2.4	1.2	1.8	3.7
54	1.89	2.98	2.48	2.84	3.04	1.1	0.6	0.9	1.1
55	2.45	2.61	4.06	1.65	2.89	0.2	1.6	-0.8	0.4
56	-1.13	-0.16	-1.29	-1.16	-0.94	1.0	-0.2	0.0	0.2
57	3.37	3.59	2.63	4.83	3.87	0.2	-0.7	1.5	0.5
59	3.10	3.53	3.32	2.86	2.47	0.4	0.2	-0.2	-0.6
60	0.37	-0.02	0.05	-0.26	0.44	-0.4	-0.3	-0.6	0.1
61	9.21	9.80	7.96	9.05	9.78	0.6	-1.3	-0.2	0.6
62	4.97	4.90	4.79	4.48	4.31	-0.1	-0.2	-0.5	-0.7
63	11.09	10.51	10.11	9.79	11.78	-0.6	-1.0	-1.3	0.7
64	9.01	9.47	8.67	9.79	8.98	0.5	-0.3	0.8	0.0
65	7.96	7.80	7.90	8.83	8.19	-0.2	-0.1	0.9	0.2
66	4.45	6.57	6.15	8.11	4.88	2.1	1.7	3.7	0.4



**Table 4**  
(continued)  
**VISIA-CR Image Analysis Color Data - a\* Values Left Iris**

	.01 - [REDACTED]					Lash Enhancing Serum				
67	8.34	6.74	5.03	5.57	7.94	-1.6	-3.3	-2.8	-0.4	
68	10.24	8.16	10.25	10.54	10.14	-2.1	0.0	0.3	-0.1	
69	13.28	12.97	13.44	12.96	13.27	-0.3	0.2	-0.3	0.0	
70	5.38	4.55	4.68	5.24	5.76	-0.8	-0.7	-0.1	0.4	
71	7.26	7.92	7.54	7.76	8.93	0.7	0.3	0.5	1.7	
72	8.90	9.45	9.44	9.61	9.05	0.6	0.5	0.7	0.2	
73	5.05	6.24	5.67	5.93	5.67	1.2	0.6	0.9	0.6	
74	1.25	2.52	2.28	2.21	2.05	1.3	1.0	1.0	0.8	
75	5.92	6.85	6.21	6.90	6.20	0.9	0.3	1.0	0.3	
76	7.73	7.03	9.86	9.79	8.11	-0.7	2.1	2.1	0.4	
77	9.90	10.39	9.12	8.87	9.72	0.5	-0.8	-1.0	-0.2	
78	0.05	-0.88	-1.03	-0.64	-0.57	-0.9	-1.1	-0.7	-0.6	
79	6.67	7.59	7.11	7.19	7.31	0.9	0.4	0.5	0.6	
80	5.31	6.45	6.83	6.95	6.94	1.1	1.5	1.6	1.6	
82	8.01	7.07	7.50	7.74	7.90	-0.9	-0.5	-0.3	-0.1	
84	2.50	0.42	2.76	2.23	2.08	-2.1	0.3	-0.3	-0.4	
86	8.34	7.90	7.90	7.04	8.54	-0.4	-1.0	-1.3	0.2	
87	4.76	6.32	5.96	5.35	5.25	1.6	1.2	0.6	0.5	
88	-0.03	-1.37	-0.15	0.52	-1.00	-1.3	-0.1	0.5	-1.0	
89	14.40	15.01	13.24	14.60	15.48	0.6	-1.2	0.2	1.1	
90	-3.45	-3.21	-3.00	-3.03	-3.17	0.2	0.5	0.4	0.3	
91	7.72	6.99	9.00	7.73	8.88	-0.7	1.3	0.0	1.2	
92	9.42	7.94	9.06	10.52	10.66	-1.5	-0.4	1.1	1.2	
93	-0.73	1.34	0.44	0.26	0.44	2.1	1.2	1.0	1.2	
94	10.63	11.09	9.53	11.82	11.62	0.5	-1.1	1.2	1.0	
95	2.93	1.14	2.92	3.40	1.93	-3.8	0.0	0.5	-1.0	
96	-1.16	-1.86	-1.88	-2.19	-1.61	-0.7	-0.7	-1.0	-0.4	
97	0.51	0.51	0.88	0.86	1.13	0.0	0.4	0.4	0.6	
98	7.79	10.08	10.54	7.21	9.10	2.3	2.8	-0.6	1.3	
99	3.69	3.28	3.40	3.45	4.31	-0.4	-0.3	-0.2	0.6	
100	7.83	9.71	10.07	9.12	8.63	1.9	2.2	1.3	0.8	
101	9.62	10.20	9.73	10.76	10.33	0.6	0.1	1.1	0.7	
102	15.56	12.87	12.59	14.39	13.35	-2.7	-3.0	-1.2	-2.2	
103	8.78	9.36	10.07	9.62	9.85	0.6	1.3	0.8	1.1	
104	9.01	8.97	8.32	9.35	8.30	0.0	-0.7	0.3	-0.7	
105	3.82	0.16	0.07	7.01	1.17	-3.7	-3.7	3.2	-2.6	
106	10.28	8.84	10.72	11.86	11.61	-1.4	0.4	1.6	1.3	
107	9.63	8.54	7.88	8.86	6.05	-1.1	-1.8	-0.8	-3.6	
108	-2.29	-2.50	-2.81	-2.42	-2.22	-0.2	-0.5	-0.1	0.1	
109	-0.20	-0.72	-0.62	-0.38	0.05	-0.5	-0.4	-0.2	0.2	
110	-2.01	-1.60	-2.64	-2.10	-1.43	0.4	-0.6	-0.1	0.6	
111	10.66	9.11	9.07	10.00	8.27	-1.6	-1.6	-0.7	-2.4	
112	4.47	4.54	3.79	4.01	4.53	0.1	-0.7	-0.5	0.1	
114	9.59	7.95	9.34	8.65	9.30	-1.6	-0.3	-0.9	-0.3	
115	6.50	7.42	7.29	6.78	6.76	0.9	0.8	0.3	0.3	
116	11.89	10.46	10.25	10.75	10.16	-1.4	-1.6	-1.1	-1.7	
117	0.21	-0.15	0.39	0.64	0.63	-0.4	0.2	0.4	0.4	
118	9.23	9.41	9.62	8.64	8.03	0.2	0.4	-0.6	-1.2	
119	9.72	9.41	9.30	9.56	9.76	-0.3	-0.4	-0.2	0.0	
120	10.03	9.76	9.34	9.82	9.11	-0.3	-0.7	-0.2	-0.9	
121	6.17	7.52	5.27	7.11	7.07	1.4	-0.9	0.9	0.9	
<b>Mean =</b>	<b>5.10</b>	<b>4.96</b>	<b>4.99</b>	<b>5.37</b>	<b>5.33</b>	<b>-0.14</b>	<b>-0.11</b>	<b>0.27</b>	<b>0.23</b>	
<b>Median =</b>	<b>5.01</b>	<b>5.47</b>	<b>4.91</b>	<b>5.49</b>	<b>5.37</b>	<b>-0.12</b>	<b>-0.01</b>	<b>0.14</b>	<b>0.31</b>	
<b>Standard Deviation =</b>	<b>4.58</b>	<b>4.60</b>	<b>4.54</b>	<b>4.57</b>	<b>4.60</b>	<b>1.19</b>	<b>1.26</b>	<b>1.55</b>	<b>1.16</b>	
<b>Maximum =</b>	<b>15.56</b>	<b>15.01</b>	<b>13.44</b>	<b>14.60</b>	<b>15.48</b>	<b>2.91</b>	<b>4.33</b>	<b>11.66</b>	<b>4.17</b>	
<b>Minimum =</b>	<b>-3.45</b>	<b>-3.23</b>	<b>-3.00</b>	<b>-3.14</b>	<b>-3.17</b>	<b>-4.52</b>	<b>-5.64</b>	<b>-5.29</b>	<b>-4.62</b>	

*Mean % Change From Baseline*

	Month 1	Month 2	Month 4	Month 8
	-2.7%	-2.2%	5.3%	4.5%
	Decrease	Decrease	Increase	Increase

*Totals & Percentages*

	Month 1	Month 2	Month 4	Month 8
<b>Total</b>	<b>114</b>	<b>114</b>	<b>114</b>	<b>114</b>
<b>Increased Values</b>	<b>51</b>	<b>55</b>	<b>62</b>	<b>77</b>
<b>Decreased Values</b>	<b>63</b>	<b>59</b>	<b>52</b>	<b>37</b>
<b>No Change</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Increased Values</b>	<b>44.74%</b>	<b>48.25%</b>	<b>54.39%</b>	<b>67.54%</b>
<b>Decreased Values</b>	<b>55.26%</b>	<b>51.75%</b>	<b>45.61%</b>	<b>32.46%</b>
<b>No Change</b>	<b>0.00%</b>	<b>0.00%</b>	<b>0.00%</b>	<b>0.00%</b>

Did Not Complete Subjects: 7, 51, 58, 81, 83, 85, 113

L\* values are a measure of the luminosity of the test site. The higher the value, the greater the lightness of the test site.  
a\* values are a measure of the redness of the test site. The higher the value, the greater the redness of the test site.  
b\* values are a measure of the yellowness of the test site. The higher the value, the greater the yellowness of the test site.

Table 4  
 (continued)  
 VISIA-CR Image Analysis Color Data - b\* Values Left Iris

.01 - [REDACTED] Lash Enhancing Serum

Subject #	Baseline	Month 1	Month 2	Month 4	Month 8	Difference From Baseline At :			
						Month 1	Month 2	Month 4	Month 8
1	16.65	19.77	15.66	16.73	17.75	3.1	-1.0	0.1	1.1
2	2.56	3.58	3.27	3.48	4.52	1.0	0.7	0.9	2.0
3	9.22	8.55	8.61	9.02	11.30	-0.7	-1.2	-0.2	2.1
4	20.31	19.14	20.60	19.59	18.61	-1.2	0.3	-0.7	-1.7
5	6.45	6.62	6.29	5.59	6.58	0.2	-0.2	-0.9	0.1
6	7.37	6.99	5.46	5.47	6.96	-0.4	-1.9	-1.9	-0.4
8	6.93	5.88	5.74	5.37	5.73	-1.0	-1.2	-1.6	-1.2
9	16.94	18.09	17.28	16.84	15.67	1.1	0.3	-0.1	-1.3
10	7.17	6.98	6.99	7.20	6.25	-0.2	-0.2	0.0	-0.9
11	4.61	4.45	5.00	7.51	4.81	-0.2	0.4	2.9	0.2
12	9.53	10.73	9.42	9.97	10.28	1.2	-0.1	0.4	0.7
13	6.26	6.07	5.89	6.00	6.05	-0.2	-0.4	-0.3	-0.2
14	6.29	6.22	6.15	6.30	6.25	-0.1	-0.1	0.0	0.0
15	4.55	5.02	5.90	5.56	5.59	0.5	1.4	1.0	1.0
16	8.84	7.90	8.90	9.22	9.53	-0.9	0.1	0.4	0.7
17	18.14	16.88	16.50	17.91	17.68	-1.3	-1.6	-0.2	-0.5
18	13.48	13.23	12.13	12.50	12.87	-0.2	-1.3	-1.0	-0.6
19	13.45	12.64	13.77	13.15	12.85	-0.8	0.3	-0.3	-0.6
20	3.48	3.89	2.17	2.72	2.69	0.4	-1.3	-0.8	-0.8
21	19.71	17.64	17.12	17.33	18.26	-2.1	-2.6	-2.4	-1.5
22	13.85	13.74	14.00	14.16	14.32	-0.1	0.1	0.3	0.5
23	4.45	4.61	4.49	3.63	5.47	0.2	0.0	-0.8	1.0
24	5.70	5.15	5.37	5.68	4.63	-0.5	-0.3	0.0	-1.1
25	5.31	4.47	6.30	4.99	5.35	-0.8	1.0	-0.3	0.0
26	10.79	13.00	14.62	15.09	13.27	2.2	3.8	4.3	2.5
27	13.49	12.05	11.95	12.31	14.18	-1.4	-1.5	-1.2	0.7
28	9.67	9.18	10.27	10.43	11.82	-0.5	0.6	0.8	2.1
29	10.87	14.09	13.37	17.06	14.41	3.2	2.7	6.2	3.5
30	3.71	4.00	4.28	4.87	4.14	0.3	0.6	1.2	0.4
31	5.54	4.38	4.12	5.20	5.30	-1.2	-1.4	-0.3	-0.2
32	15.56	15.76	15.89	16.09	16.53	0.2	0.3	0.5	1.0
33	12.15	11.19	12.20	11.22	12.29	-1.0	0.1	-0.9	0.1
34	14.52	14.64	14.97	13.95	15.12	0.1	0.4	-0.6	0.6
35	1.97	1.44	2.75	3.72	1.64	-0.5	0.8	1.8	-0.3
36	12.27	11.37	12.15	12.17	13.36	-0.9	-0.1	-0.1	1.1
37	7.16	6.85	6.33	6.99	6.42	-0.3	-0.8	-0.2	-0.7
38	7.45	7.96	8.64	9.40	8.09	0.5	1.2	2.0	0.6
39	22.75	21.35	21.53	22.28	23.31	-1.4	-1.2	-0.5	0.6
40	5.09	5.51	5.93	5.95	4.75	0.4	0.8	0.9	-0.3
41	6.14	5.89	5.54	6.65	6.04	-0.3	-0.6	0.5	-0.1
42	14.06	13.90	15.34	17.08	17.11	-0.2	1.3	3.0	3.0
43	7.58	7.66	7.58	7.48	7.86	0.1	0.0	-0.1	0.3
44	19.14	19.51	17.04	18.58	20.46	0.4	-2.1	-0.6	1.3
45	5.30	5.59	7.22	6.95	5.76	0.3	1.9	1.7	0.5
46	11.44	12.02	12.85	15.40	14.52	0.6	1.4	4.0	3.1
47	7.50	5.32	4.32	4.80	4.52	-2.2	-3.2	-2.7	-3.0
48	5.90	6.72	5.39	6.05	6.04	0.8	-0.5	0.1	0.1
49	11.95	11.06	13.05	12.90	12.97	-0.9	1.1	0.9	1.0
50	16.52	15.81	14.68	15.76	17.45	-0.7	-1.8	-0.8	0.9
52	9.52	13.07	13.93	12.41	14.13	3.5	4.4	2.9	4.6
53	16.90	18.42	18.64	18.95	18.50	1.5	1.7	2.0	1.6
54	5.60	5.42	5.81	5.18	5.61	-0.2	0.2	-0.4	0.0
55	6.32	6.11	5.74	6.85	6.65	-0.2	-0.6	0.5	0.3
56	5.91	6.01	6.23	6.03	6.25	0.1	0.3	0.1	0.3
57	8.73	8.44	8.78	8.48	7.26	-0.3	0.0	-0.2	-1.5
59	6.18	6.18	6.56	7.07	10.18	0.0	0.4	0.9	4.0
60	14.71	13.17	16.14	15.60	17.52	-1.5	1.4	0.9	2.8
61	12.06	12.74	12.11	11.45	12.25	0.7	0.1	-0.6	0.2
62	7.64	7.73	7.89	7.30	8.29	0.1	0.2	-0.3	0.6
63	20.09	20.08	18.63	19.68	21.08	0.0	-1.5	-0.4	1.0
64	11.49	12.34	11.45	12.22	10.89	0.8	0.0	0.7	-0.6
65	12.24	11.38	11.47	12.19	11.74	-0.9	-0.8	-0.1	-0.5
66	15.29	16.70	16.59	18.36	14.48	1.4	1.3	3.1	-0.8
67	10.38	9.15	8.97	9.08	9.26	-1.2	-1.4	-1.3	-1.1



**Table 4**  
(continued)  
**VISIA-CR Image Analysis Color Data - b\* Values Left Iris**

.01 → [Redacted] Lash Enhancing Serum

68	16.58	14.59	16.80	16.57	16.57	-2.0	0.2	0.0	0.0
69	20.13	21.14	21.64	20.58	20.66	1.0	1.5	0.5	0.5
70	6.74	7.75	7.56	8.12	7.89	1.0	0.8	1.4	1.1
71	11.07	11.53	10.35	11.47	14.49	0.5	-0.7	0.4	3.4
72	11.67	12.37	11.94	12.27	12.74	0.7	0.3	0.6	1.1
73	7.95	8.64	6.92	8.15	7.86	0.7	-1.0	0.2	-0.1
74	5.76	5.50	4.23	5.10	6.61	-0.3	-1.5	-0.7	0.9
75	9.24	9.01	8.67	9.69	9.19	-0.2	-0.6	0.5	0.0
76	15.49	14.63	16.50	16.00	15.97	-0.9	1.0	0.5	0.5
77	13.63	14.96	13.43	12.74	14.34	1.3	-0.2	-0.9	0.7
78	2.25	2.11	1.91	2.76	2.51	-0.1	-0.3	0.5	0.3
79	14.49	13.84	14.43	14.37	14.15	-0.6	-0.1	-0.1	-0.3
80	8.98	8.40	8.69	8.54	8.75	-0.6	-0.3	-0.4	-0.2
82	9.85	9.87	10.43	10.77	11.11	0.0	0.6	0.9	1.3
84	6.33	6.49	5.77	5.87	6.37	0.2	-0.6	-0.5	0.0
86	10.44	11.20	11.67	10.08	12.10	0.8	1.2	-0.4	1.7
87	7.10	7.60	9.11	8.05	8.40	0.5	2.0	0.9	1.3
88	15.27	15.60	14.31	16.13	15.59	0.3	-1.0	0.9	0.3
89	21.05	22.16	20.72	23.18	23.06	1.1	-0.3	2.1	2.0
90	3.98	4.95	5.32	4.61	4.98	1.0	1.3	0.6	1.0
91	11.11	9.97	12.07	10.61	12.43	-1.1	1.0	-0.5	1.3
92	19.48	17.59	17.68	17.76	17.45	-1.9	-1.8	-1.7	-2.0
93	7.29	7.87	7.68	7.88	7.93	0.6	0.4	0.6	0.6
94	27.82	27.17	19.53	25.92	29.02	-0.7	-8.3	-1.9	1.2
95	16.31	14.94	16.82	17.13	15.92	-1.4	0.5	0.8	-0.4
96	1.74	1.08	0.22	1.27	0.59	-0.7	-1.5	-0.5	-1.2
97	3.71	4.78	3.73	4.08	4.99	1.1	0.0	0.4	1.3
98	16.15	16.57	15.70	17.70	16.84	0.4	-0.5	1.5	0.7
99	11.59	11.68	12.54	12.15	11.78	0.1	1.0	0.6	0.2
100	16.33	18.35	18.34	18.51	17.04	2.0	2.0	2.2	0.7
101	13.86	14.65	15.06	16.30	14.61	0.8	1.2	2.4	0.8
102	20.74	16.53	16.20	15.68	17.56	-4.2	-4.5	-5.1	-3.2
103	13.66	14.64	16.09	15.36	15.64	1.0	2.4	1.7	2.0
104	14.46	14.47	13.72	15.83	15.02	0.0	-0.7	1.4	0.6
105	22.59	18.42	17.75	25.75	20.11	-4.2	-4.8	3.2	-2.5
106	12.09	11.30	13.23	14.36	14.11	-0.8	1.1	2.3	2.0
107	11.49	11.56	10.63	11.55	8.98	0.1	-0.9	0.1	-2.5
108	8.31	7.52	7.27	7.46	6.87	-0.8	-1.0	-0.9	-1.4
109	13.48	12.52	14.18	14.20	11.33	-1.0	0.7	0.7	-2.1
110	9.02	9.43	9.38	9.60	9.80	0.4	0.4	0.6	0.8
111	13.66	13.80	14.94	13.22	12.13	0.1	1.3	-0.4	-1.5
112	7.37	7.23	7.46	7.20	7.51	-0.1	0.1	-0.2	0.1
114	13.12	12.82	14.06	13.05	14.01	-0.3	0.9	-0.1	0.9
115	10.41	10.99	11.33	11.33	10.72	0.6	0.9	0.9	0.3
116	19.02	18.58	19.27	19.67	19.94	-0.4	0.3	0.7	0.9
117	2.99	2.12	2.35	4.28	2.14	-0.9	-0.6	1.3	-0.8
118	20.80	21.38	21.91	21.76	21.33	0.6	1.1	1.0	0.5
119	12.14	11.50	11.79	12.15	12.24	-0.6	-0.4	0.0	0.1
120	15.25	13.76	14.55	13.72	14.92	-1.5	-0.7	-1.5	-0.3
121	7.05	8.63	6.37	8.90	10.73	1.6	-0.7	1.9	3.7
Mean =	11.09	11.01	11.02	11.44	11.48	-0.1	-0.1	0.4	0.4
Median =	10.83	11.19	11.46	11.39	11.76	-0.1	0.0	0.2	0.4
Standard Deviation =	5.39	5.28	5.18	5.46	5.49	1.2	1.6	1.4	1.4
Maximum =	27.82	27.17	21.91	25.92	29.02	3.5	4.4	6.2	4.6
Minimum =	1.74	1.08	0.22	1.27	0.59	-4.2	-8.3	-5.1	-3.2

**Mean % Change From Baseline**

	Month 1	Month 2	Month 4	Month 8
	-0.4%	-0.4%	1.8%	2.0%
	Decrease	Decrease	Increase	Increase

**Totals & Percentages**

	Month 1	Month 2	Month 4	Month 8
Total	114	114	114	114
Increased Values	55	60	64	74
Decreased Values	59	54	50	40
No Change	0	0	0	0
Increased Values	48.25%	52.63%	56.14%	64.91%
Decreased Values	51.75%	47.37%	43.86%	35.09%
No Change	0.00%	0.00%	0.00%	0.00%

Did Not Complete Subject#s 7, 51, 58, 81, 83, 85, 113

L\* values are a measure of the luminosity of the test site. The higher the value, the greater the lightness of the test site.  
 a\* values are a measure of the redness of the test site. The higher the value, the greater the redness of the test site.  
 b\* values are a measure of the yellowness of the test site. The higher the value, the greater the yellowness of the test site.





Table 4  
(continued)

.01 [Redacted] Lash Enhancing Serum (Left)

Within-Groups Analysis For :  
VISIA-CR Image Analysis Color Data - Delta E Value

Pre-Test	Normality	Brown-Forsythe	Friedman ANOVA
P-Value	P < 0.050	Not Required	0.001

Pairwise Comparisons

Difference from Baseline	Test Type	P-value	Significance	Direction (Mean)
Month 1	Dunn's Method	0.001	Yes	Increase
Month 2	Dunn's Method	0.001	Yes	Increase
Month 4	Dunn's Method	0.001	Yes	Increase
Month 8	Dunn's Method	0.001	Yes	Increase

Within-Groups Analysis For :  
VISIA-CR Image Analysis Color Data - Delta L Value

Pre-Test	Normality	Brown-Forsythe	Friedman ANOVA
P-Value	P < 0.050	Not Required	0.896

Within-Groups Analysis For :  
VISIA-CR Image Analysis Color Data - Delta A Value

Pre-Test	Normality	Brown-Forsythe	Friedman ANOVA
P-Value	P < 0.050	Not Required	0.001

Pairwise Comparisons

Difference from Baseline	Test Type	P-value	Significance	Direction (Mean)
Month 1	Dunn's Method	1.000	No	Decrease
Month 2	Dunn's Method	1.000	No	Decrease
Month 4	Dunn's Method	0.238	No	Increase
Month 8	Dunn's Method	0.008	Yes	Increase

Within-Groups Analysis For :  
VISIA-CR Image Analysis Color Data - Delta B Value

Pre-Test	Normality	Brown-Forsythe	Friedman ANOVA
P-Value	P < 0.050	Not Required	0.001

Pairwise Comparisons

Difference from Baseline	Test Type	P-value	Significance	Direction (Mean)
Month 1	Dunn's Method	1.000	No	Decrease
Month 2	Dunn's Method	1.000	No	Decrease
Month 4	Dunn's Method	0.042	Yes	Increase
Month 8	Dunn's Method	0.001	Yes	Increase

\* = ANOVA (RM) compares the means across groups (the non-parametric version is Friedman). The null hypothesis is all means are equivalent and the alternative is that the mean of at least one group differs. If ANOVA is significant further pairwise comparisons can be made, if not then it is assumed there is no statistically significant difference among the mean (or ranks) and no further testing is done due to risk of type one error. It is possible that Friedman or RM ANOVA may be significant, but when running post-hoc test may not show any statistically significant difference due to only examining the comparisons to baseline, post-hoc test, small sample size, lack of power, or if there is borderline significance.

\* = Dunn's method is a post-hoc test commonly run after Friedman RM ANOVA. It allows for comparisons between a control group, and it is a robust, non-parametric test that adjusts for multiple comparisons.

$\Delta E$  is a measure of total color change of the test site from baseline. The larger the value, the greater the change in color.  $\Delta E$  does not provide the direction, or individual component of the change. Subsequently, the individual changes in the  $L^*$ ,  $a^*$ ,  $b^*$  values from baseline are evaluated.

$L^*$  values are a measure of the luminosity of the test site. The higher the value, the greater the lightness of the test site.

$a^*$  values are a measure of the redness of the test site. The higher the value, the greater the redness of the test site.

$b^*$  values are a measure of the yellowness of the test site. The higher the value, the greater the yellowness of the test site.

Summary:

For subjects using [Redacted] Lash Enhancing Serum, there was an overall increase in  $\Delta E$  values of the left eye indicating an increase in color change from baseline at all timepoints. When evaluating the individual  $L^*$ ,  $a^*$ ,  $b^*$  color values, there were no statistically significant differences in ocular pigmentation from baseline when looking at the change in  $L^*$ . When evaluating the  $a^*$  of the left eye compared to baseline, there was a significant difference at month 8, which represents an increase in redness at month 8. There is also a statistically significant increase at months 4 and 8 when compared to baseline for the delta b color value, indicating an increase in yellowness.

Table 4  
(continued)  
VISIA-CR Image Analysis Color Data - Delta E Value Right Iris

.01 = [REDACTED] Lash Enhancing Serum

Subject #	Month 1	Month 2	Month 4	Month 8
1	1.96	1.23	0.47	0.49
2	3.95	0.42	3.23	0.99
3	3.91	2.16	4.79	1.97
4	1.00	0.77	0.89	1.23
5	2.19	3.60	3.77	2.35
6	0.31	0.82	1.96	0.82
8	3.87	1.02	1.94	4.12
9	2.51	1.54	3.04	1.42
10	3.78	1.35	0.68	3.26
11	0.41	1.64	1.68	0.73
12	1.99	2.20	3.65	2.07
13	0.36	1.80	1.93	1.19
14	1.99	1.96	4.18	5.30
15	5.78	4.86	0.53	2.62
16	1.61	1.57	0.58	0.74
17	1.50	4.51	2.65	1.24
18	0.50	6.71	1.84	2.38
19	7.01	4.62	4.18	4.09
20	5.99	9.52	3.66	1.79
21	7.59	13.73	16.73	12.22
22	0.29	1.36	0.30	0.63
23	6.11	4.51	1.97	1.45
24	0.73	0.77	0.18	0.65
25	19.22	15.17	17.90	8.44
26	0.44	1.84	2.99	3.35
27	1.81	0.65	1.03	1.78
28	5.75	5.58	3.38	1.92
29	8.79	3.78	2.64	0.93
30	0.89	0.91	0.67	0.30
31	0.54	1.38	0.32	0.45
32	6.88	7.67	7.01	6.62
33	1.31	0.35	1.98	1.08
34	3.36	2.44	2.83	3.49
35	4.17	4.25	7.08	4.90
36	1.23	2.08	1.54	2.29
37	1.97	0.78	0.22	0.84
38	1.91	1.33	0.74	0.54
39	0.99	1.06	0.82	1.18
40	0.49	0.72	0.65	1.62
41	4.91	1.85	0.45	1.51
42	1.06	3.79	4.22	7.27
43	2.41	1.47	1.12	1.44
44	0.91	2.73	2.25	1.21
45	4.72	0.62	1.29	1.28
46	6.29	3.36	3.82	8.72
47	2.90	1.01	2.90	6.13
48	2.63	1.26	2.05	0.86
49	1.97	0.47	1.61	0.76
50	0.53	0.60	2.65	0.91
52	1.06	2.26	2.59	2.75
53	4.08	4.38	3.62	5.95
54	0.45	0.41	1.80	0.82
55	1.41	5.41	0.48	3.96
56	2.50	5.55	1.95	1.83
57	0.37	2.89	1.03	1.37
59	1.25	0.74	0.61	1.41
60	2.17	2.57	1.49	2.13
61	1.12	2.79	0.42	0.81
62	1.08	1.15	0.59	1.48
63	1.29	2.38	2.06	0.58
64	0.40	0.39	0.79	1.05
65	2.03	1.97	1.18	1.11
66	2.40	1.80	2.28	1.73



**Table 4**  
(continued)  
VISIA-CR Image Analysis Color Data - Delta E Value Right Iris

	.01 = [REDACTED] Lash Enhancing Serum			
67	0.90	1.28	1.41	1.01
68	3.21	0.80	1.33	1.04
69	0.47	1.09	2.17	0.80
70	1.96	2.42	0.70	1.05
71	1.26	2.19	3.27	4.10
72	1.89	0.79	1.26	1.78
73	0.78	0.60	0.94	0.81
74	2.40	1.93	1.10	0.91
75	2.30	0.74	1.28	0.58
76	2.85	2.25	3.15	0.95
77	2.52	0.78	1.59	2.13
78	8.13	6.43	6.87	8.62
79	5.84	3.07	1.82	3.02
80	1.13	0.63	2.70	1.53
82	2.48	2.46	1.46	0.23
84	6.97	0.33	0.90	3.76
86	3.37	3.96	4.19	1.73
87	2.94	2.89	3.30	2.99
88	3.37	2.48	5.39	2.71
89	1.09	2.50	1.51	2.39
90	1.36	2.42	1.65	0.87
91	3.23	0.64	0.29	2.16
92	3.13	4.87	2.26	7.52
93	5.26	9.17	5.04	4.19
94	1.53	8.70	0.51	1.84
95	1.69	3.35	2.80	1.32
96	0.75	0.47	2.73	0.64
97	0.40	1.92	1.29	0.77
98	0.79	3.64	4.72	2.07
99	1.43	2.52	1.34	2.31
100	6.48	3.85	3.95	3.45
101	1.58	1.45	0.69	1.28
102	1.69	1.35	10.38	3.66
103	2.86	5.46	1.94	3.82
104	0.55	0.79	1.13	1.90
105	3.98	5.52	2.45	3.23
106	1.78	0.22	2.80	2.20
107	1.55	4.18	0.95	3.14
108	5.10	4.57	5.87	6.21
109	4.14	4.51	9.20	2.22
110	0.67	0.79	0.91	1.20
111	7.15	4.27	0.74	5.05
112	1.61	0.97	1.95	2.97
114	1.92	1.79	1.93	4.12
115	2.52	4.17	4.27	3.86
116	2.76	2.04	2.30	3.67
117	1.79	1.24	0.35	2.22
118	2.89	1.87	1.59	3.89
119	1.14	0.71	0.14	0.55
120	2.38	1.65	2.98	0.87
121	2.88	2.19	5.66	8.29
Mean =	2.70	2.68	2.55	2.49
Median =	1.97	1.94	1.94	1.78
Standard Deviation =	2.52	2.51	2.71	2.16
Maximum =	19.22	15.17	17.90	12.22
Minimum =	0.29	0.22	0.14	0.23

Did Not Complete Subject#s: 7, 51, 58, 81, 83, 85, 113

L\* values are a measure of the luminosity of the test site. The higher the value, the greater the lightness of the test site.  
 a\* values are a measure of the redness of the test site. The higher the value, the greater the redness of the test site.  
 b\* values are a measure of the yellowness of the test site. The higher the value, the greater the yellowness of the test site.

Table 4  
 (continued)

VISIA-CR Image Analysis Color Data - L\* Value Right Iris

.01 [REDACTED] Lash Enhancing Serum

Subject #	Baseline	Month 1	Month 2	Month 4	Month 8	Difference From Baseline At:			
						Month 1	Month 2	Month 4	Month 8
1	18.70	18.83	19.58	18.55	19.07	0.1	0.9	-0.2	0.4
2	42.48	38.65	42.86	39.40	42.41	-3.8	0.4	-3.1	-0.1
3	34.60	38.43	32.96	39.30	36.47	3.8	-1.6	4.7	1.9
4	31.73	31.07	32.19	31.83	31.94	-0.7	0.5	0.1	0.2
5	12.25	10.50	8.77	8.72	10.04	-1.8	-3.5	-3.5	-2.2
6	6.91	6.74	6.93	5.19	6.18	-0.2	0.0	-1.7	-0.7
8	11.44	7.80	10.44	9.60	7.43	-3.6	-1.0	-1.8	-4.0
9	37.59	39.98	37.19	35.67	37.52	2.4	-0.4	-1.9	-0.1
10	34.85	38.16	36.00	34.93	37.96	3.3	1.2	0.1	3.1
11	7.85	7.45	6.28	7.76	7.59	-0.4	-1.6	-0.1	-0.3
12	40.18	38.45	38.01	43.79	42.15	-1.7	-2.2	3.6	2.0
13	9.87	10.16	8.33	8.20	8.87	0.3	-1.5	-1.7	-1.0
14	11.52	13.04	10.66	8.17	7.20	1.5	-0.9	-3.3	-4.3
15	5.38	10.75	9.66	5.38	7.61	5.4	4.3	0.0	2.2
16	11.54	9.97	10.09	11.01	11.00	-1.6	-1.5	-0.5	-0.5
17	22.05	21.02	25.56	24.70	23.19	-1.0	3.5	2.7	1.1
18	15.28	14.98	10.42	13.90	14.65	-0.3	-4.9	-1.4	-0.6
19	19.77	13.09	15.50	15.89	15.79	-6.7	-4.3	-3.9	-4.0
20	33.26	38.83	42.39	36.47	32.05	5.6	9.1	3.2	-1.2
21	27.40	33.07	38.43	41.36	38.11	5.7	11.0	14.0	10.7
22	13.78	13.69	14.52	13.93	13.84	-0.1	0.7	0.2	0.1
23	31.06	37.08	35.32	32.13	31.78	6.0	4.3	1.1	0.7
24	7.46	8.16	6.72	7.44	7.91	0.7	-0.7	0.0	0.5
25	15.30	5.31	9.95	6.92	10.59	-10.0	-5.3	-8.4	-4.7
26	35.38	35.70	36.05	37.30	37.57	0.3	0.7	1.9	2.2
27	17.23	15.51	17.76	16.29	18.22	-1.7	0.5	-0.9	1.0
28	12.27	17.43	17.81	14.33	13.93	5.2	5.5	2.1	1.6
29	21.42	30.16	18.31	19.93	20.75	8.7	-3.1	-1.5	-0.7
30	5.60	4.83	6.41	6.21	5.41	-0.8	0.8	0.6	-0.2
31	6.71	6.63	7.98	6.96	6.30	-0.1	1.3	0.2	-0.4
32	22.67	17.23	16.26	17.07	17.89	-5.4	-6.4	-5.6	-4.8
33	14.35	14.70	14.18	12.78	14.23	0.4	-0.2	-1.6	-0.1
34	17.98	15.66	18.21	19.08	16.61	-2.3	0.2	1.1	-1.4
35	32.63	35.59	35.40	26.35	36.86	3.0	2.8	-6.3	4.2
36	12.89	13.14	12.04	14.42	10.89	0.3	-0.8	1.5	-2.0
37	7.22	8.82	6.70	7.20	8.00	1.6	-0.5	0.0	0.8
38	39.79	38.04	40.98	40.05	39.26	-1.8	1.2	0.3	-0.5
39	30.94	30.20	30.72	30.43	32.04	-0.7	-0.2	-0.5	1.1
40	7.43	7.58	8.02	7.12	5.89	0.1	0.6	-0.3	-1.5
41	7.39	11.86	5.73	7.22	5.96	4.5	-1.7	-0.2	-1.4
42	13.67	12.62	16.00	15.46	19.54	-1.1	2.3	1.8	5.9
43	9.16	6.98	8.00	8.19	7.89	-2.2	-1.2	-1.0	-1.3
44	24.28	24.05	21.61	22.48	23.36	-0.2	-2.7	-1.8	-0.9
45	9.36	14.03	9.08	10.34	8.25	4.7	-0.3	1.0	-1.1
46	21.02	26.84	18.05	17.64	28.02	5.8	-3.0	-3.4	7.0
47	28.51	25.68	27.87	25.70	22.55	-2.8	-0.6	-2.8	-6.0
48	10.58	8.13	9.37	8.65	11.13	-2.5	-1.2	-1.9	0.5
49	12.50	10.88	12.54	11.40	11.77	-1.6	0.0	-1.1	-0.7
50	29.53	29.09	28.99	27.22	29.62	-0.4	-0.5	-2.3	0.1
52	12.30	11.36	10.89	10.05	11.68	-0.9	-1.4	-2.2	-0.6
53	28.80	29.78	27.64	28.89	27.99	1.0	-1.2	0.1	-0.8
54	8.18	7.76	8.24	6.56	7.61	-0.4	0.1	-1.6	-0.6
55	11.35	10.04	6.19	11.05	7.55	-1.3	-5.2	-0.3	-3.8
56	31.09	29.09	36.44	32.86	32.82	-2.0	5.3	1.8	1.7
57	9.22	9.49	11.70	9.95	8.17	0.3	2.5	0.7	-1.0
59	7.64	8.81	7.01	7.49	8.88	1.2	-0.6	-0.2	1.2
60	29.29	30.72	27.08	30.08	28.39	1.4	-2.2	0.8	-0.9
61	11.47	12.52	14.09	11.40	10.91	1.1	2.6	-8.1	-0.6
62	9.22	8.28	8.13	8.93	10.47	-0.9	-1.1	-0.3	1.2
63	20.98	20.73	19.35	19.26	20.62	-0.3	-1.6	-1.7	-0.4
64	11.93	11.92	12.20	11.97	10.93	0.0	0.3	0.0	-1.0
65	10.84	9.13	9.35	9.82	9.83	-1.7	-1.5	-1.0	-1.0
66	19.23	21.45	19.72	19.55	20.90	2.2	0.5	0.3	1.7

**Table 4**  
(continued)  
**VISIA-CR Image Analysis Color Data - L\* Value Right Iris**

.01 = [Redacted] Lash Enhancing Serum

67	9.97	10.64	8.74	9.24	9.26	0.7	-1.2	-0.7	-0.7
68	14.00	17.01	13.22	13.48	14.84	3.0	-0.8	-0.5	0.8
69	21.45	21.42	20.89	22.54	20.82	0.0	-0.6	1.1	-0.6
70	7.52	9.14	9.52	7.96	8.34	1.6	2.0	0.4	0.8
71	14.16	14.88	14.15	15.47	13.89	0.7	0.0	1.3	-0.3
72	12.60	14.40	13.34	11.90	14.23	1.8	0.7	-0.7	1.6
73	9.68	10.29	9.43	9.05	9.55	0.6	-0.3	-0.6	-0.1
74	7.12	4.98	5.40	6.12	6.44	-2.1	-1.7	-1.0	-0.7
75	9.90	10.07	9.50	8.97	10.01	0.2	-0.4	-0.9	0.1
76	15.90	18.59	15.91	15.61	15.68	2.7	0.0	-0.3	-0.2
77	15.13	12.70	15.86	15.34	14.22	-2.4	0.7	0.2	-0.9
78	24.30	30.82	29.20	29.95	31.89	6.5	4.9	5.7	7.6
79	22.06	17.02	22.19	20.85	19.09	-5.0	0.1	-1.2	-3.0
80	10.79	9.88	10.22	8.51	9.48	-0.9	-0.6	-2.3	-1.3
82	10.85	10.17	9.15	11.04	10.64	-0.7	-1.7	0.2	-0.2
84	5.69	12.25	5.97	6.20	9.19	6.6	0.3	0.5	3.5
86	11.03	11.58	10.48	14.68	11.96	0.5	-0.6	3.6	0.9
87	9.18	9.09	9.01	9.56	9.89	-0.1	-0.2	0.4	0.7
88	46.28	42.94	43.88	41.42	44.18	-3.3	-2.4	-4.9	-2.1
89	19.94	20.11	21.52	19.95	20.38	0.2	1.6	0.0	0.4
90	41.62	42.95	43.68	43.26	42.44	1.3	2.1	1.6	0.8
91	8.52	11.48	8.07	8.81	10.26	3.0	-0.5	0.3	1.7
92	19.62	19.37	16.07	21.65	15.24	-0.3	-3.5	2.0	-4.4
93	38.81	34.33	29.85	34.00	35.20	-4.5	-9.0	-4.8	-3.6
94	36.77	37.68	29.98	37.15	38.52	0.9	-6.8	0.4	1.7
95	30.75	29.75	33.28	29.96	31.66	-1.0	2.5	-0.8	0.9
96	33.27	33.90	33.56	35.95	33.80	0.6	0.3	2.7	0.5
97	6.72	6.33	4.94	5.46	6.50	-0.4	-1.8	-1.3	-0.2
98	24.40	23.92	27.32	20.31	24.74	-0.5	2.9	-4.1	0.3
99	16.03	16.78	18.12	17.18	18.13	0.7	2.1	1.1	2.1
100	19.29	13.85	17.05	16.06	16.07	-5.4	-2.2	-3.2	-3.2
101	15.85	14.40	16.56	15.73	14.68	-1.5	0.7	-0.1	-1.2
102	18.75	17.81	19.21	12.12	18.67	-0.9	0.5	-6.6	-0.1
103	17.69	20.23	22.97	19.35	21.43	2.5	5.3	1.7	3.7
104	15.23	15.08	14.61	14.20	16.52	-0.1	-0.6	-1.0	1.3
105	38.65	36.98	37.25	37.28	36.87	-1.7	-1.4	-1.4	-1.8
106	13.38	13.24	13.53	15.34	15.45	-0.1	0.1	2.0	2.1
107	11.33	10.58	14.58	10.39	10.59	-0.7	3.2	-0.9	-0.7
108	35.87	38.83	40.13	40.62	40.80	3.0	4.3	4.7	4.9
109	39.95	36.00	35.62	31.20	37.94	-4.0	-4.3	-8.7	-2.0
110	38.29	38.70	38.83	39.12	39.42	0.4	0.5	0.8	1.1
111	12.20	18.34	15.56	12.25	16.16	6.1	3.4	0.1	4.0
112	11.79	10.41	11.34	9.93	8.99	-1.4	-0.4	-1.9	-2.8
114	18.34	19.96	17.77	19.54	19.19	1.6	-0.6	1.2	0.9
115	15.84	17.28	18.66	13.85	12.80	1.4	2.8	-2.0	-3.0
116	18.51	19.53	19.57	20.09	21.22	1.0	1.1	1.6	2.7
117	24.47	26.15	25.34	24.64	26.59	1.7	0.9	0.2	2.1
118	22.26	22.99	22.05	22.28	24.63	0.7	-0.2	0.0	2.4
119	12.82	12.96	12.39	12.71	12.98	0.1	-0.4	-0.1	0.2
120	16.07	16.27	14.81	13.56	16.74	0.2	-1.3	-2.5	0.7
121	9.61	11.77	7.79	14.20	16.76	2.2	-1.8	4.6	7.1
Mean =	18.96	19.15	18.85	18.54	19.08	0.25	-0.05	-0.36	0.18
Median =	15.57	15.30	15.89	15.34	15.74	0.06	-0.24	-0.13	-0.10
Standard Deviation =	10.53	10.73	10.96	10.90	11.04	2.86	2.80	2.75	2.55
Maximum =	46.28	42.95	43.88	43.79	44.18	8.74	11.03	13.96	10.71
Minimum =	5.38	4.33	4.94	5.19	5.41	-9.99	-8.96	-8.75	-5.97

**Mean % Change From Baseline**

	Month 1	Month 2	Month 4	Month 8
	1.3%	-0.3%	-1.9%	0.9%
	Increase	Decrease	Decrease	Increase

**Tallies & Percentages**

	Month 1	Month 2	Month 4	Month 8
<b>Total</b>	114	114	114	114
<b>Increased Values</b>	57	52	50	54
<b>Decreased Values</b>	57	62	64	60
<b>No Change</b>	0	0	0	0
<b>Increased Values</b>	50.00%	45.61%	43.86%	47.37%
<b>Decreased Values</b>	50.00%	54.39%	56.14%	52.63%
<b>No Change</b>	0.00%	0.00%	0.00%	0.00%

Did Not Complete Subjects: 7, 51, 58, 81, 83, 85, 113

L\* values are a measure of the luminosity of the test site. The higher the value, the greater the lightness of the test site.  
 a\* values are a measure of the redness of the test site. The higher the value, the greater the redness of the test site.  
 b\* values are a measure of the yellowness of the test site. The higher the value, the greater the yellowness of the test site.

Table 4  
 (continued)

VISIA-CR Image Analysis Color Data - a\* Values Right Iris

.01 = [Redacted] Lash Enhancing Serum

Subject #	Baseline	Month 1	Month 2	Month 4	Month 8	Difference From Baseline At :			
						Month 1	Month 2	Month 4	Month 8
1	13.39	14.66	12.74	13.67	13.46	1.3	-0.6	0.3	0.1
2	-2.55	-1.67	-2.70	-1.59	-1.95	0.9	-0.1	1.0	0.6
3	-1.57	-2.29	-0.90	-2.20	-1.61	-0.7	0.7	-0.6	0.0
4	2.59	3.30	3.18	3.47	3.72	0.7	0.6	0.9	1.1
5	3.08	4.28	3.32	4.37	3.87	1.2	0.2	1.3	0.8
6	3.44	3.35	4.23	3.61	3.65	-0.1	0.8	0.2	0.2
8	1.24	2.63	1.52	1.89	1.89	1.3	0.2	0.6	0.6
9	-1.45	-1.44	-0.52	0.28	-0.51	0.0	0.9	1.7	0.9
10	-0.30	-2.00	-0.88	-0.92	-1.12	-1.7	-0.6	-0.6	-0.8
11	2.48	2.44	2.50	3.46	3.07	0.0	0.0	1.0	0.6
12	-2.08	-1.12	-1.83	-2.01	-1.72	1.0	0.3	0.1	0.4
13	1.01	0.99	1.95	1.97	1.65	0.0	0.9	1.0	0.6
14	3.90	3.12	3.61	4.08	3.70	-0.8	-0.3	0.2	-0.2
15	2.41	1.66	2.80	2.85	2.88	-0.7	0.4	0.4	0.5
16	6.36	6.31	6.95	6.60	6.55	-0.1	0.6	0.2	0.2
17	9.82	9.14	7.82	9.73	10.18	-0.7	-2.0	-0.1	0.4
18	12.23	11.94	10.33	11.78	10.58	-0.3	-1.9	-0.4	-1.6
19	8.80	10.63	10.55	8.75	9.71	1.8	1.7	0.0	0.9
20	-0.69	-2.85	-3.35	-2.15	-1.41	-2.2	-2.7	-1.5	-0.7
21	8.97	4.19	1.45	0.52	3.11	-4.8	-7.5	-8.5	-5.9
22	13.09	13.21	12.30	13.24	13.57	0.1	-0.8	0.2	0.5
23	-0.76	-1.32	-1.54	-1.04	-0.26	-0.6	-0.8	-0.3	0.5
24	1.98	1.95	2.02	1.82	2.07	0.0	0.0	-0.2	0.1
25	12.47	1.44	2.20	1.64	7.91	-11.0	-10.3	-10.8	-4.6
26	-0.87	-0.69	-0.79	-0.67	-0.53	0.2	0.1	0.2	0.3
27	10.07	10.50	9.76	10.16	10.34	0.4	-0.3	0.1	0.3
28	9.38	6.97	8.85	10.75	9.95	-2.4	-0.5	1.4	0.6
29	0.21	0.58	-0.21	2.01	0.23	0.4	-0.4	1.8	0.0
30	2.07	2.45	1.86	1.96	2.29	0.4	-0.2	-0.1	0.2
31	1.55	1.37	1.31	1.52	1.55	-0.2	-0.2	0.0	0.0
32	8.92	12.36	12.52	12.49	12.51	3.4	3.6	3.6	3.6
33	11.66	12.57	11.60	10.95	12.47	0.9	-0.1	-0.7	0.8
34	8.37	10.41	10.09	10.14	11.00	2.0	1.7	1.8	2.6
35	-1.26	-2.61	-2.93	-0.25	-3.22	-1.4	-1.7	1.0	-2.0
36	9.02	10.06	10.82	9.10	10.05	1.0	1.8	0.1	1.0
37	4.93	3.78	4.67	5.14	4.65	-1.1	-0.3	0.2	-0.3
38	-2.40	-2.27	-2.93	-2.26	-2.35	0.1	-0.5	0.1	0.0
39	6.14	6.53	6.27	6.73	6.35	0.4	0.1	0.6	0.2
40	3.31	2.88	3.58	3.78	3.53	-0.4	0.3	0.5	0.2
41	3.69	2.62	3.94	3.29	3.76	-1.1	0.2	-0.4	0.1
42	9.59	9.70	10.91	11.59	10.88	0.1	1.3	2.0	1.3
43	4.97	5.87	5.88	5.51	5.65	0.9	0.9	0.5	0.7
44	9.73	10.29	9.59	10.95	10.13	0.6	-0.1	1.2	0.4
45	1.29	0.60	1.68	1.01	1.93	-0.7	0.4	-0.3	0.6
46	13.80	13.80	12.42	12.05	15.80	0.0	-1.4	-1.8	2.0
47	-0.92	-0.35	-0.74	-0.21	0.43	0.6	0.2	0.7	1.4
48	1.38	2.31	1.59	2.04	1.27	0.9	0.2	0.7	-0.1
49	9.60	9.03	10.04	8.81	9.79	-0.6	0.4	-0.8	0.2
50	0.31	0.59	0.35	1.59	0.71	0.3	0.0	1.3	0.4
52	6.96	6.99	8.56	6.68	9.10	0.0	1.6	-0.3	2.1
53	1.19	3.81	4.39	3.31	5.80	2.6	3.2	2.1	4.6
54	2.27	2.36	2.41	2.98	2.84	0.1	0.1	0.7	0.6
55	2.48	2.12	3.38	2.13	3.39	-0.4	0.9	-0.4	0.9
56	-1.23	0.25	-1.71	-1.45	-0.89	1.5	-0.5	-0.2	0.3
57	3.18	3.13	1.80	3.56	3.94	-0.1	-1.4	0.4	0.8
59	3.21	2.99	3.55	3.71	3.34	-0.2	0.3	0.5	0.1
60	4.09	4.06	4.65	3.81	4.45	0.0	0.6	-0.3	0.4
61	8.45	8.12	7.76	8.06	9.01	-0.3	-0.7	-0.4	0.6
62	5.07	5.25	5.12	4.60	4.38	0.2	0.1	-0.5	-0.7
63	13.82	12.94	12.71	13.02	13.36	-0.9	-1.1	-0.8	-0.5
64	7.86	8.19	7.68	8.33	8.08	0.3	-0.2	0.5	0.2
65	8.08	7.86	7.72	7.92	8.30	-0.2	-0.4	-0.2	0.2
66	5.62	5.13	6.66	6.98	5.20	-0.5	1.0	1.4	-0.4



**Table 4**  
**(continued)**  
**VISIA-CR Image Analysis Color Data - a\* Values Right Iris**

.01 - [Redacted] Lash Enhancing Serum

67	6.20	5.64	6.47	7.27	6.89	-0.6	0.3	1.1	0.7
68	10.16	9.03	10.09	10.78	10.21	-1.1	-0.1	0.6	0.1
69	13.59	13.48	14.16	12.60	13.59	-0.1	0.6	-1.0	0.0
70	5.25	4.24	4.47	4.89	4.79	-1.0	-0.8	-0.4	-0.5
71	7.28	7.34	8.16	8.10	9.62	0.1	0.9	0.8	2.3
72	10.30	9.75	10.03	9.99	10.12	-0.6	-0.3	-0.3	-0.2
73	6.53	6.89	7.06	7.20	7.24	0.4	0.5	0.7	0.7
74	2.59	2.69	2.47	3.05	3.19	0.1	-0.1	0.5	0.6
75	5.84	7.30	6.39	6.64	5.85	1.5	0.6	0.8	0.0
76	6.63	5.96	8.45	9.37	7.35	-0.7	1.8	2.7	0.7
77	9.56	9.70	9.52	8.36	8.09	0.1	0.0	-1.2	-1.5
78	3.29	-0.45	0.00	0.22	-0.26	-3.7	-3.3	-3.1	-3.5
79	8.54	9.67	7.64	9.76	8.73	1.1	-0.9	1.2	0.2
80	8.05	8.18	8.21	7.93	8.69	0.1	0.2	-0.1	0.6
82	8.47	6.91	7.58	7.40	8.41	-1.6	-0.9	-1.1	-0.1
84	2.16	0.37	2.13	2.79	1.62	-1.8	0.0	0.6	-0.5
86	9.70	6.87	6.58	7.64	8.26	-2.8	-3.1	-2.1	-1.4
87	3.98	6.57	6.55	6.89	6.42	2.6	2.6	2.9	2.4
88	-1.25	-1.46	-1.11	0.46	-1.05	-0.2	0.1	1.7	0.2
89	15.68	16.41	14.12	16.57	17.14	0.7	-1.6	0.9	1.5
90	-3.28	-3.54	-3.16	-3.26	-3.25	-0.3	0.1	0.0	0.0
91	7.04	5.74	6.84	6.98	6.84	-1.3	-0.2	-0.1	-0.2
92	12.91	10.32	11.36	11.97	10.52	-2.6	-1.5	-0.9	-2.4
93	-1.84	0.26	0.09	-0.37	-0.32	2.1	1.9	1.5	1.5
94	8.87	8.15	11.22	8.87	8.31	-0.7	2.4	0.0	-0.6
95	3.01	2.28	2.86	4.72	3.03	-0.7	-0.2	1.7	0.0
96	-1.55	-1.55	-1.23	-2.05	-1.26	0.0	0.3	-0.5	0.3
97	0.30	0.38	0.12	0.54	0.65	0.1	-0.2	0.2	0.4
98	1.39	1.71	2.34	2.89	2.75	0.3	0.9	1.5	1.4
99	3.99	4.26	3.70	3.76	4.28	0.3	-0.3	-0.2	0.3
100	4.91	8.32	7.35	6.40	6.07	3.4	2.4	1.5	1.2
101	10.28	10.71	10.87	10.66	10.65	0.4	0.6	0.4	0.4
102	16.46	15.89	17.27	13.52	13.99	-0.6	0.8	-2.9	-2.5
103	10.61	9.71	9.64	10.47	10.12	-0.9	-1.0	-0.1	-0.5
104	9.71	9.89	9.64	10.02	9.14	0.2	-0.1	0.3	-0.6
105	4.04	2.46	0.77	5.52	3.12	-1.6	-3.3	1.5	-0.9
106	12.21	11.15	12.28	13.22	12.49	-1.1	0.1	1.0	0.3
107	7.87	9.04	5.25	7.89	5.53	1.2	-2.6	0.0	-2.3
108	-0.31	-2.25	-1.58	-1.76	-2.41	-1.9	-1.3	-1.4	-2.1
109	-0.84	-0.24	-0.16	1.93	-1.14	0.6	0.7	2.8	-0.3
110	-1.40	-1.62	-1.97	-1.71	-1.70	-0.2	-0.6	-0.3	-0.3
111	11.54	8.02	9.59	10.86	8.43	-3.5	-2.0	-0.7	-3.1
112	3.77	4.59	4.22	4.30	4.71	0.8	0.5	0.5	0.9
114	6.54	5.66	7.40	7.28	7.94	-0.9	0.9	0.7	1.4
115	8.42	6.37	5.63	6.21	7.30	-2.0	-2.8	-2.2	-1.1
116	11.90	9.39	10.24	10.35	9.43	-2.5	-1.7	-1.5	-2.5
117	-0.09	0.13	0.60	0.18	0.44	0.2	0.7	0.3	0.5
118	9.92	11.92	10.97	10.16	11.18	2.4	1.5	0.6	1.7
119	10.29	10.14	10.84	10.33	10.58	-0.2	0.5	0.0	0.3
120	11.38	9.79	11.37	11.24	10.84	-1.6	0.0	-0.1	-0.5
121	6.37	6.83	5.78	7.49	7.14	0.5	-0.6	1.1	0.8
<b>Mean =</b>	<b>5.44</b>	<b>5.21</b>	<b>5.28</b>	<b>5.55</b>	<b>5.55</b>	<b>-0.23</b>	<b>-0.16</b>	<b>0.11</b>	<b>0.11</b>
<b>Median =</b>	<b>5.16</b>	<b>5.19</b>	<b>5.19</b>	<b>5.52</b>	<b>5.59</b>	<b>-0.03</b>	<b>0.04</b>	<b>0.21</b>	<b>0.25</b>
<b>Standard Deviation =</b>	<b>4.81</b>	<b>4.79</b>	<b>4.79</b>	<b>4.65</b>	<b>4.77</b>	<b>1.66</b>	<b>1.70</b>	<b>1.71</b>	<b>1.38</b>
<b>Maximum =</b>	<b>16.46</b>	<b>16.41</b>	<b>17.27</b>	<b>16.57</b>	<b>17.14</b>	<b>3.45</b>	<b>3.60</b>	<b>3.57</b>	<b>4.61</b>
<b>Minimum =</b>	<b>-3.28</b>	<b>-3.54</b>	<b>-3.35</b>	<b>-3.26</b>	<b>-3.25</b>	<b>-11.03</b>	<b>-10.27</b>	<b>-10.82</b>	<b>-5.86</b>

*Mean % Change From Baseline*

Month 1	Month 2	Month 4	Month 8
-4.2%	-3.0%	1.9%	2.0%
Decrease	Decrease	Increase	Increase

*Tallies & Percentages*

	Month 1	Month 2	Month 4	Month 8
<b>Total</b>	<b>114</b>	<b>114</b>	<b>114</b>	<b>114</b>
<b>Increased Values</b>	<b>53</b>	<b>59</b>	<b>69</b>	<b>78</b>
<b>Decreased Values</b>	<b>61</b>	<b>55</b>	<b>45</b>	<b>36</b>
<b>No Change</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Increased Values</b>	<b>46.49%</b>	<b>51.75%</b>	<b>60.53%</b>	<b>68.42%</b>
<b>Decreased Values</b>	<b>53.51%</b>	<b>48.25%</b>	<b>39.47%</b>	<b>31.58%</b>
<b>No Change</b>	<b>0.00%</b>	<b>0.00%</b>	<b>0.00%</b>	<b>0.00%</b>

Did Not Complete Subject#: 7, 51, 58, 81, 83, 85, 173

L\* values are a measure of the luminosity of the test site. The higher the value, the greater the lightness of the test site.  
a\* values are a measure of the redness of the test site. The higher the value, the greater the redness of the test site.  
b\* values are a measure of the yellowness of the test site. The higher the value, the greater the yellowness of the test site.



Table 4  
(continued)

VISIA-CR Image Analysis Color Data - b\* Values Right Iris

.01 - [Redacted] Lash Enhancing Serum

Subject #	Baseline	Month 1	Month 2	Month 4	Month 8	Difference From Baseline At :			
						Month 1	Month 2	Month 4	Month 8
1	18.40	19.89	17.83	18.75	18.72	1.5	-0.6	0.3	0.3
2	4.15	4.51	4.24	4.26	4.93	0.4	0.1	0.1	0.8
3	7.20	6.91	5.97	5.97	7.87	-0.3	-1.2	0.7	0.6
4	19.81	19.55	20.00	19.82	19.37	-0.3	0.2	0.0	-0.4
5	6.85	7.36	6.00	6.71	6.99	0.5	-0.9	-0.1	0.1
6	5.31	5.07	5.52	4.38	5.00	-0.2	0.2	-0.9	-0.3
8	6.04	5.88	6.11	6.27	5.30	-0.2	0.1	0.2	-0.7
9	14.24	15.00	15.39	15.84	15.31	0.8	1.2	1.6	1.1
10	4.94	5.61	5.35	4.68	5.46	0.7	0.4	-0.3	0.5
11	4.99	4.94	4.55	6.35	5.34	-0.1	-0.4	1.4	0.3
12	13.58	11.86	11.28	12.06	12.09	0.3	-0.3	0.5	0.5
13	5.54	5.33	5.44	5.31	5.65	-0.2	-0.1	-0.2	0.1
14	8.20	7.19	6.46	5.70	5.13	-1.0	-1.7	-2.5	-3.1
15	4.01	6.02	6.29	4.30	5.30	2.0	2.3	0.3	1.3
16	8.33	7.98	8.34	8.38	8.81	-0.4	0.0	0.1	0.5
17	18.32	17.46	16.33	18.35	18.61	-0.9	-2.0	0.0	0.3
18	15.19	14.93	10.98	14.05	13.60	-0.3	-4.2	-1.1	-1.6
19	14.81	13.77	14.77	13.27	14.61	-1.0	0.0	-1.5	-0.2
20	3.55	3.10	3.23	2.60	2.45	-0.5	-0.3	-1.0	-1.1
21	22.17	20.56	18.97	18.49	21.75	-1.6	-3.2	-3.7	-0.4
22	15.19	14.94	14.36	15.40	15.59	-0.3	-0.8	0.2	0.4
23	4.64	3.76	3.37	3.00	5.79	-0.9	-1.3	-1.6	1.2
24	4.87	5.09	4.63	4.79	5.32	0.2	-0.2	-0.1	0.5
25	16.06	3.89	6.27	4.52	10.75	-12.2	-9.8	-11.5	-5.3
26	12.39	12.64	14.10	14.67	14.90	0.2	1.7	2.3	2.5
27	14.61	14.23	14.82	14.18	16.06	-0.4	0.2	-0.4	1.5
28	11.46	10.66	11.90	13.75	12.27	-0.8	0.4	2.3	0.8
29	9.58	10.49	7.48	10.82	8.94	0.9	-2.1	1.2	-0.6
30	4.23	3.95	4.56	4.47	4.32	-0.3	0.3	0.2	0.1
31	4.54	4.04	5.02	4.75	4.37	-0.5	0.5	0.2	-0.2
32	14.96	17.36	17.14	17.19	17.80	2.4	2.2	2.2	2.8
33	14.17	14.99	13.85	13.18	14.88	0.8	-0.3	-1.0	0.7
34	13.83	15.16	15.55	15.74	15.66	1.3	1.7	1.9	1.8
35	7.20	4.59	4.45	4.08	5.69	-2.6	-2.7	-3.1	-1.5
36	11.82	12.42	12.43	11.99	11.39	0.6	0.6	0.2	-0.4
37	6.10	6.23	5.58	6.14	6.25	0.1	-0.5	0.0	0.2
38	6.61	5.86	6.88	7.29	6.49	-0.7	0.3	0.7	-0.1
39	21.96	21.42	20.92	22.20	22.32	-0.5	-1.0	0.2	0.4
40	5.40	5.20	5.71	5.71	4.93	-0.2	0.3	0.3	-0.5
41	5.59	7.31	4.79	5.48	5.09	1.7	-0.8	-0.1	-0.5
42	13.43	13.55	16.11	16.68	17.52	0.1	2.7	3.2	4.1
43	6.92	6.42	6.92	6.78	6.87	-0.5	0.0	-0.1	0.0
44	20.75	21.42	20.18	21.34	21.43	0.7	-0.6	0.6	0.7
45	5.25	5.25	5.65	6.06	5.22	0.0	0.4	0.8	0.0
46	15.05	17.44	14.30	14.69	19.85	2.4	-0.8	-0.4	4.8
47	6.76	6.83	6.00	6.74	7.10	0.1	-0.8	0.0	0.3
48	5.52	5.72	5.77	5.68	6.18	0.2	0.2	0.2	0.7
49	11.66	10.69	11.82	10.79	11.79	-1.0	0.2	-0.9	0.1
50	12.52	12.39	12.26	12.80	13.33	-0.1	-0.3	0.3	0.8
52	10.10	9.63	10.85	8.84	11.73	-0.5	0.7	-1.3	1.6
53	15.09	18.05	17.85	18.02	18.76	3.0	2.8	2.9	3.7
54	5.11	5.26	5.49	4.77	5.26	0.1	0.4	-0.3	0.2
55	6.32	5.97	4.98	6.22	5.67	-0.4	-1.3	-0.1	-0.6
56	5.09	4.84	6.50	5.87	5.57	-0.2	1.4	0.8	0.5
57	6.33	6.56	6.84	6.95	5.87	0.2	0.5	0.6	-0.5
59	5.48	5.88	5.31	5.79	6.14	0.4	-0.2	0.3	0.7
60	18.02	19.65	19.20	19.25	19.92	1.6	1.2	1.2	1.9
61	10.75	10.93	11.39	10.59	10.91	0.2	0.6	-0.2	0.2
62	6.55	6.05	6.20	6.74	6.98	-0.5	-0.3	0.2	0.4
63	20.14	19.23	18.80	19.35	20.12	-0.9	-1.3	-0.8	0.0
64	10.18	10.40	9.98	10.81	9.97	0.2	-0.2	0.6	-0.2
65	10.36	9.30	9.12	9.81	9.95	-1.1	-1.2	-0.5	-0.4
66	15.07	15.85	16.46	16.87	15.16	0.8	1.4	1.8	0.1
67	8.31	8.07	8.12	8.85	8.50	-0.2	-0.2	0.5	0.2





Table 4  
(continued)

VISIA-CR Image Analysis Color Data - b\* Values Right Iris

.01 [Redacted] Lash Enhancing Serum

68	13.54	13.65	13.70	14.60	14.17	0.1	0.2	1.1	0.6
69	22.34	22.79	23.07	20.74	21.85	0.5	0.7	-1.6	-0.5
70	6.02	6.49	7.13	6.43	6.48	0.5	1.1	0.4	0.5
71	9.90	10.93	11.91	12.78	13.24	1.0	2.0	2.9	3.3
72	12.35	12.28	12.29	11.35	13.05	-0.1	-0.1	-1.0	0.7
73	8.70	9.00	8.56	8.51	9.07	0.3	-0.1	-0.2	0.4
74	4.94	3.87	4.08	4.89	4.89	-1.1	-0.9	0.0	-0.1
75	7.53	9.29	7.81	7.89	8.10	1.8	0.3	0.4	0.6
76	13.08	13.75	14.41	14.63	13.66	0.7	1.3	1.5	0.6
77	13.32	12.70	13.61	12.29	12.08	-0.6	0.3	-1.0	-1.2
78	5.89	2.77	3.33	3.48	3.89	-3.1	-2.6	-2.4	-2.0
79	18.91	16.20	15.99	19.50	18.48	-2.7	-2.9	0.6	-0.4
80	9.72	9.06	9.93	8.27	9.23	-0.7	0.2	-1.5	-0.5
82	10.17	8.37	8.64	9.19	10.14	-1.8	-1.5	-1.0	0.0
84	4.48	6.01	4.65	4.88	5.74	1.5	0.2	0.4	1.3
86	10.17	8.43	7.78	10.12	9.87	-1.7	-2.4	0.0	-0.3
87	6.11	7.51	7.43	7.63	7.70	1.4	1.3	1.5	1.6
88	15.33	15.04	14.77	16.93	17.03	-0.3	-0.6	1.6	1.7
89	21.14	21.94	20.01	22.36	22.99	0.8	-1.1	1.2	1.8
90	5.99	5.79	7.25	6.18	5.71	-0.2	1.3	0.2	-0.3
91	8.12	8.25	7.72	8.15	9.39	0.1	-0.4	0.0	1.3
92	19.88	18.14	16.92	20.17	14.24	-1.7	-3.0	0.3	-5.6
93	7.16	8.95	7.02	7.58	8.65	1.8	-0.1	0.4	1.5
94	29.43	28.43	24.51	29.08	29.55	-1.0	-4.9	-0.3	0.1
95	18.62	17.46	20.81	20.70	19.58	-1.2	2.2	2.1	1.0
96	0.87	0.48	1.05	0.88	1.08	-0.4	0.2	0.0	0.2
97	3.66	3.67	2.98	3.69	4.31	0.0	-0.7	0.0	0.6
98	11.17	11.70	13.13	12.99	12.69	0.5	2.0	1.8	1.5
99	11.91	13.10	13.29	12.57	12.83	1.2	1.4	0.7	0.9
100	12.57	13.48	14.54	14.29	13.03	0.9	2.0	1.7	0.5
101	14.61	14.15	15.72	15.16	14.97	-0.5	1.1	0.6	0.4
102	20.59	19.30	21.57	13.16	17.90	-1.3	1.0	-7.4	-2.7
103	15.57	16.55	16.58	16.57	16.21	1.0	1.0	1.0	0.6
104	13.34	13.84	12.86	13.67	14.62	0.5	-0.5	0.3	1.3
105	23.25	20.01	19.03	24.64	20.73	-3.2	-4.2	1.4	-2.5
106	14.12	12.71	13.97	15.86	14.83	-1.4	-0.2	1.7	0.7
107	9.96	10.66	9.83	9.84	8.00	0.7	-0.1	-0.1	-2.0
108	12.65	8.98	11.59	9.52	9.50	-3.7	-1.1	-3.1	-3.2
109	14.85	13.79	13.79	15.49	13.97	-1.1	-1.1	0.6	-0.9
110	12.09	12.57	12.03	12.32	12.35	0.5	-0.1	0.2	0.3
111	12.94	14.01	14.72	13.20	12.57	1.1	1.8	0.3	-0.4
112	7.39	7.55	8.11	7.17	7.09	0.2	0.7	-0.2	-0.3
114	10.65	11.17	12.12	11.97	14.44	0.5	1.5	1.3	3.8
115	12.43	12.14	11.15	9.36	10.34	-0.3	-1.3	-3.1	-2.1
116	19.69	19.15	19.14	19.06	19.78	-0.5	-0.6	-0.6	0.1
117	8.67	8.10	8.11	8.81	8.23	-0.6	-0.6	0.1	-0.4
118	19.67	21.11	20.83	21.13	22.28	1.4	1.2	1.5	2.6
119	12.44	11.32	12.34	12.36	12.88	-1.1	-0.1	-0.1	0.4
120	15.23	13.47	14.17	13.63	15.11	-1.8	-1.1	-1.6	-0.1
121	7.64	9.49	6.57	10.75	11.76	1.9	-1.1	3.1	4.1
Mean =	11.23	11.07	11.01	11.26	11.50	-0.2	-0.2	0.0	0.3
Median =	10.70	10.66	11.06	10.77	11.15	-0.1	-0.1	0.2	0.3
Standard Deviation =	5.54	5.54	5.41	5.71	5.68	1.6	1.7	1.8	1.6
Maximum =	29.43	28.43	24.51	29.08	29.55	3.0	2.8	3.2	4.8
Minimum =	0.87	0.48	1.05	0.88	1.08	-12.2	-9.8	-11.5	-5.6

Mean % Change From Baseline

Month 1	Month 2	Month 4	Month 8
-0.8%	-1.2%	0.1%	1.4%
Decrease	Decrease	Increase	Increase

Totals & Percentages

Total	Month 1	Month 2	Month 4	Month 8
Increased Values	114	114	114	114
Decreased Values	54	54	70	71
No Change	0	0	0	0
Increased Values	47.37%	47.37%	61.40%	62.28%
Decreased Values	52.63%	52.63%	38.60%	37.72%
No Change	0.00%	0.00%	0.00%	0.00%

Did Not Complete Subjects: 7, 51, 58, 81, 83, 85, 113

L\* values are a measure of the luminosity of the test site. The higher the value, the greater the lightness of the test site.  
 a\* values are a measure of the redness of the test site. The higher the value, the greater the redness of the test site.  
 b\* values are a measure of the yellowness of the test site. The higher the value, the greater the yellowness of the test site.




Table 4  
(continued)

.01 [Redacted] Lash Enhancing Serum (Right)

Within-Groups Analysis For :  
VISIA-CR Image Analysis Color Data - Delta E Value

Pre-Test	Normality	Brown-Forsythe	Friedman ANOVA
P-Value	P < 0.050	Not Required	0.001

Pairwise Comparisons

Difference from Baseline	Test Type	P-value	Significance	Direction (Mean)
Month 1	Dunn's Method	0.001	Yes	Increase
Month 2	Dunn's Method	0.001	Yes	Increase
Month 4	Dunn's Method	0.001	Yes	Increase
Month 8	Dunn's Method	0.001	Yes	Increase

Within-Groups Analysis For :  
VISIA-CR Image Analysis Color Data - Delta L Value

Pre-Test	Normality	Brown-Forsythe	Friedman ANOVA
P-Value	P < 0.050	Not Required	0.151

Within-Groups Analysis For :  
VISIA-CR Image Analysis Color Data - Delta A Value

Pre-Test	Normality	Brown-Forsythe	Friedman ANOVA
P-Value	P < 0.050	Not Required	0.001

Pairwise Comparisons

Difference from Baseline	Test Type	P-value	Significance	Direction (Mean)
Month 1	Dunn's Method	1.000	No	Decrease
Month 2	Dunn's Method	1.000	No	Decrease
Month 4	Dunn's Method	0.004	Yes	Increase
Month 8	Dunn's Method	0.001	Yes	Increase

Within-Groups Analysis For :  
VISIA-CR Image Analysis Color Data - Delta B Value

Pre-Test	Normality	Brown-Forsythe	Friedman ANOVA
P-Value	P < 0.050	Not Required	0.001

Pairwise Comparisons

Difference from Baseline	Test Type	P-value	Significance	Direction (Mean)
Month 1	Dunn's Method	1.000	No	Decrease
Month 2	Dunn's Method	1.000	No	Decrease
Month 4	Dunn's Method	0.375	No	Increase
Month 8	Dunn's Method	0.003	Yes	Increase

\* = ANOVA (RM) compares the means across groups (the non-parametric version is Friedman). The null hypothesis is all means are equivalent and the alternative is that the mean of at least one group differs. If ANOVA is significant further pairwise comparisons can be made, if not then it is assumed there is no statistically significant difference among the mean (or ranks) and no further testing is done due to risk of type one error. It is possible that Friedman or RM ANOVA may be significant, but when running post-hoc test may not show any statistically significant difference due to only examining the comparisons to baseline, post-hoc test, small sample size, lack of power, or if there is borderline significance.

² = Dunn's method is a post-hoc test commonly run after Friedman RM ANOVA. It allows for comparisons between a control group, and it is a robust, non-parametric test that adjusts for multiple comparisons.

ΔE is a measure of total color change of the test site from baseline. The larger the value, the greater the change in color. ΔE does not provide the direction, or individual component of the change. Subsequently, the individual changes in the L\* a\* b\* values from baseline are evaluated.

L\* values are a measure of the luminosity of the test site. The higher the value, the greater the lightness of the test site.

a\* values are a measure of the redness of the test site. The higher the value, the greater the redness of the test site.

b\* values are a measure of the yellowness of the test site. The higher the value, the greater the yellowness of the test site.

Summary:

For subjects using [Redacted] Lash Enhancing Serum, there was an overall increase in ΔE values of the right eye indicating an increase in color change from baseline at all timepoints. When evaluating the individual L\* a\* b\* values, there were no statistically significant differences in ocular pigmentation from baseline when looking at the change in L\*. When evaluating the a\* value of the test site on the right side compared to baseline, there was a significant difference at month 4 and month 8. These changes represent an increase in redness at month 4 and an increase in redness at month 8. There is also a statistically significant increase at month 8 when compared to baseline for the b\* value, indicating more yellowing of the test site.



---

*Commitment & Credibility since 1976*

### **Memorandum**

To: Expert Panel for Cosmetic Ingredient Safety Members and Liaisons  
From: Priya Cheria, MS, Senior Scientific Analyst/Writer, CIR  
Date: November 20, 2023  
Subject: Wave 2 – Data on Hydrolyzed Saccharomyces Cell Wall

Data were received on Hydrolyzed Saccharomyces Cell Wall derived from *Saccharomyces pastrianus* (*data\_Yeast\_wave2\_122023*). These data include manufacturing process information, composition/impurities data, an in vitro dermal irritation assay, an in vitro ocular irritation assay, an in vitro dermal sensitization assay, a 24-h occlusive human patch test, and an HRIPT. It should be noted that according to this data, Hydrolyzed Saccharomyces Cell Wall may be derived from *Saccharomyces cerevisiae*, *Saccharomyces bayanus*, or *Saccharomyces pastorianus*.

In addition, comments on the Draft Tentative report have been received from Council. These comments may be found herein as *PCPCcomments\_Yeast\_Wave2\_122023*.



## Memorandum

**TO:** Bart Heldreth, Ph.D.  
Executive Director - Cosmetic Ingredient Review

**FROM:** Alexandra Kowcz, MS, MBA  
Industry Liaison to the CIR Expert Panel

**DATE:** November 16, 2023

**SUBJECT:** Draft Tentative Report: Safety Assessment of Yeast-Derived Ingredients as Used in Cosmetics (draft prepared for the December 2023 meeting)

The Personal Care Products Council respectfully submits the following comments on the draft tentative report, Safety Assessment of Yeast-Derived Ingredients as Used in Cosmetics.

### Key Issues

Although mentioned in the Draft Discussion, if it is correct, it would be helpful to state in the Introduction that this report assesses the safety ingredients made from yeast used in cosmetic products and not live yeast cells.

When a test material is used in a study as provided, the CIR report should not state “test concentration not stated”. In many cases the report will say the test material is x. This means that x was tested undiluted, or as provided. In this report, Galactomyces Ferment Filtrate was tested in a number of studies (specific examples noted below) as it was provided. It should state “tested as provided” or “tested undiluted” not “test concentration not stated”.

### Additional Considerations

Memo – In the memo, it would also have been helpful to include a list of ingredients with food use for the species and no sensitization data on any of the ingredients made from that species, and which ingredients have sensitization data but no information on food use.

Abbreviations – “9-aminoadridine” should be “9-aminoacridine”; “1-ethyl-2-nitro-3-nitroguanidine” – “nitroguanidine” should either be “nitroguanidine” or “nitrosoguanidine”; “Tmax” is usually “time to maximum blood concentration” not “maximum blood perfusion”

It is confusing when multiple abbreviations have the same definitions. The cell lines should be defined more specifically for example:

Caco-2 – human colon epithelial cells from a male with colorectal adenocarcinoma (current definition adenocarcinoma of the colon)

DLD1 – human colorectal adenocarcinoma cell line (current definition adenocarcinoma of the colon)

HCT116 – human colorectal carcinoma cell line (current definition adenocarcinoma of the colon)

MCF-7 – human breast cancer cell line with estrogen, progesterone and glucocorticoid receptors (current definition human metastatic breast cancer cell line)

ZR-75-1 – mammary gland epithelial cell line from a female with ductal carcinoma (current definition human metastatic breast cancer cell line)

Acute – As the cosmetic ingredients are not live yeast cells, are the acute studies of live yeast cells relevant to this report (references 41 and 42)?

Dermal Irritation and Sensitization – More details of the completed studies should be included in the text. For example, it should be made clear which studies are single insult patch tests compared to multiple patches. The study on Galactomyces Ferment Filtrate (tested as supplied [should not say test concentration not stated]) was a 40-day study (reference 70). Since the *in chemico/in vitro* sensitization assays assess different endpoints in the sensitization adverse outcome pathway, it should be made clear in the text which ingredients were tested in which assays.

The number of subjects tested in the HRIPTs should be stated in the text.

It should be stated that Galactomyces Ferment Filtrate was tested as supplied in the phototoxicity (rabbits reference 88) and photosensitization (guinea pigs reference 87) tests. The number of animals used in the photo tests should be stated in the text.

Ocular Irritation – Galactomyces Ferment Filtrate was tested as supplied in the rabbit eye irritation test.

Summary – The Summary should make it clear that HSCAS was a 10% solution. Please correct “mice s using”

Since they assess different endpoints, the *in chemico* and *in vitro* sensitization assays should be named.

Table 8 – If an isolated product of fermentation is used in food (rather than the yeast itself), it should be presented in the Other Non-Cosmetic Uses column rather than the Food Use/Presence column. For example, Pepsin and Myoglobin produced by *Pichia pastoris* should be moved to the other column. It would be helpful to indicate that *Bos taurus* is cattle.

21CFR173.165 does not use the term GRAS for *Yarrowia lipolytica*. It says that it can be safely used as an organism to produce citric acid which conforms to specifications in the Food Chemical Codex.

Table 10, Oral – “10 HSCAS” should be corrected to “10% HSCAS”

---

**Safety test results of the cosmetic ingredient  
"Hydrolyzed Saccharomyces Cell Wall" on skin.**

---



Vitamin C60 BioResearch Corporation

## TABLE OF CONTENTS

<b>Introduction</b>	.....	<b>3</b>
<b>Summary of Safety Evaluation</b>	.....	<b>4</b>
<b>Appendix 1 :Definition of Yeast Cell Wall on JSFA</b>	.....	<b>5</b>
<b>Appendix 2 : Composition of Yeast Veil®</b>	.....	<b>6</b>
<b>Appendix 3 : TDS of Yeast Veil®</b>	.....	<b>7</b>
<b>Appendix 4 : <i>in vitro</i> skin irritation test</b>	.....	<b>9</b>
<b>Appendix 5 : <i>in vitro</i> eye irritation test</b>	.....	<b>10</b>
<b>Appendix 6 : <i>in vitro</i> skin sensitization test KeratinoSens®</b>	.....	<b>11</b>
<b>Appendix 7 : 24-Hour occlusive human patch test</b>	.....	<b>12</b>
<b>Appendix 8 : Repeated Insult Patch Test (RIPT)</b>	.....	<b>14</b>

## Introduction

We, Vitamin C60 BioResearch corporation, have been manufacturing and providing cosmetic ingredients named "Yeast Veil" since May 2023.

"Yeast Veil" is a cosmetic ingredient that consists of the yeast cell wall, which originates from brewer's yeast (*Saccharomyces pastrianus*) and is approved as a food additive in Japan (Appendix 1), added with alcohol, preservatives, and water for antiseptic purposes.

The INCI name "Hydrolyzed Saccharomyces Cell Wall" contained in this product (Yeast Veil) is equivalent to Yeast Cell Wall, approved as a food additive in Japan.(Appendix 2,3 )

This report summarizes the skin safety tests conducted on "Yeast Veil" for use as a cosmetic ingredient.




Fig. 1 Outline of Manufacturing Process



## Summary of Safety Evaluation

Since this product, Hydrolyzed Saccharomyces Cell Wall (yeast cell wall), has been approved as a food additive in Japan, we believe its oral safety is assured. Therefore, we conducted a safety study for the external application of the product as a cosmetic ingredient.

*In vitro* skin irritation test using three-dimensional skin was conducted with Yeast Veil undiluted solution and determined to be "non-irritant". Considering the possibility that yeast-veil-containing cosmetics may be used around the eyes (eye area), an *in vitro* eye irritation test was conducted using an undiluted yeast-veil solution, and the results were classified as "non-irritant". A single human patch test was conducted using Yeast Veil's undiluted solution, with negative results in all subjects. Based on these results, it was concluded that Yeast Veil undiluted solution does not cause skin irritation.

Since cosmetics are used for an extended period, sensitization by yeast cell walls was a concern, and *in vitro* sensitization tests and RIPT were conducted. *In vitro*, sensitization testing was performed on KeratinoSens®, tested by OECD Key event-based test guideline 442D, and determined to be "negative". Moreover, RIPT results on human subjects showed no cumulative irritation or sensitization.

Based on these results, we concluded that Yeast Veil, which contains about 8% of the hydrolyzed Saccharomyces Cell Wall, is safe for use in cosmetic ingredients.

Table 1 List of Safety Test Results

Test title	Sample	Results	Appendix No.*
<i>in vitro</i> skin irritation test	Yeast Veil (as is)	non-irritation	4
<i>in vitro</i> eye irritation test	Yeast Veil (as is)	non-irritation	5
<i>in vitro</i> skin sensitization test KeratinoSens®	Yeast Veil (as is)	Negative	6
Human patch test	Yeast Veil (as is)	non-irritation	7
RIPT (Repeated Insult Patch Test)	Yeast Veil (20% water solution)	non-irritation No sensitization	8

\* Since the original report is in Japanese, English translations and edited figures and tables are attached for important data.

## Appendix 1 : Definition of Yeast Cell Wall on JSFA

Database of Japan's Standards and Specifications for Food Additives			
D. MONOGRAPHS : Detail			
Code	FA_code: FA023300	T_code:	E_code: E00135
Name	Yeast Cell Wall		
Japanese name	酵母細胞壁		
	Class: existing	Preparation / Source: gentai	
Definition	Yeast Cell Wall is obtained from the yeast <i>Saccharomyces cerevisiae</i> , <i>Saccharomyces bayanus</i> , or <i>Saccharomyces pastorianus</i> and consists mainly of polysaccharides.		
Description	Yeast Cell Wall occurs as a whitish to brownish-red powder or suspension having a slight, characteristic odor.		
Identification	<p>1) If the sample is a powder, prepare a suspension by magnetically stirring 1 g of it with 100 mL of water at a high speed. If the sample is a suspension, use as is for testing. Examine the suspension sample with a 200–400 power microscope. Egg-shaped or flat single cells with a long axis diameter of 1 to 12 μm or their fragments, are observed.</p> <p>2) To 1 g of a powder sample or a previously dried suspension sample, add 50 mL of phosphate buffer (pH 6.8), magnetically stir at a high speed, and allow to stand for 30 minutes. It swells.</p>		
Purity	<p>1) Lead Not more than 2 μg/g as Pb (2.0 g of a powder sample or previously dried suspension sample, Method 1, Control Solution: Lead Standard Solution 4.0 mL, Flame Method).</p> <p>2) Arsenic Not more than 1.5 μg/g as As (1.0 g of a powder sample or previously dried suspension sample, Method 3, Standard Color: Arsenic Standard Solution 3.0 mL, Apparatus B).</p> <p>3) Total nitrogen Not more than 5.6% (on the dried basis, about 1.0 g, Semi-micro Kjeldahl Method).</p> <p>4) Starch To 1.0 g of a powder sample or previously dried suspension sample, add 1 drop of iodine TS, and examine microscopically. Little or no blackish-purple stained particles are observed.</p>		
Loss on drying	<p>Powder sample: Not more than 8.0% (120°C, 2 hours).</p> <p>Suspension sample: Not more than 92.0% (120°C, 2 hours).</p>		
Ash	Not more than 10.0% (1.0 g of a powder sample or previously dried suspension sample).		
Microbial limits	<p>Proceed as directed in the Microbial Limit Tests (excluding the Method Suitability Test).</p> <p>Total plate count: Not more than 5000 per gram.</p> <p>Yeasts and molds: Not more than 500 per gram.</p> <p><i>Escherichia coli</i> : Negative per test.</p> <p><i>Salmonella</i>: Negative per test.</p> <p><i>Sample Fluid</i> Prepare as directed in Method 1 for total plate count and the enumeration of yeasts and molds.</p> <p><i>Pre-enrichment Culture</i> Prepare as directed in Method 1, respectively, for the <i>Escherichia coli</i> test and the <i>Salmonella</i> test.</p>		
Memo 1	訂正①181203 (薬生食基発1130第6号)		

<Definition of the Japan's Specifications and Standards for Food Additives (JSFA)>

"Yeast cell wall" based on the definition of "9th edition of the Japan's Specifications and Standards for Food Additives (JSFA)" is; 【Yeast cell wall is obtained from the yeast *Saccharomyces cerevisiae*, *Saccharomyces bayanus*, or *Saccharomyces pastorianus* and consists mainly of polysaccharides.】

In addition, "the 9th edition of the JSFA ManualManual" explains as the following;

【Yeast cell wall is obtained as an insoluble fraction by enzymatically treating common beer yeast and baker's yeast and separating and removing solubilized components. Further processing of the insoluble fraction also corresponds to this.】

## Appendix 2 : Composition of Yeast Veil®

Document No. VC0092QC

Creation date : August 9, 2023



Vitamin C60 BioResearch Corporation

### Composition

Product name : **Yeast Veil®**

Company name : Vitamin C60 BioResearch Corporation

The ingredient list

No.	INCI US	INCI EU	CAS #	Chemical Name	%
1	Hydrolyzed Saccharomyces Cell Wall	Hydrolyzed Saccharomyces Cell Wall	68876-77-7	Yeast Cell Wall	8.0 - 10.0
2	Water	Aqua	7732-18-5	Water	Residue
3	Phenoxyethanol	Phenoxyethanol	122-99-6	Phenoxyethanol	0.5
4	Lactic Acid	Lactic Acid	79-33-4	Lactic Acid	0.16 - 0.22
5	Alcohol Denat.	Alcohol Denat.	64-17-5	Alcohol	4.0
				Fragrance	< 0.1
					Total : 100

## Appendix 3 : TDS of Yeast Veil®

**Fervere**


Natural yeast moisture veil for  
anti-aging and luxurious texture

# Yeast Veil

**World's first cosmetic ingredient made of yeast cell walls**  
**Velvety skin feel and wrinkle reduction**  
**Natural, Sustainable, UPCYCLE**

Yeast Veil is the world's first yeast cell wall cosmetic ingredient that utilizes yeast owned by Mitsubishi Corporation Life Sciences. Nutritious yeast, obtained as a byproduct of the food manufacturing process, is upcycled using proprietary processing and extraction technologies. Only the yeast cell walls, which are mainly composed of polysaccharides, are extracted and manufactured.

The highly processed yeast cell walls line up evenly on the skin without gaps, forming a moisture veil that is like a second skin. This moisture veil has a unique moisturizing effect that both inhibits moisture evaporation and replenishes moisture, and clinical tests have shown that it has an excellent wrinkle-reduction effect. Try the effect of "Yeast Veil", which imparts a silky, elegant, luxurious texture.




Vitamin C60 BioResearch Corporation

## Product Information


INCI	Yeast Polysaccharides, Alcohol Denat., Phenoxyethanol, Lactic Acid, Water
Characteristics	Slurry
Shelf Life / Storage Conditions	18 months if stored at 25°C
Packaging	3kg
Recommended dosage	3%
NMPA	Be ready soon
Benefits	Wrinkle-reduction, Moisturizing, Improve skin texture
Formulation Advices	Mix before use as yeast cell walls are insoluble in water. Note when formulating preservative system as 0.5% Phenoxyethanol is contained. For more information, please see the formulation guidelines.

## Manufacturing Process and Upcycling



## Clinical Study


### Wrinkle improvement (VISIA:(Unit: pcs.))



### 55 yrs old woman



### Skin Moisture Content



### 52 yrs old woman



 Vitamin C60 BioResearch Corporation

Nihonbashi-dori 2-chome Bldg. 4F, 2-2-6 Nihonbashi, Chuo-ku,  
Tokyo 103-0027, Japan TEL: +81-3-3517-3252 FAX: +81-3-3517-3260  
e-mail: info@vc60.com

The information contained in this brochure is, to the best of our knowledge, correct at the time of publication. The brochure is not intended to provide legal advice or to offer a warranty of non-infringement of any patents to any persons and information contained herein should be checked with qualified legal personnel in order to determine specific recommendations in each particular product formulation and application.

2023.07

## Appendix 4 : *in vitro* skin irritation test

Study institution : CERI (Chemicals Evaluation and Research Institute, Japan)

Guideline : OECD Guidelines for Testing of Chemicals, No.439

Sample Name : VC60-YW (Yeast Veil)

Conclusion :

*In vitro* skin irritation was evaluated using LabCyte EPI-MODEL24 SIT, and the average cell viability of the sample group was 94.1%.

Therefore, under the conditions of this study, this product was determined to be "non-irritant" (not classified under UN GHS).

Results of Skin Irritation Test							
Treatment	Culture Cups No.	Measurements		cell viability (%)			Judgment of Skin Irritation
		Mean	SD Value	Mean	SD Value	SD Value	
Negative control (water)	1	0.927		100.4			
	2	0.918	0.923	99.5	100.0	0.5	
	3	0.923		100.0			
Positive control (5w/v% SDS Sol.)	1	0.009		1.0			
	2	0.024	0.016	2.6	1.7	0.8	
	3	0.016		1.7			
Sample (VC60-YW) =Yeast Veil (as is)	1	0.832		90.1			Non-irritation
	2	0.882	0.869	95.6	94.1	3.5	
	3	0.893		96.7			

## Appendix 5 : *in vitro* eye irritation test

Study institution : CERI (Chemicals Evaluation and Research Institute, Japan)

Guideline: OECD Guidelines for the Testing of Chemicals, No. 492

Sample Name: VC60-YW (Yeast Veil)

Conclusion:

*In vitro* eye irritation was evaluated using LaboCyte CORNEA-MODEL24 EIT, and the mean cell viability of the sample group was 102.4%.

Therefore, under the conditions of this study, this product was determined to be "non-irritant" (not classified under UN GHS).

Results of Eye Irritation Test							
Treatment	Culture Cups No.	Measurements		cell viability (%)		Judgment of Eye Irritation	
		Adjustment value	Mean	Mean	SD Value		
Negative control (DPBS(-))	1	1.197		105.0			
	2	1.103	1.140	96.8	100.0		4.4
	3	1.121		98.3			
Positive control (Ethanol)	1	0.026		2.3			
	2	0.012	0.031	1.1	2.7		1.9
	3	0.056		4.9			
Sample (VC60-YW) =Yeast Veil (as is)	1	1.235	1.237	108.5		Non-irritation	
	2	1.156	1.158	101.6	102.4		5.7
	3	1.105	1.107	97.1			

## Appendix 6 : *in vitro* skin sensitization test KeratinoSens®

Study institution : CERi (Chemicals Evaluation and Research Institute, Japan)

Guideline : Key Event Based Test Guideline 442D

Sample Name : VC60-YW (Yeast Veil)

### Conclusion:

The test substance was exposed to the cells for 48 hours, and the luciferase gene's expression induction was measured. A total of 12 doses were designed with a maximum dose of 400 ug/mL, considered the upper limit in the test method, and diluted at an equal ratio of 2. In addition, this study was conducted twice.

The results showed that both experiments showed that the maximum induction factor (I<sub>max</sub>) of luciferase activity in the test substance group was less than 1.5.

Therefore, under this test's conditions, the product's skin sensitizing potential was judged to be "negative".

表1 本試験結果

Material	Dose (μg/mL)	Examination 1		Examination 2		Final Value	
		Induction factor	Cell viability(%)	Induction factor	Cell viability(%)		
Test Substances =Yeast Veil (as is)	0.195	0.961	101.41	0.890	103.47		
	0.391	1.017	105.47	0.925	107.84		
	0.781	0.906	99.54	0.975	107.56		
	1.56	0.963	102.86	0.951	111.98		
	3.13	0.986	99.04	0.960	117.77		
	6.25	0.934	98.15	0.970	114.88		
	12.5	0.924	97.17	0.947	110.60		
	25.0	1.016	99.52	0.919	113.48		
	50.0	1.091	97.57	1.131	104.18		
	100	1.000	94.43	1.006	101.32		
	200	1.049	84.37	0.984	95.92		
	400	1.156 *	78.62	1.189 *	84.32		
	I <sub>max</sub>		1.156		1.189		1.173
	EC <sub>1.5</sub> (μg/mL)		-		-		-
IC <sub>50</sub> (μg/mL)		-		-		-	
IC <sub>30</sub> (μg/mL)		-		-		-	
Material	Dose (μM)	Examination 1		Examination 2		Final Value	
		Induction factor	Cell viability(%)	Induction factor	Cell viability(%)		
Positive control Cinnamaldehyde	4.00	1.233 *	99.66	1.224	101.25		
	8.00	1.231 *	105.40	1.211	108.25		
	16.0	1.563 *	101.56	1.400 *	109.24		
	32.0	2.006 *	104.21	1.862 *	110.79		
	64.0	4.894 *	103.09	2.395 *	115.49		
	I <sub>max</sub>		4.894		2.395		3.644
	EC <sub>1.5</sub> (μM)		14.47		19.45		16.78
Negative control	Coefficient of variation of the luminescence (%; n=18 well)		3.952		5.040		



## Appendix 7 : 24-hour occlusive human patch test

Study institution : SOUKEN Co., Ltd (Tokyo,Japan)

Sample Name : Dispersion of yeast cell wall (Yeast Veil)

Subjects : 20 Japanese (10 males, 10 females)

Conclusion:

Samples were applied to subjects with 24-hour occlusion. After 60 minutes and 24 hours of sample removal, the results were judged by a physician to be negative in all subjects, and the product was classified as a "safe product".

Table 1: Acceptance criteria for the patch test

Response	Criteria in Japan		Score
No reaction	Negative	(-)	0
Very slight erythema	Weakly positive	(±)	0.5
Well defined erythema	Positive	(+)	1.0
Erythema with swelling ,papule	Strongly Positive	(++)	2.0
Erythema with swelling ,papule, small blisters	Strongly Positive	(+++)	3.0
Large Blisters	Strongly Positive	(++++)	4.0

Table 2: Classification of cosmetics by skin irritation index

Skin irritation index	Classification
Not more than 5.0	Safe product
5.0~15.0	Acceptable product
15.0~30.0	Product requiring improvement
Not less than 30.0	Dangerous product

Table 3: Results of patch test

Results of patch test			
Sample Name	Judgment	Removed after 60min.	Removed after 24hrs.
		Number of subjects	
Dispersion of yeast cell wall =Yeast Veil (as is)	陰 性 (一)	20	20
	弱陽性 (±)	0	0
	陽 性 (+)	0	0
	強陽性 (++)	0	0
	強陽性 (+++)	0	0
	強陽性 (++++)	0	0
Saline solution	陰 性 (一)	20	20
	弱陽性 (±)	0	0
	陽 性 (+)	0	0
	強陽性 (++)	0	0
	強陽性 (+++)	0	0
	強陽性 (++++)	0	0
white petrolatum	陰 性 (一)	20	20
	弱陽性 (±)	0	0
	陽 性 (+)	0	0
	強陽性 (++)	0	0
	強陽性 (+++)	0	0
	強陽性 (++++)	0	0

< 結果 > Results		
被験品 Sample Name	皮膚刺激指数 Skin irritation index	評価 Classification
酵母細胞壁分散液 Dispersion of yeast cell wall	0.0	安全品 Safe product

## Appendix 8 : Repeated Insult Patch Test (RIPT)

Study institution : SOUKEN Co., Ltd (Tokyo,Japan)

Sample : 20% VC60-YW Solution (20% Yeast Veil / Water)

Subjects : 50 Japanese (25 male, 25 female)

Conclusion :

- 1st observation period: The patch was applied thrice weekly for three consecutive weeks. The patch was removed 24 hours after it was applied. Skin irritation was observed 24 and 48 hours after sample removal.
- Rest period: 2 weeks
- 2nd observation period: A patch was applied to the same area as the first observation period, and 24 hours after the patch was applied, the patch was removed, and a judgment was made 60 minutes later. The judgment was also made 24 hours after the patch was removed.

As a result, the physician's evaluation concluded that this product does not cause cumulative irritation or sensitization to the skin.

Table 1: Schedule of the study

Schedule		Assesments	Sign informed consent	physician's judgment	Product application Product removal
Day 1	Monday	Before application	○	-	○
Day 3	Wednesday	24hr.after removal	-	○	○
Day 5	Friday	24hr.after removal	-	○	○
Day 8	Monday	48hr.after removal	-	○	○
Day 10	Wednesday	24hr.after removal	-	○	○
Day 12	Friday	24hr.after removal	-	○	○
Day 15	Monday	48hr.after removal	-	○	○
Day 17	Wednesday	24hr.after removal	-	○	○
Day 19	Friday	24hr.after removal	-	○	○
Day 22	Monday	48hr.after removal	-	○	-
Rest period : 2 Weeks					
Day 36	Monday	Before application	-	-	○
Day 37	Wednesday	60 min. after removal	-	○	-
Day 38	Friday	24hr.after removal	-	○	-

Table 2 : Acceptance criteria for the patch test

Response	Criteria in Japan
No reaction	Negative (-)
Very slight erythema	Weakly positive (±)
Well defined erythema	Positive (+)
Erythema with swelling ,papule	Strongly Positive (++)
Erythema with swelling ,papule, small blisters	Strongly Positive (+++)
Large Blisters	Strongly Positive (++++)

Table 3 : Judgment

<p>On day 3, 50 subjects were negative (-), 0 were weakly positive (±), 0 were positive (+), 0 were strongly positive (++) , 0 were strongly positive (+++), 0 were strongly positive (++++).</p> <p>On day 5, 50 subjects were negative (-), 0 were weakly positive (±), 0 were positive (+), 0 were strongly positive (++) , 0 were strongly positive (+++), 0 were strongly positive (++++).</p> <p>On day 8, 50 subjects were negative (-), 0 were weakly positive (±), 0 were positive (+), 0 were strongly positive (++) , 0 were strongly positive (+++), 0 were strongly positive (++++).</p> <p>On day 10, 50 subjects were negative (-), 0 were weakly positive (±), 0 were positive (+), 0 were strongly positive (++) , 0 were strongly positive (+++), 0 were strongly positive (++++).</p> <p>On day 12, 50 subjects were negative (-), 0 were weakly positive (±), 0 were positive (+), 0 were strongly positive (++) , 0 were strongly positive (+++), 0 were strongly positive (++++).</p> <p>On day 15, 50 subjects were negative (-), 0 were weakly positive (±), 0 were positive (+), 0 were strongly positive (++) , 0 were strongly positive (+++), 0 were strongly positive (++++).</p> <p>On day 17, 50 subjects were negative (-), 0 were weakly positive (±), 0 were positive (+), 0 were strongly positive (++) , 0 were strongly positive (+++), 0 were strongly positive (++++).</p> <p>On day 19, 50 subjects were negative (-), 0 were weakly positive (±), 0 were positive (+), 0 were strongly positive (++) , 0 were strongly positive (+++), 0 were strongly positive (++++).</p> <p>On day 22, 50 subjects were negative (-), 0 were weakly positive (±), 0 were positive (+), 0 were strongly positive (++) , 0 were strongly positive (+++), 0 were strongly positive (++++).</p>
<p>On day 37, 60 min. after removal, 50 subjects were negative (-), 0 were weakly positive (±), 0 were positive (+), 0 were strongly positive (++) , 0 were strongly positive (+++), 0 were strongly positive (++++).</p> <p>On day 38, 24 hrs. after removal, 50 subjects were negative (-), 0 were weakly positive (±), 0 were positive (+), 0 were strongly positive (++) , 0 were strongly positive (+++), 0 were strongly positive (++++).</p>

Fig 1 : Conclusions by Physicians

<p>本報告書に記載した試験を行った結果、<span style="background-color: black; color: black;">XXXXXXXXXX</span>、酵母細胞壁分散液には皮膚への累積刺激性及び感作性はないと判断した。</p> <p>Based on the studies described in this report, it was determined that <span style="background-color: black; color: black;">XXXXXXXXXX</span> and dispersion of 以上 yeast cell wall have no cumulative irritation or sensitization potential to the skin.</p> <p style="text-align: right;">試験統括医師： <u>小池 田 崇史</u></p> <p style="text-align: center;">Chief Study Physician</p>
--